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Summary 
 
Over the last decade, Scotland has witnessed a rising incidence in squamous cell 
carcinomas of the head and neck (HNSCC), a phenomenon thought to be linked to 
infection with high-risk Human Papillomavirus (HPV). HPV-associated HNSCC are a 
distinct disease presenting unique epidemiological, biological and clinical challenges. 
However, establishing HPV-related disease is impaired by non-standardised testing 
protocols and lack of a consensus on the efficacy of existing biomarkers such as p16. 
This is further complicated by the absence of additional biological markers and a dearth 
in our understanding of the molecular mechanisms underlying HPV-driven 
tumourigenesis. While HPV positivity is more commonly detected in the oropharynx, 
its prevalence and clinical impact in other head and neck subsites remains largely 
unexplored. The research presented in this thesis was undertaken to determine the 
prevalence of high-risk HPV in a heterogeneous cohort of 293 HNSCC patients from 
Tayside and to evaluate the validity of EBP50, a scaffolding protein involved in cell 
polarity which is targeted by high-risk HPV, as a potential marker for HPV-driven 
HNSCC.    
  
The p16 status of the patients in the cohort was already known and tissue specimens 
were genotyped for HPV using PCR. HPV infection, defined as p16 positivity and a 
positive HPV DNA status, was identified in 14% of the cohort. The majority (83%) of 
the HPV-positive tumours involved the oropharynx while the oral cavity, pharynx and 
the nasal cavity (17%) were involved to a much smaller extent. High-risk HPV type 16 
was the most prevalent HPV type.  Patients with HPV-positive tumours had 
significantly improved overall survival (OS) (2 year OS, 77% vs 57%) and recurrence 
free survival rates (RFS) (2 year RFS, 92% vs 77%) compared to patients with HPV-
negative tumours. A positive tumour HPV status was found to be an independent 
prognostic indicator (HR 0.216; 95% CI 0.06 – 0.771) and so, given the high morbidity 
and debilitating physical and psychological problems associated with prevailing 
aggressive treatment regimens, it is imperative that this knowledge is harnessed to 
develop and improve treatment strategies.  
  
EBP50 expression was evaluated, by immunohistochemical analysis, first in normal oral 
mucosa and followed up in a smaller subset of 156 HNSCC patients from the main 
cohort. In the normal tissue EBP50 expression was predominantly membranous. In the 
tumour samples four distinct EBP50 expression patterns were observed and, of these, 
xviii 
 
weak/ negligible cytoplasmic EBP50 expression showed a strong correlation, only 
marginally lower than p16 overexpression, with HPV DNA status and was observed 
largely in patients with tumours of the oropharynx and no history of smoking.   Absence 
of EBP50 expression in the plasma membranes of tumour cells was a recurring pattern 
in a majority of the tumour samples. 
 
The scale of this study, comprising a Tayside cohort of unprecedented size, will 
undoubtedly contribute to the existing knowledge of HPV incidence in head and neck 
cancer in Scotland. Furthermore, this study presents compelling preliminary evidence 
for further researching weak/negligible cytoplasmic EBP50 expression as being a 
potential indicator of HPV-positivity in HNSCC.  
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Chapter 1  
INTRODUCTION 
1.1 Squamous cell carcinomas of the head and neck  
 
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of 
tumours arising in the moist mucosal surfaces lining the upper aero-digestive tract and 
constitute the majority of head and neck malignancies [107]. Depending on the specific 
head and neck subsite/area in which they originate, primary tumours are categorised 
into those arising in the oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, 
paranasal sinuses and nasal cavity and the salivary glands (Figure 1). An estimated 
600,000 new cases of HNSCC are reported worldwide each year with the most common 
sites being the oral cavity, the larynx and the pharynx [196], [26]. 
 
 
Figure 1.1 (National Cancer Institute) Illustration of head and neck subsites.  
 
1.1.1 Incidence of HNSCC in the UK and Worldwide  
 
HNSCCs account for approximately 4% of all malignancies and 5% of cancer related 
mortality worldwide with considerable variation in incidence rates depending on 
geographic location and gender.  Globally, the highest incidence rates for HNSCC, 
particularly cancers of the oral cavity and oropharynx, have been reported in South and 
Southeast Asia (e.g. Sri Lanka, India, Pakistan and Taiwan), parts of Western Europe 
(e.g. France) and Eastern Europe (e.g. Hungary, Slovakia and Slovenia), parts of Latin 
 2 
 
America and the Caribbean (e.g. Brazil, Uruguay and Puerto Rico) and in the Pacific 
regions (e.g. Papua New Guinea and Melanesia) [316]. Incidence rates are generally 
more than two-times higher in men compared to women, although incidence rates up to 
ten-fold higher have been reported in the Republic of Slovakia and Belarus [280].  
In the United Kingdom, oral and pharyngeal cancers accounted for 2% of all new 
cancers diagnosed in 2013 [34]. According to Cancer Research UK, there are 14 new 
cases of oral cancer for every 100,000 males and 7 new cases for every 100,000 females 
[34]. Incidence rates are higher in Scotland than other parts of the UK for both men and 
women [50]. Surprisingly, a rising incidence of oral cancers in young people under the 
age of 45 years has been recorded by UK cancer registries [316].  
 
1.1.2 Aetiology of HNSCC 
 
Major risk factors for HNSCC are alcohol consumption and tobacco use and they 
account for nearly three-quarters of all head and neck cancers. While tobacco and 
alcohol use independently increase the risk of head and neck cancer, cigarette smoking 
is more strongly associated with an increased risk, especially, of laryngeal cancer [113]. 
The chewing of areca nut and betel quid (with or without tobacco) are additional risk 
factors specific to South Asian countries where the use of these products is 
widespread[86]. 
 
As is the case with many other diseases, the risk of head and neck cancer increases 
when an individual is predisposed to it as a result of specific genetic variations which 
are often inherited. For example, individuals with deletion polymorphisms in the genes 
GSTM1 and GSTT1 that encode for the Glutathione S Transferase family of enzymes 
responsible for metabolising and detoxifying carcinogens found in tobacco smoke, were 
found to be at an increased risk of developing head and neck cancer [230]. In yet 
another example, pooled analyses of epidemiological studies of risks associated with 
head and neck cancer found that a family history of the disease increased the likelihood 
of the close blood relatives developing the disease [50].  
 
Infectious agents, predominantly viruses, have been recognised as a risk factor for head 
and neck cancer - the earliest evidence for which is the association between 
nasopharyngeal cancer and infection with the Epstein-Barr virus. In the recent years, 
infection with high-risk Human papillomavirus (HPV) has emerged as a strong risk 
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factor for the development of head and neck cancer, especially that of the oropharynx 
[196].   
 
Social deprivation has been linked to HNSCC risk in high and low income countries 
across the world. While the reasons for this are poorly understood, it has been suggested 
that the low levels of income and education associated with social deprivation may 
affect nutrition, living conditions and access to health care and also influence risky 
health behaviour patterns [51], [303].  Other risk factors include occupational exposure, 
poor oral hygiene and reduced intake of fruit and vegetables [196].  
1.1.3 Clinical signs and symptoms 
 
Patients with HNSCC present with a variety of symptoms, some of which are specific 
and depend on the function of the tumour site of origin while others are relatively non-
specific. Patients with cancers of the oral cavity often present with non-healing mouth 
ulcers whereas a common presentation of laryngeal cancer is hoarseness of voice.  
Many patients often present with painless swelling in the neck and non-specific 
symptoms such as persistent sore throat or ear pain [196]. Practice guidelines outlined 
by the National Institute of Clinical Excellence (NICE) recommend urgent referral and 
specialist consultation for patients presenting with certain signs and symptoms that 
persist for more than three weeks (Table 1.1) [225].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 “Red Flag” symptoms and signs in head and neck cancer [225]  
Symptoms Signs 
  Sore throat 
  Hoarseness 
  Difficulty in 
swallowing/breathing 
  Lump in the neck 
  Unilateral ear pain 
  Red or white patch 
in the mouth 
  Oral ulceration 
  Mobile tooth 
  Lateral neck mass 
  Rapidly growing 
thyroid mass 
  Cranial nerve palsy 
  Orbital mass 
  Unilateral ear 
effusion 
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1.1.4 Diagnosis and treatment 
 
In a specialist head and neck clinic, patients undergo clinical examination followed by a 
series of diagnostic tests. Suspicious lesions are biopsied and sent for histological 
examination which often confirms a diagnosis of cancer at the primary site. 
Additionally, computed tomography and magnetic resonance imaging techniques may 
be used to determine the extent of the primary tumour. Nodal metastasis may be 
investigated through ultrasound guided fine needle aspiration cytology and occult 
primaries and distant metastasis are investigated through Positron Emission 
Tomography [196]. 
 
Although the contribution of HNSCC to global cancer burden is relatively small, it is 
associated with high morbidity, high mortality due to the aggressive nature of the 
disease, and limited therapeutic options, therefore making early diagnosis and treatment 
paramount.  Prognosis for patients with HNSCC is dependent on several factors, the 
most important ones being the site and stage of the disease.  Head and neck cancer 
staging is based on the universally accepted TNM classification system of the Union for 
International Cancer Control (UICC) and the American Joint Committee on Cancer 
(AJCC). The TNM system describes the extent of the primary tumour (T), presence and 
extent of regional lymph node metastasis (N), and presence or absence of distant 
metastasis (M). This classification may be assigned before or after histopathologic 
examination of the biopsied/resected primary tumour and is referred to as clinical or 
pathologic TNM classification respectively [298]. The TNM classifications for the most 
common head and neck cancer sites are described in Table 1.2. Table 1.3 is a summary 
of HNSCC staging based on TNM classifications. 
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Site Primary tumour (T) Regional lymph 
nodes (N) 
Distant 
metastasis (M) 
 
 
 
 
 
 
 
TX - Primary tumour cannot 
be assessed 
T0 - No evidence of primary 
tumour 
Tis - Carcinoma in situ 
 
 
NX - Regional nodes 
cannot be assessed 
N0 - No regional 
lymph node metastasis 
 
M0 - No distant 
metastasis 
M1  -  Distant 
metastasis 
Oral cavity T1 - Tumour≤ 2cm 
T2 - Tumour > 2cm but < 
4cm 
T3 -  Tumour > 4cm 
T4a - Tumour invades 
through cortical bone, 
deep/extrinsic muscle of 
tongue, maxillary sinus, skin 
T4b - Tumour invades 
through masticator space, 
pterygoid plates, skull base, 
internal carotid artery 
N1 - Metastasis in a 
single ipsilateral lymph 
node ≤ 3 cm 
N2 - Metastasis in a 
single ipsilateral lymph 
node > 3 cm but < 6 
cm; or in multiple 
ipsilateral lymph 
nodes, none > 6 cm; or 
in bilateral or 
contralateral lymph 
nodes, none > 6 cm 
N2a - Metastasis in a 
single ipsilateral lymph 
node > 3 cm but not 
more than 6 cm 
N2b - Metastasis in 
multiple ipsilateral 
lymph nodes, none > 6 
cm 
N2c - Metastasis in 
bilateral or 
contralateral lymph 
nodes, none > 6 cm 
N3 - Metastasis in a 
lymph node > 6 cm 
 
Oropharynx T1 - Tumour≤ 2cm 
T2 - Tumour > 2cm but < 
4cm 
T3 - > 4cm or extension to 
lingual surface of the 
epiglottis 
T4a - Tumour invades the 
larynx, deep/extrinsic 
muscle of the tongue, medial 
pterygoid, hard palate, or 
mandible 
T4b - Tumour invades 
lateral pterygoid muscle, 
pterygoid plates, lateral 
nasopharynx, or skull base 
or encases the carotid artery 
 
Hypopharynx T1 - Tumour ≤ 2 cm and/or 
limited to one subsite 
T2 - Tumour >2 cm but < 
4cm or invades more than 
one subsite 
T3 -  > 4 cm or with 
hemilarynx  fixation 
T4a - Tumour invades 
thyroid/cricoid cartilage, 
hyoid bone, thyroid gland, or 
central compartment soft 
tissue  
T4b - Tumour invades 
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prevertebral fascia, encases 
carotid artery, or involves 
mediastinal structures 
Larynx - 
Supraglottis 
T1 - Tumour limited to 1 
subsite of the supraglottis 
with normal vocal cord 
mobility 
T2 - Tumour invades 
mucosa of more than 1 
adjacent subsite of the 
supraglottis or glottis or 
region outside the 
supraglottis 
T3 - Tumour limited to the 
larynx with vocal cord 
fixation and/or invades any 
of the following: postcricoid 
area, pre-epiglottic space, 
paraglottic space, and/or 
inner cortex of the thyroid 
cartilage 
T4a - Tumour invades 
through the thyroid cartilage 
and/or invades tissues 
beyond the larynx  
T4b - Tumour invades 
prevertebral space, encases 
carotid artery, or invades 
mediastinal structures 
Larynx-Glottis T1 - Tumour limited to the 
vocal cord(s) (may involve 
anterior or posterior 
commissure) with normal 
mobility 
T1a - Tumour limited to 1 
vocal cord 
T1b - Tumour involves both 
vocal cords 
T2 - Tumour extends to the 
supraglottis and/or 
subglottis, and/or with 
impaired vocal cord mobility 
T3 - Tumour limited to the 
larynx with vocal cord 
fixation and/or invasion of 
the paraglottic space, and/or 
inner cortex of the thyroid 
cartilage 
T4a - Tumour invades 
through the outer cortex of 
the thyroid cartilage and/or 
invades tissues beyond the 
larynx  
T4b - Tumour invades 
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prevertebral space, encases 
carotid artery, or invades 
mediastinal structures 
Larynx-
Subglottis 
T1 - Tumour limited to the 
subglottis 
T2 - Tumour extends to 
vocal cord(s) with normal or 
impaired mobility 
T3- Tumour limited to the 
larynx with vocal cord 
fixation 
T4a - Tumour invades 
cricoids or thyroid cartilage 
and/or invades tissues 
beyond the larynx 
T4b - Tumour invades 
prevertebral space, encases 
carotid artery, or invades 
mediastinal structures 
 
Table 1.2 TNM classification for primary tumours of the oral cavity, oropharynx, hypopharynx 
and larynx [243] 
 
 
 
 
Table 1.3 Head and neck cancer staging [243] 
 
UICC stage Primary tumour 
(T) 
Regional 
lymph node (N) 
Distant 
metastasis (M) 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 
T1 
T2 
T3 
N0 
N1 
N1 
N1 
M0 
M0 
M0 
M0 
IVA 
 
T4a 
T4a 
T1 
T2 
T3 
T4a 
N0 
N1 
N2 
N2 
N2 
N2 
M0 
M0 
M0 
M0 
M0 
M0 
IVB 
 
T Any 
T4b 
N3 
N Any 
M0 
M0 
IVC T Any N Any M1 
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Patients with tumours involving metastases to the regional lymph nodes and other 
tissues have poorer survival [299], and comorbid illnesses can also significantly affect 
patient survival [233]. In addition, certain histopathological features such as the degree 
of tumour differentiation, tumour invasive pattern and perineural invasion and 
extracapsular spread are reliable indicators of prognosis in patients with head and neck 
cancer [274], [293], [76].  Although a few molecular markers such as epidermal growth 
factor, tumour hypoxia associated markers and vascular endothelial growth factors have 
been studied and reported to be associated with poor prognosis, none have been 
included in routine clinical reporting [197]. 
 
Given the complex nature of the disease, patients with head and neck cancer are often 
treated by multidisciplinary teams to ensure that they receive a high standard of care. 
Surgery and radiotherapy are the two most common treatment options and the choice of 
treatment depends on factors related to the site and stage of the tumour as well as patient 
preference [197]. About one-third of the patients present with early stage disease and 
are treated with surgery or radiotherapy with favourable prognosis. The majority, 
however, present with locally advanced tumours and are treated with a combination of 
surgery and post-operative chemotherapy and radiotherapy. Over the last decade, the 
standard of care has shifted from aggressive treatment protocols to organ preserving 
multi-modal therapy that combines treatment with systemic chemotherapeutic drugs and 
loco-regional radiation. The very advanced hypopharyngeal and laryngeal carcinomas 
are treated by surgery followed by post-operative (chemo) radiation.  Little has changed 
in the overall 5-year survival for the advanced disease in decades because patients 
frequently develop relapse at the primary site, distant metastases and second primary 
tumours [27]. 
 
Treatment regimens for head and neck cancer are associated with early and long term 
complications which are often severely debilitating, thereby greatly affecting the 
patient’s quality of life [228]. To ensure tumour clearance, surgery may require the 
sacrifice of important neuromuscular structures such as the sternocleidomastoid muscle 
which causes loss of contour to the neck and, occasionally, injury to the spinal 
accessory nerve during surgery leads to shoulder dysfunction [149]. Radiotherapy is 
associated with serious late toxicities such as xerostomia, osteo-radionecrosis and 
dysphagia [108]. Survivors of head and neck cancer present with functional problems 
such as dry mouth, difficulty in swallowing, speech defects and weak shoulders all of 
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which significantly impair long term quality of life [180].  Less aggressive treatment 
protocols with a focus on personalised care based on diagnostic and prognostic markers 
could reduce morbidity in this patient population.  
 
1.1.5 Screening and prevention  
 
Despite recent advances in treatment options, HNSCC is associated with significant 
morbidity and mortality and the costs related to management of the disease are high 
[325].  Part of the problem may be attributed to the lack of screening programmes for 
HNSCC and that patients often present with locally advanced disease. Early detection 
through screening programmes has certainly proven to be effective in reducing 
mortality and incidence rates of other major cancers such as breast and cervical cancers 
[67], [52]. There are no national population based screening programmes available for 
HNSCC. However, a few instances of opportunistic visual screening in high-risk groups 
in areas of high incidence have been reported [262]. Although adjunctive methods such 
as toluidine blue, brush biopsy and fluorescence imaging are available for detection of 
precancerous lesions, there is no evidence to support the efficacy of these methods in 
the general population, and furthermore, such methods may not be productive for 
detecting precursor lesions in clinically inaccessible head and neck subsites. The net 
result of all this is that, currently, clinical examination and biopsy form the mainstay of 
HNSCC screening [153].   
 
Lifestyle risk factors and negative health behaviours associated with HNSCC are linked 
to public knowledge of this disease and can influence early detection. Public awareness 
of head and neck cancer in the UK is limited, although local initiatives are being set up. 
A qualitative study conducted by Scott et al. found that a high-risk target population had 
limited knowledge about oral cancer (particularly signs and symptoms) and also found 
that participants were uncertain about when to seek help for oral symptoms [270]. 
Efforts to raise awareness among the public and healthcare professionals alike by 
developing strategies to change lifestyle risk factors and to detect early signs and 
symptoms may decrease the disease burden of HNSCC. 
 
1.2 Changing epidemiology of head and neck squamous cell 
carcinomas 
 
The use of tobacco remains an undisputed risk factor for the development of HNSCC. 
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In the United States, mounting evidence against the hazards of tobacco use and its 
association with various diseases has resulted in decreased consumption since the mid 
1960s and it was anticipated that the incidence of HNSCC would decline with a 
decrease in tobacco use [6]. Indeed, the incidence rates of carcinoma of the larynx, floor 
of the mouth and other oral cavity sites have declined steadily since 1980s in the US, 
the UK and Europe [37]. On the contrary, a small subset of HNSCC, the oropharyngeal 
squamous cell carcinomas (OPSCC) which involves the tonsils, base of tongue, soft 
palate and pharyngeal wall has been rising rapidly and steadily over the last decade in 
the US, the UK, Sweden, Greece and Australia [6], [194]. A compelling body of 
evidence points to infection with high-risk Human Papillomavirus (HPV) as the main 
contributor in this changing epidemiological trend [111], [189].  
 
1.3 Human Papillomavirus and cancer  
 
Viruses have had a long-standing association with cancers and are linked to an 
estimated 15-20 percent of all human cancers worldwide, representing a significant 
portion of the global cancer burden [331]. Since the discovery, in the 1950s, of the 
Epstein-Barr virus in Burkitt's Lymphoma cells [60], marking the emergence of the first 
conclusive evidence of the role of viruses in the pathogenesis of human cancers, several 
distinct groups of viral pathogens carcinogenic to humans have been identified - 
Hepatitis B and C viruses (liver cancer), Human Papillomaviruses (cervical, anogenital 
and oropharyngeal cancers), Herpesvirus (Kaposi's sarcoma), and human T-cell 
lymphotropic virus (adult T-cell leukemia), among others [24] .  
 
Not all viral infections progress to cancer and, in fact, viral carcinogenesis is a result of 
several years, sometimes decades, of chronic inflammation complicated by additional 
events and host factors such as host genetic predisposition, somatic mutations, immune 
suppression and exposure to carcinogens. Both DNA and RNA viruses have been 
shown to be capable of causing cancer in humans [171]. Of the DNA viruses with a 
malignant potential, Hepatitis B virus, Human Herpes Virus 8, Epstein Barr Virus and 
HPV have been widely studied [171]. 
 
Human Papillomavirus  is a member of the papillomaviridae family which comprises a 
diverse group of more than one hundred and fifty related viruses with different 
epithelial tropisms and life cycle strategies [61]. These viruses are classified, based on 
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their nucleotide sequences, into 5 groups: the Alpha, Beta, Gamma, Nu and Mu 
papillomaviruses [61]. The Alpha papillomaviruses constitute the largest group and are 
further subdivided into high-risk and low-risk depending on their prevalence in the 
general population and their carcinogenic potential [64]. The low-risk HPV types are 
rarely ever associated with cancer development; however, they are known to cause 
recurrent and debilitating disease conditions such as recurrent respiratory papillomatosis 
in some individuals which may eventually conclude in metastatic tumours of the lower 
respiratory tract [64],  [96].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Classification of Human Papillomaviruses. They are divided into 5 groups based on their 
nucleotide sequences; the Alpha, Beta, Gamma, Nu and Mu papillomaviruses. The Alpha 
papillomaviruses constitute the largest group and are further subdivided into high-risk and low-
risk types. The high-risk HPVs are of particular aetiological importance in the development of 
cervical, anogenital and head and neck cancer.  
 
The global incidence of HPV-related cancers has been on the rise over the last decade 
and is now a major worldwide public health concern [236]. The WHO currently 
recognises twelve HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) as high-
risk cancer causing types and types 68, 73 as ‘possibly’ cancer causing [24]. The high-
risk HPV types 16 and 18 are responsible for the majority of HPV-related cancers [24]. 
In fact, HPV type 16 is responsible for almost 99.9% of cervical cancer and cervical 
intraepithelial neoplasia grade 3 worldwide [314]. HPVs are also implicated in a 
variable proportion of non-cervical neoplasms including anal (90%), vaginal (40%) and 
penile (40%) [8].  
 
Human 
Papillomavirus 
Alpha Papillomavirus 
Cutaneous 
Mucosal 
High risk 
Low risk 
Beta 
Papillomavirus 
 
Gamma 
Papillomavirus 
Mu Papillomavirus 
Nu Papillomavirus 
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 In the upper aerodigestive tract, HPV has been linked to cancers of the oral cavity, 
oropharynx and the larynx. A systematic review conducted by Ndiaye et al. showed that 
45.8% of OPSCC, 24.2% of oral cavity and 22% of all laryngeal cancers were attributed 
to HPV [219]. While the role of HPV in the development of oral cavity and laryngeal 
cancers is contentious, its attribution to OPSCC is certain [119], [178]. There has been 
substantial variability in the reported worldwide prevalence of HPV-associated HNSCC 
ranging from 16%-46% [148]. This geographic heterogeneity may be due to small study 
samples, sample selection and variability in classification of head and neck subsites 
[148].   
 
While cancers attributable to HPV are more common in women compared to men, 
owing to the large burden of cervical cancer, this gender disparity varies significantly 
with geographic distribution and economic development of the country. The Population 
Attributable Fraction (PAF) of HPV in women ranged from less than 2.5% in North 
America and Australia to 25% in India and sub-Saharan Africa and that of men was 
highest in India (1.8%) [102]. The lack of robust cervical screening programmes leading 
to a higher incidence in cervical cancer coupled with lower incidence in HPV-related 
OPSCC might explain the gender disparity observed in less developed countries.  On 
the other hand, industrialised countries have witnessed a decline in the incidence of,  
and mortality from, cervical cancer due to the introduction of successful cervical 
screening programmes [6]. However, this decline is offset by an increase in the 
incidence of HPV-related non-cervical cancers especially, oropharyngeal cancers [194], 
[181]. 
 
1.3.1 Molecular mechanisms underlying HPV-driven tumourigenesis – a cervical 
cancer model 
 
Our understanding of the natural history of HPV infection is gleaned from cervical 
cancer studies. Cervical cancer which arises from the cervical transformation zone is a 
complex, typically progressive series of events beginning with transmission of viral 
infection followed by viral persistence, progression of a group of abnormal cells to pre-
cancer and culminating in invasion.  
 
HPV infections are primarily sexually transmitted via direct skin or mucosa contact and, 
as such. are common in young sexually active individuals [65]. The majority of these 
infections are cleared spontaneously in 12 -24 months through effective cell-mediated 
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immune responses in the host. However, a small fraction of infections persist for several 
years and carry with them an increased risk of pre-cancer diagnosis [268], [267]. The 
time-to-appearance of pre-cancer following infection with the virus can be as short as 3-
5 years with highly carcinogenic HPV-16 [266]. Progression to invasive carcinoma due 
to persistent infection is believed to be partly due to an inability of the host to develop 
an effective cell-mediated immune response and is exacerbated in combination by 
immune evasion strategies developed by the virus [65].  
 
The HPV genome comprises a circular double stranded DNA molecule of 8000 base 
pairs organised into three regions: a 4000 bp region that encodes proteins involved in 
cell transformation and viral replication, a 3000 bp region which encodes structural 
proteins of the virus and a 1000 bp region which contains the origin of the viral DNA 
replication and transcriptional regulatory elements [210]. There are two clusters of 
genes that constitute the viral genome; the early genes E1, E2, E4, E5, E6 and E7 and 
the late genes L1 and L2 (Figure 1.3). The early genes E1 and E2 encode regulatory 
proteins which are essential for DNA replication. E4 and E5 also contribute to viral 
genome amplification although E4 appears to be expressed in the late stages of viral 
infection. The viral genes E6 and E7 encode oncoproteins responsible for host cell 
transformation. The late genes L1 and L2 encode two structural capsid proteins which 
are utilised in the construction and assembly of new viral particles [248].  
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Figure 1.3 The HPV-16 genome comprises 7904 bp (shown in black). The early genes E1, E2, E4 
(green), E6 and E7 (red) are expressed from either the early promoter p97 or the late promoter 
p670 (marked as black arrows). The late genes L1 and L2 (yellow) are also expressed from p670. 
The LCR (long control region) extends from 7156 – 7184 bp and harbours E2 binding sites and the 
TATA binding element of the p97 promoter  [64]. 
 
 
The HPV life cycle is closely linked to the host epithelial cell differentiation pattern. 
Normal stratified squamous epithelium has a basal layer of slow-cycling, self-renewing 
population of cells that are ideal for maintenance of the virus. The virus enters the tissue 
through wounds or epithelial trauma and infects the epithelial basal stem cells.  The 
cervical transformation zone is especially susceptible to infection and cancer 
progression owing to the presence metaplastic cells at the site, particularly at puberty 
and the presence of cuboidal stem-like cells at the squamo-columnar junction [106], 
[118]. The precise mode of viral entry is unclear, but interactions with heparin 
proteoglycans and α6 integrin have been suggested [239], [193]. Following infection of 
the basal cells, the HPV early genes E1 and E2 support the synthesis of low copy 
numbers of episomal genomes through viral DNA replication (Table 1.4). As the 
infected cells differentiate and migrate to the supra-basal layers of the epithelium, viral 
late genes products initiate the vegetative phase of the HPV lifecycle, resulting high-
level amplification of the viral genome. Viral DNA is encased in capsid proteins in the 
outer epithelial layers and progeny virions are released to initiate infection once again. 
Although the progeny virions are highly immunogenic, they encounter limited immune 
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surveillance as they are synthesised in the upper layers of the epithelium [217]. In 
addition, the E6 and E7 proteins affect the host immune response by interfering with 
JAK/STAT (Janus kinase/signal transducers and activators of transcription) signalling, 
induction of Interferon Response Factor-1 (IRF-1) and reducing the levels of MHC-1 
(Major Histocompatibility Complex) antigen presentation [169], [307]. Such immune 
evasion mechanisms allow the virus to remain as a chronic asymptomatic infection. 
 
Early 
genes 
       E1 
E2 
E4 
E5 
 
E6 
 
 
 
 
E7 
Function 
 
Initiation of viral genome replication 
Viral DNA replication and transcription 
Packing of viral particles 
Host cell transformation. Inhibition of apoptosis in late events of HPV 
carcinogenesis. 
Inactivates p53 protein and blocks apoptosis. Interacts with many host 
proteins with PDZ domains, (PSD-95 - a 95 kDa protein involved in 
signalling at the post-synaptic density, DLG - the Drosophila 
melanogaster Discs Large protein and ZO-1 the zonula occludens 1 
protein) involved in maintenance of epithelial polarity. 
Inactivates pRb protein. Promotes host DNA synthesis and proliferation. 
Late genes 
L1 
L2 
Function 
Major capsid protein 
Minor capsid protein 
 
Table 1.4 Early and late genes of the HPV genome and their functions [248]. 
 
 
The carcinogenic potential of high-risk HPVs may be attributed to the viral 
oncoproteins E6 and E7. Integration of viral DNA into the host cell genome appears to 
be an important step in the malignant transformation of host tissue. Integrated viral 
DNA has a greater potential for neoplastic transformation by initiating a series of events 
which lead to overexpression of the E6 and E7 oncoproteins [64]. The E6 and E7 
oncoproteins in most HPV types stimulate host cells in mid-epithelial layers to re-enter 
the cell cycle, thereby facilitating viral genome amplification [65]. Furthermore, they 
promote carcinogenesis in the infected tissues by targeting and disrupting multiple 
cellular pathways (Table 1.4).  
 
Both E6 and E7 are necessary to induce and maintain cellular transformation. The most 
important function of the E6 protein in cellular transformation is to support the 
accumulation of mutations by disrupting p53 mediated DNA repair. The p53 tumour 
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suppressor protein plays an important role in the induction of cell cycle arrest and 
apoptosis following DNA damage. Moderate DNA damage is countered by a p53 
dependent cell cycle arrest followed by DNA repair but when the damage is severe, 
apoptosis is induced [217]. The E6 protein combines with p53 and cellular ubiquitin 
ligase E6 associated protein (E6AP) to form a tripartite complex which leads to 
proteasome mediated degradation of p53. As a result, cells expressing high-risk HPV 
E6 are no longer able to counter DNA damage due to the loss of p53 leading to the 
accumulation of secondary changes in the host cell genome that eventually progress to 
cancer [64]. In addition, E6 interferes with pro-apoptotic proteins such as Bak, Fas 
associated death domain (FADD) and procaspase 8 to further prevent apoptosis [301], 
[92]. Another important function of the E6 protein is its ability to induce telomerase 
activity  - whose absence in normal cells implies the natural shortening of telomeres 
with each cell division and eventually to cell senescence and death - by activating its 
catalytic subunit human telomerase reverse transcriptase (hTERT)  [138].  Due to 
induced telomerase activity, E6 infected cells are able to maintain telomere length 
leading to immortalisation [138]. High-risk E6 proteins also target and degrade PDZ 
domain containing proteins such as human homologue of the Drosophila disc large 
protein (hDlg) and human homologue of the Drosophila scribble protein (hSrib) [90], 
[214]. Specifically, PDZ proteins play an important role in cell polarity, signalling and 
cell adhesion and high-risk E6 proteins bind to these proteins through their C-terminal 
PDZ binding domain (PBM) and stimulate their degradation. E6 induced degradation of 
PDZ domain proteins is thought to result in the loss of cell polarity seen in HPV-
induced cervical cancers owing to a disruption of tight junctions [191].  
 
The most important function of the high-risk E7 protein is to promote cellular 
proliferation by binding to, and, inactivating the Retinoblastoma protein (pRB) and its 
family members p107 and p130. The pRB proteins, in their hypophosphorylated state, 
bind to transcription factor E2F to supress the transcription of genes involved in DNA 
synthesis and cell-cycle progression.  Phosphorylation of pRb by G1 cyclin-dependent 
kinases releases E2F leading to cell cycle progression into the S phase.  E7 is capable of 
binding to unphosphorylated pRB and, in doing so, may force the cells to enter S phase 
prematurely by disrupting pRB-E2F complexes. Another consequence of E7 mediated 
degradation of pRB proteins is the overexpression of cyclin dependent kinase inhibitor 
p16 INK4a (p16). p16 is a tumour suppressor that prevents phosphorylation of pRB. 
However, disruption of the pRB-E2F complex can cause the transcriptional factor E2F 
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to induce p16 INK4a expression. p16 overexpression is thus controlled by the functional 
status of pRB and E7 mediated inactivation of pRB can result in its overexpression 
[129].  
 
Other transforming properties of E7 include association with histone deacetylases 
(HDAC) to promote cell growth and cyclin dependent kinase (CDK) inhibitors p27 and 
p21 to abrogate cell-cycle inhibition [217]. Table 1.5 summarises all the important cell 
processes affected by the E6 and E7 proteins [202]. 
 
Viral 
oncoprotein 
      Transforming property    Biological impact 
E6 Degradation of tumour suppressor 
protein p53 
Accumulation of cellular 
abnormalities increasing 
the potential for 
malignant transformation 
E6 Impairment of p53-induced gene 
transcription by binding to 
transcriptional co-activators CREB 
binding protein (CBP) and p300 
Interference with cell 
differentiation and cell 
cycle progression 
E6 Degradation of  cell polarity and 
PDZ domain proteins 
Loss of cell-cell adhesion 
increasing the invasive 
potential of transformed 
cells 
E6 Degradation of pro-apoptotic 
protein Bak 
Inhibition of cell death 
and accumulation of 
abnormal cells 
E6 Increased transcription of Human 
Telomerase Reverse Transcriptase 
(hTERT) 
Immortalisation of 
affected cells and 
indefinite proliferation 
E7 Inactivation of tumour suppressor 
protein pRb 
Disruptions of cell cycle 
check points. Increased 
cell proliferation 
E7 Binding to cyclin-dependent-
kinase (CDK) inhibitors p21 and 
p27 
Disruption of cell cycle 
and increased cell 
proliferation 
E6 and E7 Inhibition of expression of toll-like 
receptor 9 (TLR9) 
Evasion of immune 
surveillance 
 
 
Table 1.5 The biological impact of HPV transforming proteins E6 and E7. Both E6 and E7 promote 
and maintain cellular transformation. The E6 protein supports the accumulation of mutations by 
disrupting p53 mediated DNA repair. The E7 protein promotes cellular proliferation by 
inactivating pRB. In addition, the E6 and E7 proteins interfere with the functions of several other 
cellular proteins.  
 
1.4 HPV and HNSCC 
 
HPV-induced carcinogenesis in the upper aerodigestive tract is less well understood in 
comparison to cervical cancers. Oral HPV infection is a supposed precursor of HPV-
related OPSCC and is strongly associated with sexual behaviour [55]. The rising 
 18 
 
incidence of HPV-positive OPSCC in the USA has been attributed to changes in sexual 
norms such as lower age of first sexual encounter and higher numbers of lifetime sexual 
partners per individual  [100]. The natural history of oral HPV infection, its clearance 
and persistence are all crucial to understanding how oral HPV infection progresses to 
malignancy. Attempts to study the progression of oral HPV infection to malignant 
cancer have been hampered by the lack of robust screening methods and a general 
absence of pre-malignant lesions in the head and neck regions as compared to cervical 
intraepithelial neoplasia (CIN) [59].  
1.4.1 Oral HPV infection  
 
The overall prevalence of oral HPV in the general population has been estimated to be 
between 1.8 – 7.5% [160]. In a pooled analysis, Kreimer et al. reported the prevalence 
of oral HPV infection in healthy adults to be 4.5% and the prevalence of oncogenic 
HPV-16 to be 1.3% [147]. In a recent large-scale, multi-centre study conducted across 
ten European countries including the UK, HPV-16 L1 antibodies were detected in 2.6% 
of the healthy cancer-free subjects. Additionally, this study also found that HPV-16 
seropositivity was associated with an increased risk of oral cavity and oropharyngeal 
cancer [30].  
 
Identifying risk factors for oral HPV infection is not only important in understanding 
the natural history of the disease but also in identifying high-risk populations. 
Independent risk factors which have been identified for oral HPV infection include 
gender, age, tobacco use, high-risk sexual behaviour and immunosuppression [160]. 
Oral HPV infection has been shown to be significantly higher in men than in women 
[56] and differences in risk behaviours and immune response to viral acquisition and 
clearance influenced by sex hormones may account for this  [160].  While increasing 
age has been significantly associated with oral HPV infection, probably owing to age 
related loss of immunity, a study by Gillison et al. reported a bimodal pattern where 
prevalence peaked among individuals aged 30 to 34 years and 60 to 64 years [99]. With 
respect to tobacco use, higher oral HPV prevalence was found in current tobacco users 
compared to ex-smokers [77] and those who never smoked. Additionally, smoking 
appears to increase the risk of persistence of oncogenic HPV infection which is crucial 
for malignant transformation [133]. Given that the primary mode of transmission of 
HPV infection is sexual contact, evidence suggests that certain high-risk sexual 
behaviour patterns are associated with transmission of oral HPV infection and 
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subsequent malignant transformation. A large scale multi-center study conducted by 
The Head and Neck Epidemiology Consortium (INHANCE) reported an increased risk 
of oropharyngeal cancers for individuals with a history of six or more lifetime sexual 
partners, four or more lifetime oral sexual partners, early age at sexual debut and a 
history of same-sex sexual contact among men [116].  The higher incidence and 
prevalence of oral HPV infection and OPSCC seen in HIV-affected individuals 
indicates that oral HPV is strongly associated with immunosuppression [12].  
 
1.4.2 HPV-driven tumourigenesis in the upper aerodigestive tract 
 
HNSCC cancers are most commonly associated with high-risk HPV-16 which is 
perhaps the most aggressive type. This may be explained in part by the high prevalence 
of HPV-16 in the general population and evolution of the oral epithelium making it 
accessible only to the most virulent HPVs. Evidence exists to show that unlike cervical 
cancers, DNA integration is not necessary for the development of head and neck cancers 
and that the virus can exist in episomal forms. For example, Koskinen et al. reported 
that in their cohort of head and neck cancers, 61% were HPV DNA positive. HPV-16 
was the dominant sub-type, and found in 84% of HPV-positive cancers. Real time (RT-
PCR) analysis demonstrated that of the HPV-16-positive samples, 48% were integrated, 
35% were episomal and 17% were mixed with both episomal and integrated forms 
[141]. 
 
Viral particle internalisation into target cells is thought to be initiated by binding to cell 
surface heparan-sulfonated proteoglycans (HSPGs) and also by interacting with 
secondary receptors [65]. There is evidence to suggest that during the process of 
infection, HPV activates growth factor receptors triggering the PI3K/Akt/mTOR 
(Phosphoinositide 3-kinase/ serine-threonine protein kinase B/mammalian Target Of 
Rapamycin) signalling pathway [292]. The PI3K pathway has been implicated in 
multiple human cancers and is activated when Epidermal Growth Factor Receptor 
(EGFR) binds to its ligand activates leading to the phosphorylation of 
phosphatidylinositol on the 3’- hydroxyl group. The product, phosphatidylinositol-3, 4, 
5-triphosphate activates AKT kinase which in turn phosphorylates many downstream 
proteins that regulate cell growth and survival [66]. A study conducted by Surviladze et 
al. showed that the Akt/mTOR signalling pathway was rapidly activated when human 
keratinocytes were exposed to HPV type 16 pseudovirions (PsVs) suggesting that HPV 
infection stimulates the PI3K/Akt/mTOR pathway via α-6 β -4 integrins [292]. HPV 
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oncoprotein expression confers a very distinct molecular profile on HNSCC.  For 
example, HPV-positive HNSCCs show lower rates of p53 and p16INK4a alterations 
when compared to their negative counterpart (Table 1.6) [29]. Additionally, viral E6/E7 
oncoprotein expression in various anatomic sites in the head and neck will often control 
specific cell signalling pathways. A few studies have provided valuable insight into the 
role HPV E6 expression in the activation and manipulation of the Wnt cell signalling 
pathway which is essential in regulation of proliferation and differentiation responses 
during normal development.  Activation of the Wnt signalling pathway inhibits GSK-3β 
which leads to accumulation of cytoplasmic β- catenin and its translocation into the 
nucleus where it binds to the T-cell factor/lymphoid enhancer factor (TCF/LEF) family 
of transcription factors and induces expression of numerous proto-oncogenes, including 
c-myc and cyclin D1, as well as genes which regulate growth and tumour progression, 
such as MMP7, PPARδ, gastrin, connexin 43, and WISP proteins [33]. In a study 
conducted by Smeets et al. the authors showed that immortalisation of normal oral 
keratinocytes (OKCs) by HPV E6 expression caused an activation of Wnt pathway 
which was consistent with the finding that nuclear β - catenin protein levels were 
upregulated in HNSCCs and HPV16-positive oropharyngeal cancer cell lines [284]. 
1.4.3 Implications of high-risk HPV-driven tumourigenesis in the upper 
aerodigestive tract 
 
Over the past decade, one of the most significant developments in the field of head and 
neck oncology is the establishment of the prevalence of HPV in a small subset of 
HNSCC.  The incidence of HPV-associated HNSCC has risen steadily over the last 40 
years [43], [189], [218] and is set to escalate over the next twenty years [246]. Patients 
with HPV-positive HNSCC represent a demographically and clinically distinct patient 
population with improved prognosis [189]. Furthermore, HPV-positive tumours have 
specific histopathological features [324]. The rising incidence of HPV-related HNSCC 
has several clinical implications with patient survival being, perhaps, the most important 
one.  
 
1.4.3.1 Demographic, clinical and histopathological characteristics of patients 
with HPV-related HNSCC 
 
Demographically,  patients  afflicted with HPV-related HNSCC are more likely to be 
younger or middle aged men with little or no history of smoking and alcohol 
consumption (Table 1.6) [6]. The role of smoking in HPV-related HNSCC is debatable. 
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While some studies have shown that HPV-positive OPSCC patients are never smokers, 
others have reported no significant differences in HPV-positive and negative OPSCC 
groups [30], [305]. It is possible that although HPV-positive OPSCC is noted in 
individuals with no history of smoking, they may have a history of tobacco use [39], 
[54]. However, this group of patients is more likely to have a higher number of sexual 
partners and oral sex partners [189]. 
 
 HPV-associated HNSCC arises most commonly in the oropharynx, more specifically, 
in the lingual and palatine tonsillar crypts unlike those unrelated to HPV which 
originate from the superficial epithelium [323]. The tonsillar crypt is lined by a 
specialised lymphoepithelium known as reticulated epithelium. It is hypothesised that 
this reticulated epithelium provides an immune-privileged site by inhibiting virus-
specific T- cells and facilitating immune evasion at the time of initial HPV infection and 
subsequent virus-induced malignant transformation [323].  Furthermore, disruptions in 
the reticulated epithelium leave the basement membrane exposed to viral particle 
deposition without the need for mechanical abrasion of the mucosa [323]. This makes 
the tonsils more susceptible to HPV infection and subsequent malignant transformation.  
HPV-associated tumours also have a distinct clinical presentation and differ from non-
HPV- related HNSCC in the tumour, nodes, metastases stage distribution at the time of 
diagnosis (Table 1.6). HPV-positive tumours are generally diagnosed in an earlier T-
category and a more advanced N-category than HPV-negative HNSCC [6]. Metastatic 
lymph nodes from primary HPV- positive tumours in the upper aerodigestive tract often 
show cystic degeneration at radiological imaging and histological examination. This 
feature is accepted as a trait of HPV-associated carcinomas, particularly those 
originating from the base of tongue or tonsil. It is also an indication for diagnostic 
tonsillectomy and multiple biopsies of base of tongue as part of a clinical work up for 
occult primary in the head and neck [103]. Sudden changes in the volume of lymph 
node metastases, with spontaneous shrinkage before and enlargement during radiation 
treatment, are seen in patients with HPV-related HNSCC [260]. This variability can 
have implications on clinical staging and assessing treatment complications as a 
decreasing volume of a target tumour may leave a larger part of normal tissue exposed 
to radiation. Perhaps the most clinically significant characteristic of HPV-induced 
tumours in the upper aerodigestive tract is the observation that a certain subset of these 
tumours particularly those arising in the oropharynx are associated with a better 
prognosis than those not related to HPV [79]. 
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Histologically too, HPV-positive HNSCC have a distinct profile compared to HPV-
negative tumours with the latter tending to be moderately differentiated. HPV-positive 
tumours are often interpreted as non-keratinising or ‘basaloid’ carcinomas based on the 
lobular growth of cells with hyperchromatic nuclei and a high nuclear to cytoplasmic 
ratio [323]. Table 1.6 is a summary of important differences between HPV-positive and 
negative HNSCC.  
 
 
 
 
Table 1.6 Clinical and histopathological differences between HPV-positive and negative HNSCC 
[322]. Patients with HPV-positive tumours are often younger individuals with no history of smoking 
or alcohol consumption. Tumours tend to involve the oropharynx and are often non-keratinised 
with overexpression of p16 and the presence of low levels of wild type p53. Although patients with 
HPV-positive tumours present with late stage disease, they have improved survival compared to 
those with HPV-negative tumours. 
 
 
1.4.3.2 Tumour HPV status and survival 
 
In general, HPV-associated HNSCC at presentation are stage III or IV with multilevel 
nodal metastases [189], [103]. Despite the late stage presentation, HPV positivity in the 
oropharynx is associated with improved overall survival and disease free survival [247]. 
The earliest evidence of a favourable prognosis comes from several small retrospective 
Clinical HPV-positive  HNSCC HPV-negative  HNSCC 
Age Younger individuals Older individuals 
         Aetiology Sexual practices Tobacco and Alcohol 
 
Anatomic sites 
Base of tongue, lingual and 
palatine tonsils 
Larynx and other sub-sites 
(lack of evidence). 
 
All sites 
Stage Tx, T1 – 2 Variable 
Survival Improved Unchanging 
Molecular   
Histology Non -keratinised Keratinised 
p16 p16  ↑ p16  ↓ 
p53 p53 wild type p53 mutated 
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case studies which showed that patients with HPV-positive OPSCC, treated by 
radiotherapy, chemotherapy, surgery or combined therapy had up to an 80% reduction 
in the risk of disease failure compared to patients with HPV- negative OPSCC [101]. 
Studies involving retrospective analyses of archival tumour specimens of patients who 
were enrolled in randomised clinical trials comparing accelerated-fractionation 
radiotherapy with standard-fractionation radiotherapy, each combined with cisplatin 
therapy, have also demonstrated a survival advantage in patients with HPV-related 
OPSCC [5]. In a recent meta-analyses conducted by O’rorke et al. the authors observed 
a 72% reduction in mortality and a 52 – 60% reduction in progression of HPV-positive 
HNSCC and OPSCC. In addition, HPV-positive HNSCC and OPSCC patients were less 
likely to have recurrence compared to HPV –negative patients [227]. Better overall 
survival observed in patients with HPV-positive OPSCC may be attributed to younger 
age at presentation, lower smoking and alcohol related morbidity, reduced risk of 
second primary tumours or a more aggressive treatment plan [21]. The presence of a 
functional wild type p53 and absence of field cancerisation associated with tobacco and 
alcohol exposure allows an apoptotic response of cancer cells to chemo-radiation [110]. 
This might explain the favourable treatment outcomes seen in patients with HPV-related 
OPSCC. Improved treatment outcomes in patients with HPV-associated OPSCC has 
prompted efforts to identify less aggressive treatment strategies to reduce toxic effects 
and improve quality of life.  
 
Very little is known about the significance of HPV-mediated carcinogenesis in other 
head and neck cancer subsites. It is even unclear whether HPV-positive non-
oropharyngeal cancers represent another distinct group of viral mediated cancers and 
whether these patients also have improved clinical outcomes. A recent literature review 
conducted by Isayeva et al. revealed that while high- risk HPV was associated with a 
significant proportion of oral and laryngeal cancers, there was a paucity of data to 
implicate the virus in the development of squamous cell carcinomas in other subsites 
such as the nasopharynx and the salivary glands. Moreover, the existing data is 
insufficient to establish a correlation between tumour HPV status in non-oropharyngeal 
sites and clinical outcomes highlighting the need for additional well designed studies to 
explore the impact of HPV status on overall and disease free survival [127]. 
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1.4.3.3 Tumour HPV status and response to treatment  
 
Several studies show that patients with a positive tumour HPV status are more 
responsive to treatment than those with negative tumour HPV status. In a study 
conducted by Kumar et al. pre-treatment biopsies of patients with HNSCC enrolled in 
an organ preserving trial were prospectively analysed for HPV status and EGFR 
expression. The authors found that patients positive for high-risk HPV had a better 
response to chemotherapy, better overall survival and disease specific survival [127]. 
Such preliminary observations were later strengthened by data from prospective clinical 
trials. In a landmark trial conducted by Fakhry et al. in 2008, patients with HPV-
positive HNSCC were shown to have higher response rates to induction chemotherapy 
and chemoradiation treatment with improved overall and progression free survival [79]. 
Better prognosis seen in HPV-positive HNSCC has been hypothesised to be due to an 
increased radiosensitivity conferred by low levels of normally functioning p53 in HPV-
positive cells following radiation exposure leading to prolonged cell cycle arrest and 
apoptosis [136] and an impairment of homologous recombination-mediated DNA repair 
response regulated by p16 overexpression [62]. It has also been postulated that an 
improved treatment response may be related to an enhanced anti-tumour immune 
response. For example, Vermeer et al. were able to demonstrate that radiation therapy 
induced a dose-dependent decrease in tumour surface protein CD47 expression. A 
reduction of CD47 increased phagocytosis of tumour cells by dendritic cells and 
induced immune activation of mixed lymphocytes [311]. 
 
It is important to note that improved outcomes for HPV-related HNSCC were 
consistently reported for tumours involving the oropharynx where non-surgical 
treatment modalities are often the norm [159], [253]. Studies analysing the impact of 
HPV status on prognosis in non-oropharyngeal tumours found no differences in survival 
or loco-regional control between HPV-positive and negative patients [177], [47], 
although one must view these findings with caution considering the small sample sizes 
they were working with.  
 
1.4.3.4 Improving therapeutic strategies for patients with HPV-positive HNSCC  
 
Current treatment protocols for HNSCC are associated with debilitating side effects and 
long term toxicities. Head and neck cancer survivors have to cope with significant and 
persistent physical, functional and psychological problems. Laryngeal cancer patients 
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who undergo chemoradiation or total laryngectomy and radiation therapy will often 
experience problems with swallowing, chewing, speech and shoulder function [179]. 
Long-term side effects of xerostomia and problems with dentition have been reported 
by 5-year survivors of HNSCC [68]. A high level of depression is also common among 
patients treated for head and neck cancer [207].   
 
Given the younger age and improved treatment performance status of patients with 
HPV-positive HNSCC, de-intensification of therapeutic strategies is being studied by 
several groups. Prospective clinical trials focusing on new HPV- specific treatment 
strategies are underway. Modifying radiation dosage is one way of reducing toxicity and 
there are currently two ongoing trials, a Phase II trial by Mehrota et al. [198] and the 
Eastern Cooperative Oncology Group Trial (ECOG 1308) [190], focusing on reduction 
of the standard dose of definitive radiotherapy. In both trials, patients with a positive 
tumour HPV status received induction chemotherapy followed by a dose reduced 
chemoradiation for those patients who responded well to induction chemotherapy. 
Replacement of Cisplatin, currently the drug of choice for chemoradiation, with 
Cetuximab, a monoclonal antibody against EGFR with less toxicity is an alternative 
strategy being investigated in the DeESCALaTE HPV and RTOG (Radiation Therapy 
Oncology Group) 1016 trials [192]. Other novel strategies to reduce morbidity include 
less invasive surgical procedures like Trans Oral Robotic Surgery (TORS) where 
surgery is the primary treatment modality and immunotherapy where patients are treated 
with vaccines intended to stimulate an immune response to the tumour [312], [165]. 
 
1.4.3.5 Prophylactic vaccination and patient counselling  
 
The rising incidence of HPV-related HNSCC in many parts of the world has highlighted 
two important issues; the importance of cancer prevention by way of prophylactic 
vaccines and the ethics of informed decisions by way of patient counselling. 
 
Currently, the available prophylactic vaccines for oncogenic HPV are indicated for use 
in women only in the prevention of cervical cancers. The two FDA approved vaccines 
are Cervarix, a bivalent vaccine manufactured by Glaxo SmithKline and Gardasil, a 
quadrivalent vaccine manufactured by Merck. While Cervarix is approved for females 
aged 10 – 12 years and protects primarily against HPV types 16 and 18, Gardasil has 
been validated for use in females and males aged 9 to 26 years and protects against HPV 
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types 6 and 11 in addition to types 16 and 18 [211]. As cervical carcinogenesis takes at 
least 20 years after infection with a high-risk HPV virus, the impact of vaccination 
programmes on the population would not be expected until 20 to 30 years after 
implementation. Additionally, screening programmes are able to reduce incidence and 
mortality of cervical cancers in adult women who are ineligible for vaccination in less 
developed countries [261].  
 
A higher incidence of oral HPV infection and HPV-positive HNSCC is seen in men 
[189]. Additionally, HPV infection also increases the risk of anal cancer in men [58]. 
This has prompted a vigorous campaign for vaccination of boys against HPV.  
Consequently, the world’s first National Human Papilloma Virus (HPV) Immunisation 
program for boys was launched by the Australian government in 2013 [9].  Presently, a 
similar vaccination programme for boys is unavailable in the UK. However,  such an 
initiative will come with a caveat that determining its efficacy in the prevention of 
oropharyngeal cancers will be a difficult, if not impossible, task as these neoplasms are 
not known to be associated with evaluable pre-cancerous lesions [78]. 
 
 Presently, determination of tumour HPV status does not impact treatment decisions or 
patient care other than to provide insight into the disease prognosis. As a result, perhaps, 
there are no established guidelines for informing patients of the potential link between 
high-risk HPV infection and cancer. For patients, making informed decisions on 
treatment choices is dependent partly on receiving accurate medical information. 
Recommendations have been made to educate patients with HPV-related HNSCC 
regarding the transmissibility of the virus and the uncertainty concerning health 
behaviours and epidemiology [279]. Disseminating prognostic information of HPV-
related tumours to patients has also been suggested [279]. Attitudes of men toward HPV 
vaccination need to be clarified in order to draw up education and vaccination 
campaigns [160]. 
1.5 Diagnosis of HPV-related HNSCC  
 
It is evident that testing for HPV in HNSCC, especially for those arising in the 
oropharynx in research settings and in routine clinical practice, is paramount. Indeed, in 
the light of the knowledge that OPSCC are a distinct subset of HNSCC, the National 
Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (USA) has 
recommended testing of OPSCC for high-risk oncogenic HPV [222].  
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Diagnosis of head and neck cancer requires the acquisition of tissue samples or cells in 
the form of biopsies. Typically, the acquired diagnostic tissue specimens are fixed in 
formalin, processed in the laboratory and embedded in paraffin wax (Formalin Fixed 
Paraffin Embedded (FFPE), to preserve morphological features of cells and tissue 
architecture. This process can sometimes cause degradation of sample DNA, RNA and 
proteins.  HPV tests used in diagnostics must be capable of reliably identifying viral 
markers in fixed tissue samples in addition to being reproducible and economically 
viable [256]. In clinical practice, the methods commonly employed for HPV detection 
are: p16 Immunohistochemistry (IHC), Polymerase Chain Reaction assays (PCR), 
Quantitative Reverse Transcriptase PCR (qRT-PCR) to quantify viral load and DNA In 
Situ Hybridisation (ISH).  
 
Owing to its simplicity and reliability, p16 IHC is perhaps the most widely used assay 
to determine the presence of transcriptionally active HPV in OPSCC [166]. The p16 
gene, a member of the INK4 class of cell cycle inhibitors, plays an important role as a 
tumour suppressor whereby it binds to cyclin dependent kinases 4 and 6 and blocks its 
interaction with D-type cyclins. This allows the tumour suppressor gene retinoblastoma 
(Rb) to maintain its hypophosphorylated state and bind to E2F transcription factor 
preventing cell cycle progression [134]. Integration of high-risk HPV into the host 
genome results in a loss of the viral E2 gene promoter, which in turn causes increased 
transcription of viral oncoproteins E6 and E7. The E7 protein binds to and inactivates 
the tumour suppressor Rb protein leading to a compensatory overexpression of nuclear 
and cytoplasmic p16 in HPV infected tumour cells [290]. PCR based tests rely on the 
detection of HPV DNA in a given specimen. A DNA polymerase is used to amplify the 
target gene and the amplified product is visualised on gels or detected by specific 
probes. Quantitative reverse transcriptase PCR is the current ‘gold standard’ for 
demonstration of oncogenic HPV infection [283]. By amplifying high-risk E6/E7 
mRNA transcripts, it is able to measure viral load in fresh tissue samples. Conventional 
ISH allows for localisation of expression of a gene in its cellular environment. A 
labelled DNA probe is used to hybridise to a known target DNA sequence in a given 
sample. An antibody is then used to detect the label on the probe. As is the case with 
most testing methods, these diagnostic assays have advantages and disadvantages 
(Table 1.7). 
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One of the earliest studies to observe a link between HPV-related squamous cell 
carcinomas arising in the tonsils and increased levels of p16 was conducted by 
Klussmann et al. in 2003 [139]. The authors determined the HPV status of 34 tumours 
using consensus and real time PCR and found that a majority of the HPV-positive 
tumours were strongly positive for p16 by immunohistochemistry while the HPV-
negative cases were not [139]. The results of this study have been bolstered by several 
other studies examining the link between p16 expression and HPV status in HNSCC, 
making a strong case for using overexpression of p16 in head and neck cancers as a 
surrogate marker for oncogenic HPV infection [13], [250]. Although p16 IHC is an 
excellent assay, there are many caveats associated with its use as a single test to 
determine tumour HPV status.  Comparative studies using p16 IHC, ISH and qRT-PCR 
have demonstrated that although p16 IHC is highly sensitive for HPV infection, it lacks 
specificity for the presence of transcriptionally active HPV [275], [242]. For example, 
in a study comparing the prognostic value of qRT-PCR with DNA ISH and p16 IHC in 
a cohort of OSCC samples, Shi et al. reported p16 concordance of 92% and 86% with 
HPV-16 ISH and qRT-PCR respectively [275]. Some authors argue that in discordant 
cases, those that are p16-positive but HPV DNA/mRNA negative, p16 overexpression is 
a result of interplay of other mechanisms unrelated to HPV [264]. Given that 
overexpression of p16 is a direct consequence of deregulation of Rb, it has been 
postulated that the loss of heterozygosity of Rb may result in increased p16 expression 
[258]. The threshold for p16 positivity is currently subjective and disparate. For 
example, Smeets et al. defined p16 positivity as any amount of staining regardless of 
percentage of tumour cells labelled or staining intensity [283] while Schache et al. 
defined p16 positivity as staining greater than 70% of the tumour [264]. Furthermore, 
the choice of reagents and the protocol for IHC varies across laboratories and 
institutions [255]. Additionally, p16 appears to be an effective surrogate marker of high-
risk HPV infection only in OPSCC. Its specificity in non-oropharyngeal sites has not 
been established [175], [46]. Despite the debate on the efficiency of p16 IHC to detect 
clinically relevant high-risk HPV infection in HNSCC, there is sufficient evidence to 
support the argument that p16 overexpression is a favourable prognostic indicator of 
locoregional control and overall survival irrespective of HPV status and treatment 
modality [5], [253], [306]. 
 
PCR based assays are highly sensitive, capable of detecting as little as one copy of a 
target sequence in a given sample. Therefore, in principle, they are an ideal method for 
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use on specimens with low DNA content. However, PCR assays are also greatly 
affected by sample integrity which is especially important in FFPE archival specimens. 
The presence of foreign material in such a clinical sample can often inhibit the 
amplification reaction [91].  Because of its high sensitivity, HPV DNA PCR tests tend 
to overestimate the presence of HPV infection resulting in a few false positive cases. In 
addition, HPV DNA is widely present in some clinically and histologically normal 
tissues, head and neck squamous dysplasia, SCCs and even in papillomas [295]. 
Therefore, detection of HPV DNA in a sample does not make it clinically or 
biologically relevant. Furthermore, there exists the possibility of false negative results 
with HPV L1 consensus PCR in cases where L1 ORF (open reading frame) is disrupted 
as a result of viral integration into the host genome [70]. These observations argue 
against the use of PCR assays alone in the detection of high-risk HPV infection in 
HNSCC. 
 
Although qRT-PCR is capable of establishing the presence of transcriptionally active 
HPV, its utility in clinical practice is limited because of the challenges associated with 
preservation of RNA in routine biopsy samples [255]. Nevertheless, in a seminal study 
conducted by Shi et al. a qRT-PCR assay developed specifically for FFPE samples was 
able to detect HPV-16 E6/E7 mRNA transcripts with great accuracy despite the 
technical challenges of obtaining amplifiable mRNA from the FFPE samples [275]. 
 
DNA ISH is specific, permitting direct visualisation of viral DNA in the tumour cells as 
punctate nuclear signals. Additionally, this assay can be performed on FFPE tissue 
employing widely available automated IHC platforms and interpreted using 
conventional light microscopy [16]. However, DNA ISH has limited sensitivity, 
especially in tumour samples with low viral copy numbers and therefore will fail to 
detect HPV in them [16]. Hybridisation signals may be faint or scant in some tumour 
samples making it difficult to interpret the results. Furthermore, the presence of 
significant background non-specific signal in some DNA ISH platforms can lead to 
false positives or obscure true positives [16]. There is a general consensus that the 
detection of transcriptionally active high-risk HPV E6/E7 (i.e detection of E6/E7 
mRNA), p16 overexpression and viral integration support a hypothesis of HPV 
mediated carcinogenesis. In that regard, it must be stressed that DNA ISH merely 
detects viral DNA and does not provide any information on the presence 
transcriptionally active high-risk HPV. It has been suggested that p16 IHC may be 
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employed as a first line assay which when positive can be followed up by either DNA 
ISH, PCR or both [283], [256], [255].  
 
In addition to the detection methods discussed above, newer assays for the detection of 
HPV in a diagnostic setting are continually being evaluated. In a breakthrough study, 
Wang et al. described a fluorescent RNA ISH assay, the RNAscope, to detect E6/E7 
mRNA of seven high-risk HPV genotypes (HPV16, 18, 31, 33, 35, 52, and 58) using a 
pool of genotype-specific probes in FFPE tissue samples [315]. The RNAscope has 
since been validated against the ‘gold standard’ q-RT PCR by a few groups with 
excellent analytical and performance in FFPE tissue samples of OPSCC [263], 
[306],[17]. 
 
Method of HPV 
detection 
Advantages Disadvantages 
p16 IHC  1. Easy to perform in labs. 
 2. Ease of interpretation of 
results. 
 3. Highly sensitive 
 4. Relatively inexpensive 
 
 1. Low specificity 
 2. Low validity in detecting HPV 
infection in non-oropharyngeal 
sites 
PCR  1. Highly sensitive and specific 
 2. Consensus primers can 
detect a wide spectrum of 
low-risk and high-risk HPV 
types 
 
 1. High sensitivity can lead to false 
negatives 
 2. Cannot distinguish between 
transcriptionally active and 
inactive HPV 
 3. Primers detect sequences in the L1 
region which may be lost upon 
integration of the virus into the 
host genome. Therefore, PCRs 
may give false negative results if 
the virus is in the integrated form 
 
qRT-PCR  1. Highly sensitive and specific  1. Requires intact RNA 
 2. Requires considerable technical 
expertise 
 3. Optimally performed on fresh 
frozen samples 
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In Situ Hybridization  1. Highly specific 
 2. Compatible with standard 
automated IHC platforms 
and FFPE sections 
 3. Results can be interpreted in 
context to the tissue 
 4. Results can be visualized on 
a standard microscope 
 1. Low sensitivity 
 2. Interpretation of results is 
sometimes difficult 
 
Table 1.7 Pros and cons of current HPV testing methods [16]. 
 
1.5.1 Standardising HPV testing practices  
 
Establishing high-risk HPV infection in HNSCC patients is crucial to determining its 
true prevalence, risk stratification, predicting clinical outcomes, patient counselling and 
understanding more about the natural history and molecular underpinnings of the 
disease.  However, HPV testing in routine practice and research settings is not directed 
by standardised guidelines and protocols. Working groups such as the American Joint 
Committee on Cancer (AJCC) and the Royal College of Pathologists, UK now 
recommend reporting HPV status for OPSCC in routine clinical practice [255]. Clinical 
guidelines for treatment of head and neck cancers only necessitates determination of 
HPV status for OPSCC as there is insufficient evidence to recommend testing at other 
subsites such as the oral cavity and the larynx [255]. In order to assign a diagnosis of 
HPV positivity, the clinical specimen must harbour high-risk HPV DNA along with 
evidence of viral oncogene expression. Assays currently employed for diagnosis such as 
PCR, DNA ISH, and p16 IHC vary considerably in detection rates making it difficult to 
compare the results of existing prevalence studies [28]. Furthermore, some of these tests 
are economically non-viable, riddled with technical challenges and are not governed by 
standardised guidelines for interpretation of results as seen in the case of p16 IHC. They 
are, therefore, selected based on the resources and facilities available to each laboratory 
[255]. In 2013, we conducted an online survey to gather information about practice 
trends related to HPV testing for HNSCC across the Scottish NHS centres (Unpublished 
data, see Appendix A). We found that most NHS centres were employing p16 IHC 
alone or in combination with PCR for routine detection of high-risk HPV in HNSCC. In 
addition, we noted that p16 IHC reporting criteria was inconsistent and disparate across 
the NHS boards. There is a general consensus that the aforementioned diagnostic assays 
cannot be used alone and must be used in combination for optimal HPV status 
determination. Where only FFPE samples are available, a combination of p16 IHC and 
PCR/DNA ISH is recommended [256]. While such a diagnostic algorithm can be easily 
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adopted by most pathology laboratories, the techniques, their protocols and reporting 
criteria must be standardised and bound by stringent quality assurance measures [256].  
1.5.2  Identification of novel markers of high-risk HPV-related HNSCC 
 
In cancer research and diagnostics, biomarkers are invaluable tools to identify the 
presence of a tumour, to determine patient prognosis and for treatment selection. 
Personalised medicine employing predictive markers could improve outcomes and 
encourage better treatment planning. In HNSCC, a definitive example of disease 
management with the help of biological markers is the targeting of EGFR with the 
monoclonal antibody, Cetuximab [20]. Extensive studies on cervical carcinogenesis 
have led to the identification of certain host molecules, involved in cell cycle regulation, 
which are altered by the HPV oncoproteins [244], [287]. These candidate biomarkers 
have shown promise in improving diagnostic accuracy for cervical cancer. 
Unfortunately, biomarker studies on HNSCC related to high-risk HPV are few and far 
in between.  
 
Detection of viral E6/E7 oncogene transcripts is regarded as the gold standard for the 
presence of clinically relevant high-risk HPV infection. Detection of E6/E7 mRNA has, 
however, proven to be very challenging using the conventional methods [17].  In order 
to establish a causal link between the virus and HNSCC, pathologists must be able to 
review the specimen and assess the marker within the tissue microenvironment of 
clinical specimens.  Recent advances in HPV biomarker detection like the visualisation 
of E6/E7 mRNA using RNA ISH (RNAscope) have shown promise in providing a 
highly sensitive and specific platform for detection of HPV biomarkers in HNSCC 
samples [263], [28].  
  
Investigators have also sought to identify alternate biomarkers for clinical assessment of 
HPV-related HNSCC. For instance, in a study conducted by Liang et al. in 2012, the 
authors attempted to establish a correlation between serological markers of HPV 
infection and HNSCC.  The presence of antibodies to HPV-16 L1, E6 and E7 was 
determined for 488 patients with HNSCC.  Immunohistochemical analysis of p16 
expression was determined in a subset of 233 cases and the presence of HPV-16 DNA 
was determined by PCR in a subset of 179 cases. Each biomarker was considered 
individually in the subset of patients studied for all endpoints. The authors found that 
seropositivity for E6 and E7 proteins was significantly associated with enhanced overall 
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survival in oropharyngeal cancer both as a single assay and in combination with HPV 
DNA PCR [170]. In another example, Mroz et al. examined next generation sequencing 
data and associated clinical records of a cohort of 302 HNSCC patients with 32 HPV-
positive cases. The researchers found that mutant-allele tumour heterogeneity (MATH) 
scores for HPV-positive tumours were lower compared to HPV-negative HNSCC 
patients [208]. Intra-tumour heterogeneity or variation between tumour cells within a 
patient’s tumour is often a source of treatment resistance and failure. MATH is a marker 
of intra-tumour heterogeneity based on tumour next generation exome sequencing and 
is an indicator of poor outcome [257]. Thus, MATH scores in HPV-positive tumours 
indicate a more homogeneous tumour and improved clinical outcomes. 
 
1.6 Molecular targets of high-risk HPV and their validity as 
biomarkers 
 
The E6 and E7 high-risk viral oncoproteins promote cellular transformation by 
interacting with and inactivating several cellular proteins, most importantly the tumour 
suppressor proteins p53 and pRB [64]. E6 is a small protein, with a molecular weight of 
18 kDa, composed of two zinc binding domains and a highly conserved C-terminal PDZ 
binding motif through which it interacts with its cellular binding partners [204]. On the 
other hand, E7 is a nuclear protein of 98 amino acids divided into three domains or 
conserved regions (CR), CR1, CR2 and CR3. CR1 is composed of amino acids 1–20, 
CR2 contains residues 21–39, and CR3 has 40–98 amino acid residues. E7 dimerizes in 
the CR3 domain via a zinc-finger motif which is essential for proper functioning of the 
protein [41].  
 
The ability of high-risk E7 to bind to members of the retinoblastoma protein (pRb) 
family, which play an important role in cell cycle regulation, is perhaps the most crucial 
property of this viral oncoprotein. Hypophosphorylated pRb binds to transcription 
factors of the E2F family and represses the transcription of certain cell cycle genes. 
When cells progress from G0 through G1 to S-phase, pRb gets hyperphosphorylated by 
G1 cyclin–dependent kinases, releasing the transcription factor E2F, which in turn 
activates genes involved in DNA synthesis and cell cycle progression [72]. E7 binds to 
hypophosphorylated pRb and thereby induces cells to enter into premature S-phase by 
disrupting Rb-E2F complexes [123], [238], [327]. E7 also contributes to growth 
stimulation of infected cells by interfering with the inhibitory activities of cyclin kinase 
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inhibitors p21 and p27 [330]. E7 also associates with and influences other cellular 
proteins (Table 1.8).  
 
 
Binding partner 
 
 
Consequence of interaction 
Activator protein (AP1) family members Abrogation of interferon regulatory factor-1 (IRF-
1) transcriptional activity 
c-myc 
 
Enhancement of c-myc-induced transcription 
Insulin growth factor binding protein-3 
(IGFBP3) 
 
Anti-apoptotic effect 
Stimulation of cell proliferation 
p21 
 
Growth stimulation via deregulation of cell cycle 
 
p27 Growth stimulation via deregulation of cell cycle 
 
Subunit4 ATPase pRb degradation via proteasome 
 
Table 1.8 Molecular interactions of HPV oncoprotein E7 [23]. Besides its interaction with the pRB 
protein, the E7 oncoprotein of high-risk HPV types target various other cellular proteins and 
disrupt multiple cellular pathways.   
 
The primary target of the E6 oncoprotein, p53, is a transcription factor which stimulates 
the expression of genes such as the cyclin dependent kinase inhibitor (CDK1) which is 
involved in cell cycle arrest and apoptosis. The E6–p53 interaction is mediated by 
E6AP (E6 associated protein), an E3 ubiquitin ligase which facilitates binding of E6 to 
p53 leading to ubiquitin mediated degradation of the latter [265]. E6 binding of p53 also 
inhibits its translocation into the nucleus preventing it from activating or repressing 
target genes [201]. 
 
The E6 protein also contributes to carcinogenesis by disrupting multiple cellular 
pathways, one of which is mediated through its interaction with PDZ (Postsynaptic 
density 95, PSD-85; Discs large, Dlg; Zonula Occludens-1, ZO-1) domain proteins 
[191]. A study conducted by Simonson et al. in an E6 transgenic mouse model showed 
that interaction of E6 with its PDZ domain partners induced spontaneous tumours and 
contributed to the promotion stage of skin carcinogenesis, suggesting that the ability of 
E6 to target PDZ proteins is an important step in tumourigenesis [281]. HPV E6 
proteins interact with a large number of PDZ domain containing cell proteins through 
their C- terminal PDZ binding motif. Whether this interaction is always mediated by 
E6AP is unclear. For example, Grm and Banks [109] reported that E6 degradation of 
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Dlg and MAG1 family of proteins is E6AP independent in vitro, while a study 
conducted by Kuballa et al. [151] in 2007 showed that E6 mediated degradation of Dlg 
depends on the presence of E6AP within cells. Apart from the interactions discussed 
above, the E6 oncoproteins also target other molecules to disrupt the normal functioning 
of cells (Table 1.9).  
 
 
Binding partner 
 
 
Consequence of interaction 
Pro-apoptotic protein Bak 
 
Anti-apoptotic effect 
Pro-apoptotic protein Bax  
Anti-apoptotic effect 
 
CREB binding protein (CBP/p300) 
 
Downregulation of p53-dependent transcription. 
c-myc 
 
Prevention of myc-induced apoptosis. 
Increases hTert transcription and telomerase 
activity. 
hDlg Deregulation of cell cycle. 
Loss of cell differentiation. 
hScrib Inﬂuence on cell adhesion and polarity 
Paxillin 
 
Disruption of actin cytoskeleton and cell matrix 
Interactions 
 
Table 1.9 Molecular interactions of HPV oncoprotein E6 [23]. The E6 oncoprotein of high-risk 
HPV types promotes carcinogenesis by targeting various cellular proteins and disrupting multiple 
cellular pathways.   
 
It is evident that malignant transformation of epithelial tissues by high-risk HPV 
involves multiple cellular pathways, all of which require overexpression of E6 and E7. 
Naturally then, E6 and E7 proteins have been the main focus of HPV screening, 
diagnostic and prevention methods. Diagnostic methods such as PCR and qRT-PCR 
rely on the detection of the E6/E7 genes and mRNAs respectively. E6 and E7 proteins 
are also primary targets in the development of therapeutic HPV vaccines and gene 
therapy [184], [277].  
 
1.6.1 Impact of high-risk HPV E6 on PDZ domain proteins  
 
Epithelial cells have a characteristic polarised architecture and are bound by specialised 
cell-cell junctions, including desmosomes, tight and adherens junctions [317]. This cell 
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polarity plays an important role in the organisation of signal transduction pathways that 
control important cellular processes such as proliferation, motility, differentiation and 
apoptosis and is maintained by protein complexes namely the Crumbs, Par and Scribble 
complexes [245], [156]. The Crumbs complex, made up of Crumbs, Pals1 (protein 
associated with Lin seven 1) and PatJ (PALS1-associated tight junction protein) 
maintains apico-basal polarity [245]. The Par complex which consists of Par3, Cdc42, 
Par6 and atypical protein kinase C (aPKC) is a dynamic complex and also interacts with 
the Crumbs complex. Scaffolding proteins Scribble (Scribbled planar cell polarity 
protein or Scrib), Dlg and Hugl form the Scribble complex which maintains basolateral 
polarity [245]. Loss of cell polarity, either through degradation or mislocalisation of the 
component proteins, is a key step in the transition of a benign tumour to a malignant 
one. It may lead to mislocalisation of receptors causing aberrant signalling or a 
redistribution of cell adhesion molecules promoting Epithelial-Mesenchymal-Transition 
(EMT). It may also lead to altered distribution of matrix metalloproteinases at cell 
surfaces promoting cell invasion and migration [104].  
 
Cell polarity is dependent on the correct spatio-temporal regulation of the expression 
levels of the cell polarity regulators many of which are PDZ domain containing proteins 
[89]. The PDZ domains, consisting of approximately 80-90 amino acid residues, serve 
as scaffolds for protein assembly and interactions. They have a well-defined interaction 
“pocket” which can be filled by a PDZ-binding motif (PBM) “ligand”. The PDZ-
binding motifs are specific sequences often located at the carboxyl terminus of certain 
proteins and facilitate interactions with PDZ domains [213]. Therefore, PDZ domain 
proteins are vital to cell polarity and the formation of adherens and tight junctions, 
molecular scaffolding for assembly of protein complexes and tumour suppressor 
activity [53], [80]. For instance, Dlg1 and PATJ, both PDZ domain proteins, are 
important in the formation of anterior posterior polarity in T cells and epithelial cells 
[278], [150]. The role of Dlg1 in limiting cell proliferation in Drosophila is indicative of 
a parallel function as tumour suppressor in mammalian cells. The loss of the Scribbled 
planar cell polarity protein (Scrib), a similar cell polarity protein, has been associated 
with tumour progression and invasiveness [125].  
 
PDZ domain containing proteins are common targets for inactivation by oncogenic 
viruses [24]. A unique feature of the E6 proteins of high-risk HPVs is the presence of a 
highly conserved class I –PBM located at the C-terminus. In contrast, PBMs are not 
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present in the E6 proteins of low-risk HPV types indicating that the PBM is a molecular 
signature for the malignant potential of high-risk HPV types [137], [82]. Furthermore, 
PBMs also appear to play an important role in the viral life cycle especially in the 
maintenance of viral copy numbers and of viral DNA as episomes in undifferentiated 
cells [162]. Through its C-terminal PBM, the E6 oncoprotein can interact with several 
PDZ domain proteins. Such interactions often interfere with the establishment of 
epithelial cell polarity and lead to loss of epithelial cell organisation thus contributing to 
malignancy [10]. One of the first PDZ targets of high-risk HPV E6 to be reported is 
hDlg1. It was found that degradation of hDlg1 by E6 oncoprotein contributed to 
epithelial cell proliferation and dysplasia in cervical carcinogenesis [10]. Apart from 
Dlg, several other PDZ domain substrates of high-risk HPV E6 have been described and 
these interactions affect diverse consequences ranging from loss of cell polarity and 
cell–cell attachment, and de-regulation of various cell signalling pathways (Table 1.10).  
 
Protein Function Effect on the target 
protein 
Membrane Associated 
Guanylate Kinase Inverted 
(MAGI) group of proteins 
Cell Polarity 
Tumour Suppressor 
PTEN localisation to membrane 
Ubiqutination and 
proteasomal degradation 
Multiple PDZ domain 
protein-1 (MUPP-1) 
Scaffold Protein Ubiqutination and 
proteasomal degradation 
PATJ Tight junction formation integrity Ubiqutination and 
proteasomal degradation 
PSD95 Signalling complex scaffold at synaptic 
junction 
Ubiqutination and  
proteasomal degradation 
NHERF1/EBP50 PI3K/AKT signalling Ubiqutination and  
proteasomal degradation 
TIP-2/GIPC (Tax 
Interacting Protein, clone 
2/GAIP Interacting Protein, 
C terminus) 
TGFβ signalling Ubiqutination and  
proteasomal degradation 
Cystic fibrosis 
transmembrane 
conductance regulator-
associated ligand (CAL) 
 
Intracellular trafficking Transcriptional 
repression 
 
Table 1.10 Functions and outcomes of PDZ domain substrates of the high-risk HPV E6 oncoprotein 
[302]. The E6 oncoprotein of high-risk HPV types interact with and interfere with the function of 
several PDZ domain proteins to affect diverse consequences ranging from loss of cell polarity and 
cell-cell attachments to deregulation of various cell signalling pathways.  
 
Interestingly, the affinity with which high-risk E6 proteins target their substrates is 
dependent on their PBM and minor alterations therein. For instance, hDlg is 
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preferentially targeted by HPV-18 E6 while hScrib is targeted by HPV-16 E6 [302]. 
Furthermore, E6 preferentially targets specific cellular pools of PDZ domain containing 
proteins for proteasome degradation [191]. 
1.7 Ezrin-Radixin-Moesin Binding Protein 50 
 
The focus of this thesis is a PDZ domain containing substrate of the high-risk HPV E6 
protein called Ezrin-Radixin-Moesin Binding Protein 50 (EBP50). EBP50 was first 
identified as a cofactor for inhibition of the Na+/H+ exchanger 3 by PKA (Protein 
Kinase A) in the renal brush border membrane and was also found to associate with 
high affinity to members of the ERM protein family (Ezrin-Radixin-Moesin) [320], 
[249] The ERM proteins play a crucial role in the organisation of complex membrane 
domains by interacting with transmembrane proteins and the underlying cytoskeleton 
[81]. EBP50 stabilises the ERM proteins at the plasma membrane, serving to facilitate 
their role in strengthening the cell cortex and regulating signal transduction pathways. It 
also functions as a molecular scaffold, promoting the assembly of macromolecular 
protein complexes at the apical membrane of epithelial cells. For example, the 
stabilisation of membrane receptors like PDGFR (Platelet Derived Growth Factor) and 
G protein coupled receptors and the turnover of ion transport proteins like CFTR 
(Cystic Fibrosis Transmembrane Regulator) is mediated via their interaction with 
EBP50 [95]. 
 
The structure of EBP50 comprises of tandem and homologous PDZ domains in which 
amino acids 11-97 constitute PDZI and amino acids 150-237 constitute PDZ II. The C-
terminal ERM binding region (EB) is made up of 30 amino acids. EBP50 interacts with 
more than 30 proteins, some of which have been implicated in human diseases such as 
cystic fibrosis, chronic kidney disease and cancer [95], [94]. Most protein-protein 
interactions takes place through PDZ I (Figure 1.4). However, some proteins bind 
specifically to PDZ II [206]. EBP50 normally adopts an intramolecular, folded 
conformation in which the C-terminal EB region binds to the PDZ II masking the 
interaction of this domain with its binding partners [206]. This head-to-tail folding is 
facilitated by the presence of a consensus PDZ motif in the EB region of EBP50 (Figure 
1.4). The ERM proteins bind to the EB region of the EBP50 disrupting the folded 
conformation and thereby allowing the association of proteins to the PDZ domains to 
form macromolecular protein complexes [15]. EBP50 interactions with its protein 
partners are regulated by phosphorylation. For example, Serine 289 (Ser 289) is 
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phosphorylated by GRK6A (G protein coupled receptor kinase A) which binds to PDZ I 
of EBP50. Additionally, EBP50 is phosphorylated at Serine 279 (Ser279) and Serine 
301(Ser301) by cyclin dependent kinase, Cdc2 [115]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Structure of EBP50 (inactive and active conformations). EBP50 comprises of tandem 
and homologous PDZ domains, PDZ1 and PDZII, and a C-terminal ERM binding region (EB). 
Most protein interactions take place through PDZ1 (GRK6A is shown binding to PDZ1). EBP50 
normally adopts an intramolecular, folded conformation in which the C-terminal EB region binds 
to the PDZ II masking the interaction of this domain with its binding partners. Unfolding of this 
closed conformation is facilitated by binding of ERM proteins to the EB region of the EBP50 and 
thereby allowing the association of proteins to the PDZ domains to form protein complexes. 
 
1.7.1 The role of EBP50 in cancer 
 
It has been widely speculated that EBP50 is an important player in cancer. However, its 
exact role in tumourigenesis is controversial. Under physiological conditions EBP50 
localises to the apical membrane of polarised epithelial cells where it stabilises 
transmembrane receptors and junctional complexes through interactions with its PDZ 
domains and with ERM proteins through the EB region [205]. Aberrant EBP50 
expression has been observed in numerous malignant tumours including breast cancer, 
colorectal cancer, and hepatocellular carcinoma with EBP50 reported to be either absent 
or overexpressed in an altered intracellular distribution [288], [114], [276]. Such 
expression patterns led to a postulation that EBP50 may act as a tumour suppressor 
when it is localized at the plasma membrane and as an oncogenic protein when it is 
localized in the cytoplasm [95]. A study conducted by Molina et al. revealed that 
EB  
PDZ I  
PDZ II  
EBP50 closed 
conformation 
Binding of Ezrin to EB 
region 
PDZ I  PDZ II  EB  
EBP50 open 
conformation 
GRK6A Ezrin Radixin 
Moesin 
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EBP50 was mislocalised from the plasma membrane to the cytoplasm in Glioblastoma 
Multiforme resulting in destabilisation and inactivation of PTEN (Phosphatase and 
tensin homologue), a key suppressor of the PI3 kinase/ Akt pathway [203]. In another 
study, conducted on mouse embryonic fibroblasts, Kriemann et al. show that cortical 
stabilisation of β-catenin by EBP50 is essential to suppress anchorage independent 
growth [146]. These studies support a tumour suppressor role of EBP50. In contrast, 
Shibata et al. noted overexpression of EBP50 in hepatocellular carcinomas. 
Furthermore, they observed that EBP50 overexpression promoted Wnt signalling by 
enhancing β-catenin/TCF mediated transcriptional activation [276]. An overexpression 
of EBP50 with relocalisation to the cytoplasm was observed in Estrogen Receptor (ER) 
positive breast cancers where it was associated with metastatic progression and poor 
prognosis [94]. The EBP50 gene promoter contains Estrogen Response Elements (ERE) 
which might explain increased expression in estrogen receptor positive breast tumours 
[73]. These studies indicate that overexpression of EBP50 may have an oncogenic role 
and may also be associated with tumour stage, metastasis and poor prognosis. The 
contrasting reports from these studies indicate a possible dual role of EBP50 as an 
oncogene and tumour suppressor depending on its localisation at the plasma membrane 
or its redistribution to the cytoplasm. Indeed, Georgescu et al. have proposed a 
reconciliatory model to illustrate the involvement of EBP50 in cancer. According to the 
authors, EBP50 serves as a tumour suppressor in normal cells by recruiting and 
stabilising membrane protein complexes including PTEN tumour suppressor and β-
catenin thereby restricting signalling downstream of growth factor receptors and 
merging β-catenin/E-cadherin complexes at the plasma membrane. By recruiting PTEN 
to the membrane, EBP50 facilitates the formation of a complex by bridging PTEN to 
PDGFR. This restricts the activation of the PI3K (Phosphoinositide 3 kinase) pathway 
following activation by PDGF (platelet derived growth factor [94]. Disruption or 
absence of EBP50 at the plasma membrane could interfere with its growth suppressive 
effects as evidenced by prolonged activation of the PI3K pathway and increased 
migration of MEF cells (mouse embryonic fibroblasts) in response to PDGF [296]. 
Although, the oncogenic effect of EBP50 when it is overexpressed in the cytoplasm of 
tumours requires further elucidation, it is likely to stem from a failure to consolidate 
protein complexes at the plasma membrane or an organisation of complexes with 
different ligands in the cytoplasm [95].  
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1.7.2 Mechanism of EBP50 regulation by high-risk HPV 
 
The discovery of EBP50 and its role in carcinogenesis, coupled with the knowledge that 
PDZ domain containing proteins are targeted by high-risk HPV E6 proteins, led to 
speculations that EBP50 might in fact be a substrate of high- risk HPV E6 oncoprotein. 
Accardi and colleagues were the first to investigate this possibility and the authors 
found that HPV-16 E6 associated with EBP50 via the C- terminal PBM and promoted 
its degradation in vitro [2]. Surprisingly, a similar interaction was absent between HPV-
18 E6 and EBP50, despite possessing nearly identical PBMs,  indicating  that EBP50 
degradation was exclusive to the E6 oncoprotein of HPV-16 and also reiterating 
previous reports that E6 proteins do not target their PDZ domain containing substrates 
with equal affinity [2], [302]. The authors also noted that degradation of EBP50 was 
assisted by the E7 oncoprotein which by activation of the cyclin-dependent kinase 
complexes, promoted the accumulation of a phosphorylated form of EBP50, which was 
preferentially targeted by E6. As with other PDZ targets of the E6 oncoprotein, 
degradation of EBP50 was also mediated by the E6AP ubiquitin ligase via the 
proteasome pathway [2]. Results of in vivo studies showed that EBP50 protein levels 
were downregulated in HPV-16 positive cervical cancer derived cell lines; SiHa and 
CaSki as well as in cervical intraepithelial neoplasia (CIN) corroborated the in vitro 
findings. Furthermore, HPV16 E6 mediated degradation of EBP50 correlated with the 
activation of the phosphatidylinositol-3′-OH kinase (PI3K)/AKT signalling pathway[2].  
 
 Data from our lab has also identified EBP50 as a novel target for high-risk HPV-16 E6 
oncoprotein [237] and our findings are consistent with the report published by Accardi 
et al. Results of in vitro studies on H1299 cells (human non-small cell lung carcinoma 
cell line) transfected with high-risk HPV-16 E6 expression plasmids showed decreased 
EBP50 levels. On the contrary, the levels of EBP50 protein remained relatively 
unchanged following transfection of H1299 cells with control plasmids pcDNA3 and 
pcDNA3 Hdm2 suggesting that degradation of EBP50 was brought about by high-risk 
HPV-16 E6.  
 
It is evident that HPV-16 interferes with EBP50 function by targeting it for proteasome 
mediated degradation. Data from the report published by Accardi et al. also indicate that 
EBP50 expression may be an early marker of cervical carcinogenesis [2]. Whether such 
a role exists for EBP50 in the development of HNSCC, a small proportion of which are 
associated with high-risk HPV, is a question that merits investigation. 
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1.7.3 Impact of EBP50 deregulation by high-risk HPV  
 
Given that there is currently very little information available on the biological impact of 
EBP50 regulation by the high-risk HPV E6 protein, we can only speculate based on 
extrapolation of results from studies on other well characterised E6 substrate PDZ 
domain proteins such as the MAGI family of proteins, hDlg1 and hScrib.  
 
High-risk E6 protein interaction with MAGI-1, a key component of epithelial tight 
junctions[212], offers a more probable conjecture for HPV- induced carcinogenesis in 
the context of PDZ domain protein targets. Findings of a systematic analysis by Kranjec 
and Banks indicate that the E6 proteins of HPV-16 and 18 target membrane bound 
forms of MAGI-1 resulting in the loss of epithelial tight junctions [145]. Using ZO-1 
(zonula occludens) a marker of tight junction integrity, they demonstrated that these 
junctions are mostly absent in HPV-18-positive HeLa cells and that ablation of E6 
expression results in a re-accumulation of MAGI-1 at the cell membrane and restoration 
of tight junctions [145]. Tight junctions play an important role in keratinocyte 
differentiation by promoting exit from the cell cycle [3]. Additionally, they participate 
directly in the regulation of cell proliferation by modulating signalling cascades such as 
mitogen-activated protein kinase (MAPK), PKB/Akt, and RhoA signalling [168], [142], 
[3]. Thus, binding to MAGI-1 through its PBM motif, may allow the virus to stabilise 
E6 protein expression in the early stages of its life cycle [226], [213]. Additionally, 
targeting MAGI-1 for proteasome mediated degradation allows the virus to undermine 
tight junctions and promote cancer progression by inducing EMT like morphological 
changes in the epithelial cells [213].  
 
PDZ domain containing proteins hDlg and hScrib are key components of the epithelial 
adherens junctions and play an important role as tumour suppressors [213]. By binding 
to hDlg and hScrib in the early stages of the viral life cycle through its E6 PBM, HPV-
16 has been shown to be able to persist in its episomal state [226]. The E6 oncoprotein 
appears to differentially regulate the localisation and expression of both hDlg and 
hScrib as evidenced in the progression of cervical cancer from cervical intraepithelial 
lesions to invasive cancer. A redistribution of these proteins from sites of cell-cell 
contact to the cytoplasm is observed in precursor lesions followed by a gradual 
reduction in expression and complete loss in invasive cancer [215].  Interestingly, it 
appears that E6 preferentially targets a specific sub-cellular pool of hDlg.  In a study 
conducted by Massimi et al., the authors found that E6 specifically targeted nuclear 
 43 
 
pools of the protein rather than those found within multiprotein complexes at cell-cell 
junctions [191]. It has been postulated that certain post-translational modifications of 
these PDZ domain proteins, more specifically phosphorylation, affect their localisation 
and make them more susceptible to degradation by the E6 oncoprotein. For instance, 
when phosphorylated by CDK1 and CDK2 at Ser158 and Ser442, hDlg accumulates in 
the nucleus making it more susceptible to the E6 protein [216]. The biological 
consequences of sub-cellular location specific PDZ protein-E6 interactions are unclear. 
Thus, interaction of high-risk HPV E6 with PDZ domain proteins allows the virus to 
sustain a chronic persistent infection in the host cell, abrogates the tumour suppressive 
function of these proteins, induces loss of cell-cell contact by undermining the integrity 
of tight and adherens junctions and promotes cell proliferation and migration.  
 
EBP50 functions as a scaffolding molecule to stabilise β-catenin-E-cadherin complexes 
at the plasma membrane and contributes to the integrity of adherens junctions [146]. It 
also links tumour suppressor PTEN with PDGFR in a ternary complex which attenuates 
the activity of the PI3K/Akt pathway [95]. In the absence of evidence, a conjectural 
biological consequence of EBP50 degradation by the E6 protein is disruption of β-
catenin-E-cadherin complexes and the subsequent disintegration of adherens junctions 
in epithelial cells. It may also facilitate epithelial mesenchymal transition and increased 
cell migration and invasiveness [124]. Regulation or loss of EBP50 by E6 may also 
result in the prolonged activation of the PI3K/Akt pathway in response to PDGF 
stimulation.  
1.7.4 Current role of EBP50 as a biomarker 
 
As described in section 1.7.1, EBP50 appears to have a dual function depending on its 
subcellular distribution - that of a tumour suppressor protein when it is localised at the 
plasma membrane or an oncogene when it is shifted to the cytoplasm. Expression 
patterns and distribution of EBP50 have been studied by several authors in various 
human tumours employing different methodologies such as immunohistochemistry, ISH 
and immunofluorescence [285]. These studies show differential expression patterns and 
suggest an emerging role for EBP50 as a potential tumour marker.  
 
The earliest evidence with respect to EBP50 as a potential biomarker was provided by 
Shibata and colleagues. The authors found that EBP50 associated with β-catenin to 
promote Wnt signalling in hepatocellular carcinoma cell lines. The authors also noted 
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overexpression of EBP50 in surgical specimens of hepatocellular carcinoma suggesting 
that EBP50 may work with β - catenin to drive tumour formation in liver cancer [276]. 
Indeed, aberrant activation of Wnt/β-catenin signalling has been reported in a wide 
range of hepatocellular carcinomas [220].  
 
EBP50 expression has been studied extensively in breast cancer. A major cause of death 
in women, breast cancer has varied clinical outcomes and response to treatment. Loss of 
heterozygosity at the EBP50 gene locus is seen in more than 50% of the tumours and 
very rarely in other types of cancer. Although, differential EBP50 expression has been 
described in other cancers such as hepatocellular carcinoma and schwannoma, the data 
is most representative for breast cancer [14]. For instance, Cardone et al. analysed 
EBP50 expression in human breast tumours and contiguous normal tissues from the 
same patients and found that EBP50 was overexpressed in all the tumours when 
compared to the adjacent normal lobules [35]. In yet another study, Mangia et al. 
described a change in subcellular localisation of EBP50 wherein, EBP50 was mostly 
localised in the cytoplasm of epithelial cells in primary or metastatic tumours compared 
to membranous immunoreactivity seen in the luminal aspects of normal breast epithelial 
cells. Additionally, they also noted that cytoplasmic/membranous EBP50 expression 
ratio progressively increased from ductal carcinoma in situ to primary invasive cancer 
suggesting that it plays a role in breast cancer progression [187], [288]. It was also 
noted that EBP50 expression significantly increased with increasing tumour histological 
grade and indicated poorer prognosis in breast cancer [285]. 
 
In addition to hepatocellular carcinoma and breast cancer, the prognostic impact of 
EBP50 expression has been evaluated in other tumours such as gastric, pancreatic, 
colorectal, prostate cancer and glioblastomas (Table 1.11). 
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Type of cancer EBP50 expression 
pattern  
Clinical 
significance 
Reference 
Hepatocellular 
carcinoma 
↑↑ Indicates a tumour 
suppressor function 
by inhibiting 
anchorage 
independent growth 
in hepatocellular 
carcinoma cell lines 
Xiu-lan peng et 
al.[241] 
Breast cancer ↑↑ Increasing tumour 
histological grade, 
aggressive clinical 
behaviour, 
unfavourable 
prognosis, and 
increased tumour 
hypoxia 
Bellizi et al.[14] 
Gastric cancer ↑↑ Correlates with 
tumour size 
 
Xiao Guang et al. [183] 
Pancreatic cancer ↑↑ Cytoplasmic 
overexpression 
Indicates a tumour 
suppressor function 
by inhibiting 
uncontrolled cell 
growth and 
proliferation 
Ji Meng et al. [130] 
Colorectal cancer ↑↑ Cytoplasmic 
overexpression 
Loss of 
membranous 
staining from 
colorectal adenoma 
to colorectal cancer 
and cytoplasmic 
overexpression in 
colorectal cancer 
Hayashi et al.[114] 
Glioblastoma ↑↑ Cytoplasmic 
overexpression 
Loss of 
membranous 
staining from 
normal astrocytes to 
glioblastoma 
multiforme with 
cytoplasmic 
overexpression in 
the latter 
Molina et al.[203] 
Prostatic 
adenocarcinoma 
↓↓ Progressive decrease 
in membranous 
staining from benign 
disease to metastatic 
pancreatic cancer. 
Indicative of tumour 
suppressor function? 
Barthlow et al.[11] 
 
Table 1.11 EBP50 expression and its clinical significance in human cancers. The prognostic 
significance of EBP50 expression has been studied extensively in breast cancer. It has also been 
evaluated in hepatocellular carcinomas, gastric, pancreatic and colorectal cancers, glioblastomas 
and prostatic adenocarcinomas.  
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1.7.5 Study Objective:  Investigating the validity of EBP50 as a potential marker 
for HPV-related HNSCC 
 
HPV-mediated HNSCC has emerged as a significant health threat and poses unique 
epidemiological and biological challenges. Tumour HPV status has important 
implications in the determination of true disease prevalence, disease prognosis, its 
natural history and molecular pathogenesis. While HPV positivity is more commonly 
detected in OPSCC where it confers a survival advantage and improved treatment 
response in patients [84], its prevalence and clinical impact in other head and neck 
subsites remains largely unexplored.  Current head and neck cancer treatment regimens 
carry a significant risk of debilitating side-effects and morbidity prompting researchers 
to investigate less intensive therapeutic strategies for patients with HPV-related 
HNSCC. However, HPV risk stratification is impaired by a lack of standardised 
guidelines and robust testing methods for diagnosis and the unavailability of additional 
molecular markers. Furthermore, there is a dearth in our understanding of the molecular 
mechanisms underlying HPV driven tumour development in both oropharyngeal and 
non-oropharyngeal sites.   
 
As discussed earlier the E6 and E7 proteins of high-risk HPV promote carcinogenesis 
by disrupting multiple cellular processes, the most important cellular targets being the 
p53 and pRB proteins. Apart from these interactions, the HPV E6 oncoprotein also 
targets PDZ domain proteins which act as adaptors and stabilise protein complexes 
involved in cell signalling, cell-cell adhesion and cell polarity at the plasma membranes 
of cells [302]. E6 mediated degradation of PDZ domain proteins has been shown to 
result in aberrant cell signalling and disruption of epithelial cell-cell attachments 
possibly triggering invasion and metastasis [10] , [145]. Data from our lab indicates that 
the PDZ domain protein EBP50 is targeted for degradation by the high-risk HPV E6 
protein resulting in a downregulation of the protein levels in cells [237]. EBP50 has 
already emerged as a molecular marker in the development of breast cancer [94], 
colorectal cancer [114] and hepatocellular carcinoma [276] however, the possibility of 
this scaffolding protein  as a potential marker in HPV-related HNSCC has not been 
explored previously. Therefore, it was natural to base this thesis on the following 
hypothesis:  
 
 
 
The downregulation of EBP50 may contribute to HPV-mediated malignant 
transformation of epithelial tissues in the head and neck region making EBP50 a 
potential marker for HPV-related HNSCC.  
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 In particular, this study proposes to test whether EBP50 distribution is influenced by 
tumour HPV status in a sample population of HNSCC patients in Tayside, Scotland.  
 
The main objectives and specific aims of this study are:  
 
1. Determination of the incidence of high-risk HPV and its impact on clinical 
outcomes in a sample population of HNSCC patients in Tayside, Scotland. The 
study achieves this by - 
A) determining tumour HPV status of  a selected cohort of HNSCC patients 
 
B) determining the concordance between high-risk HPV DNA positivity and p16 
status in the cohort 
 
C) linking tumour HPV status to clinical outcomes such as survival and recurrence 
in the cohort. 
 
2. Evaluation of the validity of EBP50 as a novel marker for HPV-related HNSCC. 
This is done by - 
 
A) analysing differences in expression patterns of EBP50 in high-risk HPV-
negative and positive patient samples 
 
B) determining if there is a correlation between EBP50 expression patterns and 
clinical outcomes such as survival and recurrence.  
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Chapter 2 
RESEARCH METHODOLOGY 
2.1 Cell Culture 
2.1.1 Materials 
 
The 3T3 cell line, a fibroblast cell line derived from Swiss mouse embryonic tissue was 
a kind gift from Dr. Dorothy (Sam) Crouch (Unit of Cell and Molecular Biology, 
Dundee Dental School). The HaCaT cell line, derived from human keratinocytes was a 
kind gift from Professor Irwin McLean (Division of Molecular Medicine, University of 
Dundee) and was generated as described in Boukamp et al [22]. The SiHa cell line 
expressing Human Papillomavirus type 16 was a kind gift from Dr. Pamela Robertson 
(Division of Molecular Medicine, University of Dundee). The HeLa cell line expressing 
Human Papillomavirus type 18 was from Cancer Research UK, Lincoln’s Inn Fields, 
London, UK. 
 
Dulbecco’s Modified Essential Medium (DMEM) with high glucose and sodium 
pyruvate and heat inactivated Foetal Bovine Serum (HIFBS) were purchased from 
Invitrogen Life Science (3 Fountain Drive, Inchinnan Business Park, Paisley, UK PA4 
9RF).  Trypsin solution (2.5%) was purchased from Sigma Aldrich Company Ltd. (The 
Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT). Tissue culture dishes and 
plastics were from Thermo Fisher Scientific (Thermo Fisher Scientific, Nunc A/S, 
Kamstruprej 90, P.O Box 280. DK-4000, Roskilde, Denmark). The Mistral 1000 
centrifuge was procured from Measuring and Scientific Equipment (UK) Ltd (Worsley 
Bridge Road, Lower Sydenham, London, SE26 5AZ). 
 
2.1.2 Method 
 
All the cell lines were maintained in DMEM enriched with 10% HIFBS in 9 cm dishes. 
All culture incubations were performed in a humidified 5% CO2 incubator at 37°C. 
When the cell lines had reached desired density they were washed with Phosphate-
buffered saline (PBS) and detached from the surface of the culture dish using trypsin 
and centrifuge at 900 rpm for 5 min. The media was aspirated and the cell pellet was 
stored in a freezer at -20°C for use in genomic DNA extraction.  
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2.2 Extraction of genomic DNA from mammalian cell lines 
2.2.1 Materials 
 
The QIAGEN DNeasy Blood and Tissue Kit (Catalogue No. 69506) was a kind gift 
from Dr. David Edwards (Unit of Cell and Molecular Biology, Dundee Dental School) 
and was purchased from Qiagen (Qiagen House, Fleming Way, Crawley, West Sussex, 
RH10 9NQ). Molecular biology grade absolute ethanol (Catalogue No. BP2818-500) 
was purchased from Fisher-Scientific (Fair Lawn, New Jersey 07410). Phosphate 
Buffered Saline (PBS) tablets (Catalogue No. P4417-100TAB) was from Sigma-Aldrich 
Co. (3050 Spruce Street, St. Louis, MO 63103 USA).  
 
2.2.2 Method 
 
Each frozen cell pellet was allowed to thaw and genomic DNA was extracted using the 
QIAGEN DNeasy Blood and Tissue Kit according to the manufacturer’s standard 
protocol. Briefly, the cell pellet was re-suspended in PBS (200 µl) and Proteinase K (20 
µl). Buffer AL (200 µl) was added to the solution, mixed thoroughly with a vortex 
mixer for 10 sec followed by incubation at 56 °C in a water bath for 10 min.  Next, 
ethanol (200 µl) was added to the solution and mixed. The solution was transferred to a 
DNeasy mini spin column placed in a 2 ml collection tube and centrifuged at ≥ 6000 x g 
for 1 min.  After discarding the flow-through, Buffer AW1 (500 µl) was added to the 
spin column and centrifuged at ≥ 6000 x g for 1 min. Once again the flow-through was 
discarded and the DNeasy membrane was dried by adding Buffer AW2 to the spin 
column and centrifuging at ≥ 20,000 x g for 3 min. Finally, the DNA was eluted by 
placing the column in a clean collection tube and adding Buffer AE (200 µl) to the 
DNeasy membrane. The DNA concentration was measured and the DNA samples were 
stored at 2 – 4°C for downstream experiments. 
 
2.3 Sectioning of formalin-fixed paraffin-embedded tissue specimens 
for genomic DNA extraction 
 
2.3.1 Materials 
 
The microtome HM 320 was from Microm UK Ltd. (Commerce House, Telford Road, 
Bicester OX26 4LD). The microtome blades, MB DynaSharp 34°/80mm (Product No. 
12056679) was from Fisher Scientific Uk Ltd. (Bishop Meadow Road, Loughborough 
 50 
 
 
LE11 5RG). Trial FFPE specimens of oral squamous epithelial tissue were a kind gift 
from Dr. Kevin Davey (Dundee Dental School). Trial FFPE specimen of normal oral 
tissue was a kind gift from Dr. Neil Kernohan (Department of Pathology, Ninewells 
Hospital). Archival tissue blocks of head and neck squamous cell carcinoma were 
provided by the Tayside Tissue and Tumour Bank (TTB) following an approval by the 
Tissue Bank Committee (Reference No. TR000325). 
2.3.2 Method 
 
FFPE specimens of three different sizes (0.1 cm
2
, 0.5 cm
2
 and 1 cm
2
) were employed to 
compare protocols for DNA extraction and to determine the optimum thickness of tissue 
sections for downstream experiments. Whole tissue section curls (3 – 5) ranging from 5 
- 10 µm thickness each were cut from each specimen for DNA extraction PCR.  
 
Sectioning of archival FFPE specimens in this study was undertaken by Dr. Margaret 
Florence and Mrs. Valerie Wilson from Dundee Dental School. The archival tissue 
blocks were sectioned according to the standard laboratory protocol. H&E stained 
sections were prepared for each specimen prior to and following sectioning. Slides were 
inspected under the microscope to ensure the presence of tumour and the absence of 
tissue necrosis. Following optimisation of the DNA extraction protocol, five tissue 
section curls of 10 µm each were cut from archival tissue sample and collected in a 1.5 
ml Eppendorf for DNA extraction. Appropriate precautions such as cleaning the 
microtome and using fresh blades between specimens were taken during sectioning to 
avoid inter-block DNA contamination was taken during sectioning by. 
 
2.4 Genomic DNA extraction from formalin-fixed paraffin-
embedded tissues 
 
2.4.1 Protocol A: QIAamp DNA FFPE Tissue Kit 
 
2.4.1.1  Materials 
 
The QIAamp Formalin-fixed, paraffin embedded Tissue Kit (Catalogue No. 56404) was 
purchased from Qiagen (Qiagen House, Fleming Way, Crawley, West Sussex, RH10 
9NQ). Xylene (Catalogue No. 1029364) was from BDH Prolabo ® (VWR International 
Ltd. Hunter Boulevard, Magna Park, Lutterworth, Leicestershire LE17 4XN England).  
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2.4.1.2  Method 
 
Genomic DNA was extracted using the QIAamp DNA FFPE Tissue kit according to the 
manufacturer’s standard protocol. Briefly, excess paraffin was removed from the tissue 
sections with Xylene (1 ml) and 96 – 100% ethanol (1 ml). The resulting cell pellet was 
re-suspended in Buffer ATL (180 µl) and Proteinase K (20 µl). The sample was 
incubated once at 56°C for 1 hour for sample lysis and again at 90°C for 1 hour. 
Following lysis, Buffer AL (200 µl) and 96 – 100% ethanol (200 µl) were added to the 
sample and mixed thoroughly using a vortex mixer. The lysate was transferred to a 
QIAamp MinElute column and centrifuged at 6000 x g for 1 min. After discarding the 
flow through, Buffer AW1 (500 µl) was added to the spin column and centrifuged at 
6000 x g for 1 min. The flow through was discarded and Buffer AW2 (500 µl) was 
added to the column and centrifuged at 6000 x g for 1 min. Once again the flow 
thorough was discarded and the column was centrifuged at 20,000 x g for 3 min to dry 
the membrane.  The column was transferred to a clean collection tube and the DNA was 
eluted in Buffer ATE (100 µl) by centrifuging the column at 20, 000 x g for 1 min. The 
DNA concentration was measured and the DNA samples were stored at -20°C in a 
freezer.  
 
2.4.2  Protocol B: DNA Lysis Buffer (LC) 
2.4.2.1  Materials 
 
The Lysis Buffer (10 mM Tris HCL, 50 mM KCL, 2.5 mM MgCl2, 0.45% Tween; pH 
balanced to 8.2) was a kind gift from Dr. Susan Bray (Tayside Tissue and Tumour 
Bank, Ninewells Hospital, Dundee) and is part of the standard laboratory protocol 
followed by the Tayside Tumour and Tissue Bank. The heat block DRI- BLOCK DB 
2A was from Techne (Cambridge) Ltd. (Duxford, Cambridge CB2 4PZ).  
 
2.4.2.2  Method 
 
A working solution of the lysis buffer (400 µl) and proteinase K (4 µl) was prepared and 
kept on ice. Meanwhile, excess paraffin was removed from the tissue sections with 
xylene (1 ml) and 96 – 100% ethanol (1 ml). The working solution was added to the cell 
pellet and mixed thoroughly using a vortex mixer and the sample incubated in a water 
bath at 55°C for 2 hours. Next, the sample was centrifuged at 1000 x g for 1 min and 
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incubated at 95°C for 15 min. It was allowed to cool to room temperature before sodium 
acetate (3M, 0.1 volume) was added to the DNA sample and mixed using a vortex 
mixer. Ethanol (96 – 10%; 2 volumes) was added to the sample, mixed and incubated 
overnight in a freezer at -20°C. Next, the sample was centrifuged at 20,000 x g at 4°C 
for 15 min. The supernatant was discarded without disturbing the pellet and ethanol 
(70%; 500 µl) was added to the pellet. After incubation overnight at -20°C, the sample 
was centrifuged at 20,000 x g at 4°C for 2 min. The supernatant was discarded and the 
DNA air dried at room temperature. The DNA was dissolved in TE and stored at 2-4°C 
for use in subsequent experiments.   
 
2.5 Determination of DNA concentration 
2.5.1 Materials 
 
NanoVue Plus
TM
 spectrophotometer was from GE Healthcare Ltd. (Amersham Place, 
Little Chalfont, Buckinghamshire, HP7 9NA, UK).  
2.5.2 Method 
 
The DNA quantification was carried out according to the manufacturer’s standard 
protocol. Before each DNA sample was measured, the spectrophotometer was calibrated 
using a reference sample – usually the buffer that the DNA was eluted into. With the 
sampling head lifted to a vertical position, a small amount of the DNA sample (2 µl) 
was pipetted carefully onto the bottom measurement plate. The sampling head was 
lowered and a recording was initiated according to the parameters set on the 
spectrophotometer. After each measurement was completed, the upper and lower plates 
were wiped clean using a soft laboratory tissue.  
 
2.6 Polymerase Chain Reaction (PCR) 
2.6.1 Materials 
 
Techne TC-412 thermal cycler was purchased from Keison Prodcuts (P.O Box 2124, 
Chelmsford, Essex CM1 3UP, England). The Techne Progene thermal cycler was from 
Techne (Cambridge) Ltd. (Duxford, Cambridge CB2 4PZ).  
 
Full length clones of HPV types 33 and 52 were employed as positive controls in 
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addition to DNA extracts from SiHa and Hela cell lines. DNA plasmids containing HPV 
33 (HPV 33 in pBR322 at position 2797) and HPV 52 (HPV 52 in pUC19 at position 
7559) were kindly supplied by Dr. Gerard Orth and Dr. Wayne Lancaster (International 
HPV reference Center, Karolinska Institutet, Stockholm). The consensus and type-
specific oligonucleotides were purchased from Eurofins MWG Operon (Anzinger 
Str.7a, 85560 Ebersberg, Germany).  MyTaq DNA polymerase (Catalogue No. BIO-
21106) was purchased from Bioline Reagents Ltd. (Unit 16, The Edge Business Centre, 
Humber Road, London NW2 6EW).  
 
2.6.2 Method 
 
Working stocks of the oligonucleotides (20 µM) were prepared in 1 x TE buffer. 
Consensus and type-specific primers pairs employed in the amplification of various 
HPV related genes are described in Tables 2.1 and 2. 2 
 
 
  
 
Table 2.1 List of consensus primers employed in the detection and amplification of the Human β-
globin gene, the HPV L1 and E1 genes. Oligonucleotide sequences of forward and reverse primers, 
their position on the genome and the PCR product sizes are also shown. 
 
 
 
  
Primer Oligonucleotide sequence (5’ – 3’) Target gene Nucleotide 
position on the 
genome 
Amplicon 
length 
(bp) 
GH20 GAAGAGCCAAGGACAGGTAC Human β- 
globin 
70400-70419 268 
[251]
 
PC04 CAACTTCATCCACGTTCACC Human β-
globin 
70648-70669 
MY09 CGTCCMARRGGAWACTGATC HPV L1 7150-7170 450 
[126]
 
MY011 GCMCAGGGWCATAAYAATGG HPV L1 6722-6742 
CPI TTATCA(T/A)ATGCCCA(T/C)TG
TACCAT 
HPV E1 1942-1964 188 
[304]
 
CPIIG ATGTTAAT(A/T)(G/C)AGCC 
(A/T)CCAAAATT 
HPV E1 1777-1799 
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Table 2.2 List of type-specific primers employed in the detection and amplification of the E7 genes 
of HPV 16, 18, 33 and 52. The oligonucleotide sequences of forward and reverse primers, their 
position on the genome and the PCR product sizes are also shown. 
 
 
PCR was carried out in 50 µl reactions with 100 ng of template DNA prepared as 
described in Section 2.3. The master mix was made up as follows: extracted template 
DNA (100 ng), 5 x MyTaq Reaction Buffer (5 mM dNTPs, 15 mM MgCl2, stabilisers 
and enhancers) 10 µl, Forward primer (20 µM) 1µl, Reverse primer (20 µM) 1 µl, 
MyTaq DNA Polymerase 0.5 µl and ddH2O upto 50 µl. The PCR reaction mixtures 
were placed in a thermal cycler and incubated for 3 min at 94
o
C for DNA denaturation. 
Next, 35 cycles of amplification were performed with each cycle consisting of a 
denaturation step at  94
o
C for 15 seconds, followed by primer annealing at the 
temperatures described in Table 2.3, and a chain elongation step at 72
o
C for 15 seconds. 
A final elongation was performed at 72
o
C for 5 min. Depending on the size of the 
amplicon, the PCR products were run on a 1%, 1.5% or 2% gels prepared as described 
in Section 2.7. 
 
 
 
 
 
 
 
Primer Forward 
(5’ – 3’) 
Reverse 
(5’ – 3’) 
Target gene Nucleotide 
position on the 
genome 
Amplicon  
length (bp) 
Primer 
343 & 
344 
GATGAAAT
AGATGGTC
CAGC 
GCTTTGTAC
GCACAACC
GAAGC 
HPV 16 E7 106 – 125 
192 - 213 
108 
[313]
 
Primer 
345 & 
346 
AAGAAAAC
GATGAAAT
AGATGGA 
GGCTTCAC
ACTTACAA
CACA 
HPV 18 E7 107 – 129 
191 210 
104 
[313]
 
Primer 
347 & 
348 
TGAGGATG
AAGGCTTG
GACC 
TGACACAT
AAACGAAC
TGTG 
HPV 33 E7 99 -118 
189 -208 
110 
[313]
 
Primer 
349 & 
350 
GCAGAACA
AGCCACAA
GCAA 
TAGAGTAC
GAAGGTCC
GTCG 
HPV 52 E7 139 – 158 
243 - 224 
105 
[313]
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Table 2.3 List of consensus and type-specific primers employed in the amplification and detection 
of the Human β-globin gene and various HPV-related genes along with their annealing 
temperatures and time. 
 
 
2.7 Agarose gel electrophoresis  
2.7.1  Materials 
 
Molecular grade Ultra Pure
TM
 Agarose (Catalogue No. 15510-027) was purchased from 
Invitrogen Life Science (3 Fountain Drive, Inchinnan Business Park, Paisley, UK PA4 
9RF). The nucleic acid stain, Gel Red
TM
 (Catalogue No.41003 -T) was purchased from 
Biotium, Inc. (3159 Corporate Place, Hayward, CA 94545). The DNA marker 
HyperLadder
TM 
100bp
 
Plus and 5 X sample loading buffer (Catalogue No. BIO-33056) 
were purchased from Bioline Reagents Ltd. (Unit 16, The Edge Business Centre, 
Humber Road, London NW2 6EW).  The running buffer 1 x TAE was prepared as in 
Appendix C. 
 
 
The electrophoresis power supply units, EPS 3500/200, were from Pharmacia Biotech 
AB (S-751 82 Uppsala, Sweden). The Horizon 58 gel casting systems were from Life 
Technologies Ltd. (3 Fountain Drive, Inchinnan Business Park, Paisley UK). The 
imaging system used for visualisation of agarose gels, Bio-Rad CHEMI DOC
TM
 MP 
(Catalogue No. 170-8280) was purchased from Bio-Rad Laboratories Ltd. Bio-Rad 
House, Maxted Road, Hemel Hempstead, Hertfordshire HP2 7DX).  
Primer pair Annealing temperature Time 
GH20/PC04 58
o
C 15 seconds 
MY09/MY011 50
o
C 15 seconds 
CPI/CPIIG 52
o
C 15 seconds 
Primer 343/344 54
o
C 15 seconds 
Primer 345/346 54
o
C 15 seconds 
Primer 347/348 56
o
C 15 seconds 
Primer 349/350 56
o
C 15 seconds 
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2.7.2  Method 
 
Agarose gels (1%/1.5%/2%) were prepared by weighing out agarose (1 gm/1.5 gm/2 
gm) in a conical flask. Buffer 1 x TAE (100 ml) was added to the agarose and the 
solution was heated in a microwave for 1 min. Meanwhile, a gel casting tank was 
prepared and an appropriate sized comb was inserted. When the agarose had completely 
dissolved, Gel Red stain (6 µl) was added and the cooled solution was poured into the 
prepared casting tank. The gel was allowed to set before topping with 1x running buffer 
TAE. Meanwhile, DNA samples were prepared for loading by mixing the PCR products 
(5 µl) with loading dye (2 µl). When the gel was ready the comb was removed, the 
DNA samples and a standard ladder loaded into the wells of the gel and electrophoresed 
at 80V for 50 min. The DNA bands were visualised using the Bio-Rad gel imaging 
system. 
 
2.8 Purification of PCR products for DNA sequencing 
2.8.1 Materials 
 
QIAquick Gel Extraction Kit (Catalogue No. 28704) was purchased from Qiagen 
(Qiagen House, Fleming Way, Crawley, West Sussex, RH10 9NQ).  Isopropanol was 
purchased from BDH Prolabo ® (VWR International Ltd. Hunter Boulevard, Magna 
Park, Lutterworth, Leicestershire LE17 4XN England).   
 
2.8.2 Method 
 
 PCR products were purified using the QIAquick Gel Extraction Kit according to the 
manufacturer’s standard protocol. Briefly, the DNA fragments from the agarose gel 
were excised and weighed in a colourless tube.  The agarose was solubilised with the 
addition of Buffer QG (3 volumes buffer: 1 volume gel) followed by incubation at 50°C 
for 10 min. Next, Isopropanol (1 gel volume) was added to the sample and mixed 
thoroughly.  The sample was transferred to a QIAquick spin column and centrifuged for 
1 min at 17,900 x g.  The flow through was discarded and Buffer PE (0.75 ml) was 
added to the column and centrifuged for 1 min at.  Next, the 17,900 x g flow through 
was discarded and the DNA was eluted by adding de-ionised H20 (50 µl) to the spin 
column. 
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2.9 DNA sequencing 
 
DNA sequencing of PCR products was undertaken by Dr. Andrew Cassidy, Tayside 
Centre for Genomic Analysis, Ninewells Hospital. The protocol is briefly outlined 
below. The PCR products were purified using a modification of the ExoSAP enzymatic 
clean-up method. The PCR products (5 µl) were incubated with 1 U of exonuclease I 
and 1 U of shrimp alkaline phosphatase for 20 min at 37°C then inactivated by 
incubating at 80°C for 15 min. Samples were sequenced bidirectionally using the ABI 
BigDye Terminator version 3.1 cycle sequencing kit (Applied Biosystems) and analysed 
on the Applied Biosystems 3730 DNA Analyzer (Applied Biosystems). Sequence 
analysis was performed using MacVector version 12.03 (MacVector Inc., Waterbeach, 
Cambridge, UK) [231]. 
 
2.10 Immunohistochemistry 
2.10.1 Materials 
 
The microtome HM 320 was from Microm UK Ltd. (Commerce House, Telford Road, 
Bicester OX26 4LD). The microtome blades, MB DynaSharp 34°/80mm (Product No. 
12056679) was from Fisher Scientific Uk Ltd. (Bishop Meadow Road, Loughborough 
LE11 5RG). The procurement of trial FFPE specimen of tonsil tissue and archival tissue 
specimens for the study is described in Section 2.3.1.   
 
SuperFrost ® Plus Adhesion slides (Catalogue No. 631-9483) were from Thermo Fisher 
Scientific Inc. (VWR International Ltd. Hunter Boulevard, Magna Park, Lutterworth, 
Leicestershire LE17 4XN England). Fraction V, Heat shock treated Bovine Serum 
Albumin (Catalogue No. BPE-1600-100) and clearing agent. Hydrogen Peroxide 
solution, 30% (w/w) was purchased from Sigma-Aldrich (Sigma-Aldrich Chemie 
GmbH, Riedstr, 2 D-89555 Steinheim 49 7329 970). The EBP50 polyclonal primary 
antibody (Catalogue No. PA1-090) was from Pierce Antibody (Fisher Scientific UK, 
Bishop Meadow Road, Loughborough, Leics, LE11 5RG, UK). Vectastain ABC kit was 
purchased from Vector Laboratories (3 Accent Park, Bakewell Road, Orton Southgate, 
Peterborough PE2 6XS). Diaminobenzidine was from Sigma Aldrich Company Ltd and 
DePeX mounting medium was from VWR International Ltd. The bacterial protein 
lysates of GST and GST-EBP50 were a kind gift from Dr. Sam Crouch (Department of 
Oral and Maxillofacial Clinical Sciences, Dundee Dental School).  
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2.10.2 Method 
2.10.2.1  Tissue sectioning and preparation of slides 
 
Sectioning of archival tissue specimens for immunohistochemical analysis was 
undertaken by Dr. Margaret Florence from Dundee Dental School. Sections of 5 – 6 µm 
thickness were cut using a microtome from each tissue specimen. The sections were 
transferred onto Super Frost plus slides. This was followed by heating the slides at 60
o
C 
for 20 min in an oven to allow for attachment of the tissue and melt the paraffin.  The 
slides were stored at room temperature.  
2.10.2.2 Antigen retrieval  
 
Immunohistochemistry of archival specimens for this study was undertaken by Athiva 
Shankar with technical assistance from Dr. Margaret Florence. The sections were 
prepared for antigen retrieval by de-paraffinising in two 5 min washes with the clearing 
agent xylene. This was followed by 2 min washes in graded ethanol solutions of 100%, 
90% and 70% to re-hydrate the tissue sections. The sections were rinsed with dH20. 
Meanwhile, 10 mM citrate buffer (pH 6.4) was preheated for 15 min under microwave 
pressure. The sections were gently warmed before being transferred to the preheated 
citrate buffer followed by heating for 15 min under microwave pressure. The sections 
were allowed to cool for 10 min before washing in tap water.  
2.10.2.3 Immunohistochemistry 
 
Next, the sections were incubated in 10% hydrogen peroxide for 20 min to block 
endogenous peroxidase activity. Following hydrogen peroxide incubation, the sections 
were washed thoroughly in tap water followed by rinsing with PBS. Immunoperoxidase 
staining was performed using the Vectastain ABC kit according to the manufacturer’s 
instructions. Brieﬂy, the non-speciﬁc binding sites on the tissue sections were blocked 
with normal goat serum (diluted to 1:65 in 1% BSA/PBS (w/v) for 20 min. This was 
followed by incubation with primary antibody diluted to appropriate concentration 
(PA1-090 Anti-EBP50; 1:2000) in 1% BSA/PBS (w/v) for 30 min at room temperature 
in a humidiﬁed atmosphere. The sections were washed (three 5 min washes) with wash 
buffer to remove unbound antibody followed by incubation with biotinylated secondary 
antibody diluted 1:200 in 1% BSA/PBS (w/v) for 30 min in a humidiﬁed atmosphere. 
Meanwhile, Vectastain ABC reagent was prepared by diluting Reagent A 1:50 in 1% 
BSA/PBS (w/v) and adding to Reagent B also at a dilution of 1:50 and allowed to stand 
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for 30 min. The sections were incubated for 30 min with the prepared ABC reagent after 
three 5 min washes in wash buffer and rinsing in PBS. Excess ABC reagent was 
removed from the slides by washing with wash buffer and rinsing in PBS. The sections 
were incubated in peroxidase substrate solution for 5 - 8 min and washed in tap water. 
The sections were counterstained with haematoxylin dye and dehydrated by immersing 
in graded ethanol solutions of 70%, 90% and 100%  for 2 min each followed by clearing 
in xylene (two 5 min incubations). Tissue sections were mounted with DePeX mounting 
medium using coverslips and allowed to dry before visualising under a light microscope 
(Motic BA400). Images were captured at x100 or x400 magnification (scale bar = 1 
cm).  
2.10.2.4 Antibody blocking  
 
The primary antibody, anti-EBP50 was combined with GST (2 µg, 5 µg), GST-EBP50 
(2 µg, 5 µg) or no bacterial proteins and incubated on ice for 20 min or overnight at 2-
4
o
C. The blocked antibody and controls were applied to the tissue sections as for routine 
immunohistochemistry.  
2.10.2.5 Scoring of EBP50 immunohistochemistry results 
 
The protocol for scoring of EBP50 immunohistochemistry results for this study was 
adapted from Xiao-Guang et al.[183]. The sections were analysed by two independent 
observers (Athiva Shankar and Dr. Sam Crouch) blinded to the sample identities. 
Additionally, 10% of the sections were scored by a third independent observer 
(Dr.Michaelina Macluskey). Differences in inter-observer scores were reconciled 
through discussions and repeat viewing of the sections. Five random representative 
fields of 100 cells each were viewed using x 40 magnification. Based on the percentage 
of positively stained tumour cells, membrane and cytoplasmic EBP50 expression were 
scored separately as follows:  
 
Membrane staining 
Negative – No staining in >10% of the tumour cells  
Positive – Weak or moderate staining in >10% of the tumour cells  
Mixed – Combination of the above 
 
Cytoplasmic staining 
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Negligible/Weak - Negligible/Weak staining in >10% of the tumour cells  
Positive - Moderate staining in >10% of the tumour cells  
Strong - Marked staining in >10% of the tumour cells  
Mixed – Combinations of the above 
Each specimen was assigned a final score to reflect membrane and cytoplasmic EBP50 
expression patterns. 
 
2.11 In Situ Hybridisation 
 
In Situ Hybridisation (ISH) was undertaken by the Department of Clinical Pathology, 
Ninewells Hospital. Briefly, sections of 4 μm thickness were cut and mounted on 
SuperFrost Plus slides. The INFORM HPV III probe sets capable of detecting 13 
oncogenic HPV types (Ventana Medical Systems) was employed in the assay. The ISH 
assay was performed using the BenchMark automated slide staining system (Ventana 
Medical System) according to the manufacturer’s guidelines. The slides were scored 
separately by two independent observers (Dr. Sharon White, Department of Pathology, 
Ninewells Hospital and Athiva Shankar). Punctate nuclear staining was considered a 
positive result for HPV DNA. 
2.12 Patient selection and clinical data collection 
 
This study was approved by the Caldicott Guardian and the Tayside Tissue Bank and 
conducted according to the guidelines outlined by the Research Governance Framework 
in Tayside, Scotland.  
 
Patients were selected, based on the availability of a p16 status, from an existing head 
and neck database with HNSCC patients treated between January 2006 and December 
2011 in NHS Tayside, Scotland. The parent database was developed as part of a 
previous study and involved combining two clinician-led datasets including information 
on smoking and drinking behaviours at diagnosis held in the Head & Neck unit as well 
as electronic case note reviews to identify any missing clinical (e.g. treatment) and 
pathological (e.g. tumour staging, margins, histological type, grade of differentiation, 
invasive front) data. The p16 status of the patient samples was determined by 
immunohistochemistry. The slides were analysed by a single pathologist (Dr. Sharon 
White) in the Department of Pathology, Ninewells Hospital and were scored as positive 
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if strong diffuse nuclear and cytoplasmic staining was observed in ≥ 70% of the tumour 
[282]. 
 
Following selection of patients based on p16 status, the database for this study was 
updated with survival data and clinical information where it was missing by reviewing 
case notes. Survival outcomes were assessed against p16 status, smoking and alcohol 
history, disease stage, HPV status and EBP50 expression. A completed database was 
transferred to Tayside Health Informatics Centre (HIC) for anonymisation via a secure 
NHS transfer system. For immunohistochemical analysis of EBP50 expression, a 
smaller sub-cohort was selected against the HPV status of the patients.  
 
2.13 Statistical analysis 
 
In this dataset, all clinical data related to age, diagnosis, treatment, smoking and alcohol 
history was coded according to a coding manual developed for the original database. 
Primary tumour sites were categorised according to the Royal College of Pathologists-
Datasets for histopathology reporting of mucosal malignancies of the head and neck 
[300]. Smoking
 
[63] and alcohol were classified using case note information, as follows:  
 
- Light smoker - 1-14/day 
- Moderate smoker - 15-24/day 
- Heavy smoker - ≥ 25/day 
- Light to moderate drinker - 'no history of alcohol abuse' or 'moderate drinker'. 
- Heavy drinker - alcohol consumption of ≥ 21 units/week in men and ≥ 14 
units/week in women (where figures were available in case notes) or 'excessive 
alcohol consumption' 
- Ex- heavy drinker - 'history of alcohol abuse or heavy drinking’ 
 
Data was analysed using SPSS package (IBM Statistics Version 22). Data related to 
categorical variables was described in terms of number of patients (percentages) and as 
mean or median for continuous variables. Chi-squared test of independence was used to 
report on pairwise correlation between p16 status, HPV status and EBP50 expression on 
the one hand and social demographics and clinical/histopathological characteristics of 
the cohort on the other. Statistical significance was defined as p < 0.05. The Likelihood 
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Ratio test was used to compare the relative strength of p16 and EBP50 expression as 
indicators of HPV infection. Overall Survival (OS) was defined as time (in months) 
from diagnosis to death, end of study or date of last follow-up. Recurrence Free 
Survival (RFS) was defined as time (in months) from diagnosis to locoregional 
recurrence. Disease Free Survival (DFS) was defined as time (in months) from 
diagnosis to death due to head and neck cancer.  Kaplan-Meier analysis was used to 
obtain 2-year and 5-year survival curves. The Cox Proportional hazards model was used 
to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI) for prognostic 
significance of single and multiple variables. 
2.14 Contents of laboratory kits 
 
QIAGEN  DNeasy Blood and Tissue Kit (Catalogue No. 69506) 
 
- Buffer ATL 
- Buffer AL 
- Buffer AW1 
- Buffer AW2 
- Buffer AE 
- Proteinase K 
- DNeasy mini spin columns in 2ml collection tubes 
- Collection tubes (2ml) 
- Handbook 
 
QIAamp DNA FFPE Tissue Kit (Catalogue No. 56404) 
- Buffer ATL 
- Buffer AL 
- Buffer AW1 
- Buffer AW2 
- Buffer ATE 
- Proteinase K 
- QIAamp MinElute ® Columns 
- Collections tubes (2ml) 
- Handbook 
QIAquick Gel Extraction Kit (Catalogue No. 28704) 
- QIAquick spin columns 
- Buffer QG 
- Buffer PE 
- Buffer EB 
- Collection tubes (2ml) 
- Loading buffer 
- Handbook 
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MyTaq DNA Polymerase 
- MyTaq DNA Polymerase 2 X 250µl 
- 5 x MyTaq Reaction Buffer 14 x 1.5ml 
 
2.15 General laboratory equipment and consumables 
 
The water bath was from Grant Instruments (Cambridge) Ltd. (29 Station Road, 
Shepreth, Royston, Herts SG8 6P2 England). The vortex mixer, Vortex Genie 2 was 
purchased from Scientific Industries Inc. (70 Orville Drive, Bohemia, New York 11716 
USA). The micro-centrifuge 5415D and the PCR tubes were purchased from Eppendorf 
North America Inc. (1 Catiague Road, P.O.Box 1019, Westbury, NY 11590 -0207). The 
Heraeus
TM
 Biofuge
TM
 Stratos
TM
 benchtop centrifuge for ethanol precipitation was from 
Thermo Scientific UK Ltd. (Bishop Meadow Road, Loughborough, Leicestershire 
LE115RG). The regular pipette tips were from Sarstedt Ltd. (68 Boston Road, 
Beaumont Leys, Leicester LE4 1AW, UK). The filter pipette tips used for PCR were 
purchased from Axygen BioScience, Inc. (33210 Central Avenue, Union City CA 
94587). The pipettes were from Gilson, Inc. (3000 Parmenter Street, P.O Box 620027 
USA). The Eppendorf’s were from Alpha Laboratories Ltd. (40 Parham Drive, 
Eastleigh, Hampshire SO50 4NU). 
2.16 Solutions and Buffers 
 
3M Sodium Acetate pH 5.2 
Sodium acetate 
dH2O  
Adjust pH to 5.2 with glacial acetic acid and adjust volume with dH2O 
 
 
Phosphate-buffered Saline 
PBS tablets 
dH2O 
 
1 x TAE Buffer 
Tris acetate pH 8.2  
EDTA 
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1 x TE Buffer 
Tris HCl pH 7.5  
EDTA   
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Chapter 3 
A DESCRIPTIVE PROFILE OF THE COHORT 
3.1 Selection of the sample population 
 
NHS Scotland comprises 14 regional NHS Boards (Fig. 3.1(A)), 7 special NHS Boards 
and 1 public health body. Together they are responsible for the improvement of the 
health of the Scottish population by providing a range of healthcare and specialist 
services [223].   
The sample population for this study includes patients diagnosed and treated for 
HNSCC in NHS Tayside. The health board of NHS Tayside covers an area of 7,508 sq. 
km encompassing the three local areas of Dundee City, Angus and Perth & Kinross with 
an estimated population of around 416,934 persons [224],   [7]. On an average, 75 to 80 
new cases of head and neck cancers are registered in Tayside every year. The focus of 
this study is Tayside, which is demarcated in black in Figure 3.1(A). 
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Figure 3.1 (A): Regional NHS Boards in Scotland. Fourteen regional NHS Boards constitute NHS 
Scotland along with 7 special boards and 1 public health body. The study population was selected 
from NHS Tayside (outlined in black). 
 
At the beginning of the study 436 patients were selected from an existing database of 
HNSCC patients who were diagnosed and treated in NHS Tayside between the years 
2006 to 2011. The availability of a p16 status for each patient was a key inclusion 
criterion. Patients were later excluded from the cohort at three subsequent stages: 
where tissue specimens were unavailable for analysis, where specimens were assessed 
as being unsuitable for downstream experiments and where extracted DNA from the 
tissue specimens was found to be of poor quality. This meticulous selection of tissue 
specimens ensured a robust, yet large, working sample size of 293 patients.  Figure 3.1 
(B) is a detailed schematic representation of the patient selection process for the study.  
  
 NHS Ayrshire & Arran 
NHS Borders 
 NHS Dumfries & Galloway 
 NHS Fife 
 NHS Forth Valley 
NHS Grampian 
  NHS Highland 
NHS Lanarkshire 
NHS Lothian 
NHS Orkney 
 NHS Shetland 
 NHS Western Isles 
 NHS Greater Glasgow & Clyde 
NHS Tayside 
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Figure 3.1 (B): Schematic representation of patient selection process. An existing database of 
HNSCC patients was screened and those with a definitive p16 status were included in the initial 
study cohort (n = 436). The initial cohort was filtered at 3 subsequent stages to exclude patients 
with missing biopsy specimens (n = 21), those with tissue specimens deemed unsuitable for 
downstream experiments (n = 95) and lastly, those patients for whom the quality of DNA extracted 
from tissue specimens was found to be questionable (n = 27). After exclusion of 143 patients, the 
final study cohort contained 293 patients. 
 
3.2 Social demographics of the study population 
 
A description of the study population based on social demographics is outlined in Table 
3.1.  More than half of the patient population was male (68%). Patients were categorised 
into 4 distinct age groups: ≤ 58 years (31%), 59 – 64 years (21%), 65 – 73 (25%) and ≥ 
74 years (23%). The mean age at diagnosis was 65 years.  
History of tobacco smoking and alcohol consumption was classified based on self-
reported case note information as follows:  
 Light smoker – 1 - 14/day 
HNSCC cohort with 
known p16 status 
n = 436 
 
Patients excluded – Specimens 
missing from the archive  
n = 21 
Patients excluded - Specimens 
with insufficient tissue or very 
little SCC for downstream 
experiments 
n = 95 
HNSCC cohort with 
known p16 status 
          n = 415 
 
Initial study 
population size 
n = 320 
Patients excluded – Tissue 
samples negative for the human 
β-globin gene 
n = 27 
Final study 
population size 
n = 293 
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 Moderate smoker – 15 - 24/day 
 Heavy smoker – ≥ 25/day 
 Light to moderate drinker - 'no history of alcohol abuse' or 'moderate drinker' 
 Heavy drinker - alcohol consumption of ≥ 21 units/week in men and ≥ 14 
units/week in women (where figures were available in case notes) or 'excessive 
alcohol consumption' 
 Ex- heavy drinker - 'history of alcohol abuse or heavy drinking’ 
More than one-third of the patient population were smokers at the time of diagnosis and 
while the majority were ‘Light to moderate drinkers’ (40%), nearly one-quarter had a 
history of heavy drinking (current or ex- heavy drinker).  
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Characteristic No of patients (n = 293) No of patients (%) 
Gender 
Male 
Female 
 
198 
95 
 
68 
32 
Age at diagnosis (Groups) 
≤ 58 
59 – 64 
65 – 73 
≥ 74 
 
 
92 
61 
72 
68 
 
31 
21 
25 
23 
      Mean age at diagnosis 64.5 (Range 30 – 90) 
History of smoking at 
diagnosis 
                Non – smoker 
Light smoker 
Moderate smoker 
Heavy smoker 
Ex- smoker 
Other  
Data missing or unavailable 
 
 
                         
                         47 
23 
50 
40 
74 
11 
48 
 
                       
                       16 
8 
17 
14 
25 
4 
16 
History of alcohol 
consumption at diagnosis 
                  Non-drinker 
Light to moderate drinker 
Heavy drinker 
Ex- heavy drinker 
Data missing or unavailable 
 
 
                          
                         34 
117 
71 
9 
62 
 
                         
                    12 
                    40 
                    24 
                    3 
                    21 
 
Table 3.1: Profile of study population based on social demographics. Patients were categorised into 
4 distinct age groups with the mean age at diagnosis being 65 years.  More than one-third of the 
study cohort were smokers at the time of diagnosis and nearly a quarter had a history of heavy 
drinking.  
 
3.3 Pathological features of tumours and disease staging  
 
Tables 3.2 (A) and 3.2 (B) summarise the profiles of the study population based on 
tumour site, pathological features and disease stage.  Site of primary tumour was 
categorised according to the Royal College of Pathologists Dataset for histopathology 
reporting of mucosal malignancies of the head and neck [300]. Tumours were grouped 
into those arising in the oral cavity, oropharynx, larynx, hypopharynx, unknown 
primary and other less common sites. While oral cavity and laryngeal tumours 
constituted 34% and 30% respectively, oropharyngeal tumours accounted for 21% of 
the cohort. Unknown primaries, tumours arising in the hypopharynx and other less 
common sites (pharynx, nasopharynx, nasal cavity and maxillary sinus) accounted for 
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the remaining 15%. The vast majority of tumours were either moderately differentiated 
(41%) or poorly differentiated (39%). Neck nodes involved by carcinoma was noted in 
143 (49%) patients and extracapsular spread, a manifestation of biological 
aggressiveness of tumours, was noted in 48 (16%) patients. Additional histopathological 
features of prognostic value such as the presence of a non-cohesive invasive front, 
lymphovasular and perineural invasion were also documented. While presence of a non-
invasive cohesive front was noted in 71 (24%) patients, lymphovasular invasion (12%) 
and perineural invasion (7%) were recorded only in a small percentage of the patient 
population. It is important to note here that the histopathological parameters of invasive 
front, lymphovasular and perineural invasion had significant proportions of missing 
data.  
 
Like most cancers, prognosis in mucosal cancers of the head and neck largely depends 
on tumour stage. The TNM staging system describes the anatomic extent of the primary 
tumour along with the involvement of regional lymph nodes and distant metastases, if 
any [298]. A significant proportion of patients in the cohort had histologically 
confirmed T4 stage (31%). The percentage of study population with T2, T1 and T3 was 
25%, 20% and 16% respectively. Nodal involvement at N2 stage was noted in more 
than a quarter of the study population. At the time of diagnosis nearly half the study 
population (47%) had Stage IV disease (UICC Staging). Disease stages I, II and III 
were recorded at 16%, 14% and 15% of the cohort respectively. 
 
Characteristic No of patients (n = 293) No of patients (%) 
Site of primary tumour 
Oral cavity 
Oropharynx 
Larynx 
Hypopharynx 
Unknown primary 
Other 
 
99 
60 
88 
21 
9 
15 
 
34 
21 
30 
7 
3 
5 
Grade of differentiation 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Moderate – Poorly differentiated 
Other 
Data missing or unavailable 
 
 
5 
119 
115 
28 
12 
14 
 
2 
41 
39 
10 
4 
4 
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Neck node status 
Negative 
Positive 
         Unknown 
 
146 
143 
4 
 
50 
49 
1 
Extracapsular spread 
Negative neck node status 
Yes 
No 
Inconclusive 
Data missing or unavailable 
 
148 
48 
58 
2 
37 
 
50 
16 
20 
1 
13 
Non-cohesive invasive front 
Yes 
No 
Not applicable – Unknown 
primary 
Data missing or unavailable 
 
 
71 
107 
10 
 
105 
                         
                    24 
37 
3 
 
36 
Lymphovascular invasion 
Yes 
No 
Not applicable – Unknown 
primary 
Inconclusive 
Data missing or unavailable 
                
                       36 
142 
11 
 
2 
102 
                         
                    12 
48 
4 
 
1 
35 
Perineural invasion 
Yes 
No 
Not applicable – Unknown 
primary 
Data missing or unavailable 
 
 
20 
122 
12 
 
139 
 
7 
                    42 
4 
 
47 
 
 
Table 3.2 (A): Profile of study population based on anatomic site of primary tumour, grade of 
tumour differentiation and other pathological traits. The tumours in this cohort involved mainly 
the oral cavity, the larynx and the oropharynx. The vast majority of them were either moderately 
differentiated (41%) or poorly differentiated (39%). Neck node involvement by tumours was noted 
in 49% of the cohort. Histological features for tumour aggression such as the presence of 
extracapsular spread (16%), a non-cohesive invasive front (24%), lymphovascular invasion (12%) 
and perineural invasion (7%) were also noted although a large proportion of clinical data 
pertaining to the latter was missing. 
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Variable No of patients (n = 293) No of patients (%) 
TNM Classification 
 
T (Tumour) Stage 
T1, T1a, T1b 
T2, T2a, T2b 
T3 
T4, T4a, T4b 
TX 
T stage data missing 
 
N (Node) Stage 
N0 
N1 
N2, N2a, N2b, N2c 
N3 
N stage data missing 
 
 
 
 
58 
74 
48 
90 
8 
15 
 
 
135 
42 
93 
8 
15 
 
 
 
20 
25 
16 
31 
3 
5 
 
 
46 
14 
32 
3 
5 
UICC Staging 
                    Stage I 
Stage II 
Stage III 
Stage IVA 
Stage IVB 
Unknown 
 
 
                         47 
42 
43 
131 
7 
23 
 
                    16 
                    14 
                    15 
                    45 
                     2 
                     8 
 
Table 3.2 (B): Profile of study population based on TNM Classification and UICC staging. Nearly 
half of the study population had presented with late stage disease at the time of diagnosis.  
 
3.3 Main therapeutic interventions in the treatment of the sample 
population  
 
Surgery is a standard treatment for HNSCC but is often limited by anatomical extent of 
the tumour and the physiological role of involved structures. The need to improve 
survival outcomes and preserve organ function has necessitated the use of multi-modal 
treatment strategies involving a combination of surgery, chemotherapy and/or 
radiotherapy [85]. Table 3.3 catalogues the main therapeutic interventions employed in 
the treatment of patients in the cohort, including chemotherapy regimen and 
radiotherapy dose. The sample population had undergone either single modality 
treatment in the form of radiotherapy (25%) and surgery (19%) or combined modality 
treatment in the form of chemoradiation (18%), surgery with chemoradiation (15%) and 
surgery with radiotherapy (11%). A small number of patients (n = 23; 8%) received 
only palliative care. A significant percentage of patients treated surgically had neck 
dissection (21%). Cisplatin, either alone (7%) or in combination with Fluorouracil 
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(5FU) (23%), was the drug of choice for chemotherapy with regimens administered 
neo-adjuvantly and/or concurrently. Radiotherapy dose and fractions were administered 
as 60-68 Gy in 30-34 fractions (31%) and 50-55Gy in 20 fractions (27%). 
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Treatment No of patients (n = 293) No of patients (%) 
Treatment modalities 
Surgery alone 
Radiotherapy alone 
Chemotherapy +/- Surgery 
Chemoradiation 
Surgery, Chemotherapy and Radiotherapy 
Surgery and radiotherapy 
No treatment/Palliative care 
Data missing or unavailable 
 
 
54 
74 
7 
53 
45 
32 
23 
5 
 
19 
25 
2 
18 
15 
11 
8 
2 
Type of surgery 
Surgery to primary only 
Surgery to primary and neck dissection 
Neck dissection only 
Surgery not a treatment modality 
Data missing or unavailable 
 
 
33 
62 
37 
156 
5 
 
11 
21 
13 
53 
2 
Chemotherapy – Drugs 
Cisplatin/5FU 
Cisplatin 
Other 
Chemotherapy not a treatment modality 
Data missing or unavailable 
 
68 
20 
16 
184 
5 
 
23 
7 
5 
63 
2 
Chemotherapy – Regimen 
Neo-adjuvant 
Concurrent 
Neo –adjuvant + concurrent 
Other 
Chemotherapy not a treatment modality 
Data missing or unavailable 
 
 
20 
23 
56 
5 
184 
5 
 
7 
8 
19 
2 
63 
1 
Chemotherapy – Cycles 
1 -3 
4 – 6 
7  - 8 
Chemotherapy not a treatment modality 
Data missing or unavailable 
 
46 
51 
7 
184 
5 
 
16 
17 
3 
63 
1 
Radiotherapy – dose and fractions 
60 – 68 Gy in 30 – 34 fractions 
50 – 55 Gy in 20 fractions 
40 – 44.5 Gy in 12 & 16 fractions 
Radiotherapy not a treatment modality 
Data missing or unavailable 
 
91 
78 
18 
85 
21 
 
31 
27 
6 
29 
7 
 
Table 3.3: Profile of study population based on main therapeutic interventions employed in the 
treatment of HNSCC. The patients had undergone either single modality treatment in the form of 
radiotherapy or surgery or combined modality treatment in the form of chemoradiation, surgery 
with chemoradiation or surgery with radiotherapy. A significant percentage of patients treated 
surgically had undergone neck dissection. Chemotherapy regimens were administered neo-
adjuvantly and/or concurrently with Cisplatin, either alone or in combination with Fluorouracil 
(5FU) being the drug of choice. Radiotherapy dose and fractions were administered as 60-68 Gy in 
30-34 fractions and 50-55Gy in 20 fractions. 
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3.5  Mortality and recurrence in the sample population 
 
The mean length of follow-up, defined as the date of diagnosis to the date of last follow 
up, end of study period or the date of death, was 39 months (3+ years). However, only 
around three-fourths of patient population was followed up for 60 months (5 years). 
 
At the end of the study period, 149 patients (51%) were deceased, 134 (46%) were alive 
disease free and 10 (3%) alive with disease. Out of 149 deaths, 58 (20%) were attributed 
to head and neck cancer and 42 (14%) to other causes. Cause of death data was 
unavailable for 49 patients (17%). Recurrence of primary disease was noted only in a 
small proportion of patients (19%) with commonly afflicted anatomic sites being the 
oral cavity (16/55; 29%), lymph nodes (15/55; 27%) and the larynx (12/55; 25%). 
Recurrence in the oropharynx (3/55; 6%) was relatively low (Table 3.4). 
 
Variable No of patients (n = 293) No of patients (%) 
  
End of study – Overall  
mortality                                                            
                                                        
Cause specific mortality 
 
HNC 
Other 
Cause of death unknown 
 
End of study – Alive with 
disease 
End of study – Alive disease 
free 
 
 
                     149 
    
                    
 
                      58        
                      42 
                      49 
 
                      10 
 
                     134 
 
51 
 
 
 
 
20 
14 
17 
 
3 
 
46 
Recurrence 
Yes 
No 
Data missing or unavailable 
 
                          
                      55 
                     231 
                       7 
 
19 
79 
2 
Site of recurrence 
Nodal disease 
Oral cavity 
Larynx 
Oropharynx 
Other 
 
 
15 
16 
12 
3 
9 
 
27 
29 
22 
6 
16 
 
Table 3.4: Profile of study population based on overall mortality and recurrence of disease.  At the 
end of the study period, 49% of the cohort was alive and 51% was deceased. Only 20% of the 
deaths were attributed to head and neck cancer. Recurrence of primary disease was noted in 19% 
of the patients with commonly afflicted anatomic sites being the oral cavity, lymph nodes and the 
larynx.  
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The mean Overall Survival (OS) for the cohort was 58 months and 2-year OS was at 
62% (Table 3.5). On univariate analysis, age of the patients, smoking history, site of 
primary tumour, disease stage, neck node status, extracapsular spread and treatment 
modality were found be significantly associated with OS (Table 3.5). Overall survival 
was significantly improved for patients in the age group of 59 to 64 or younger (P < 
0.0001). Patients who were smokers at the time of diagnosis had a worse prognosis 
when compared to non-smokers and ex-smokers (P = 0.002). Patients presenting with 
early stage disease (P < 0.0001) and with tumours arising in the oropharynx and larynx 
(P = 0.017) were likely to survive longer. Positive neck nodes (P < 0.0001) and 
presence of extracapsular spread (P < 0.0001) were associated with poor clinical 
outcomes. Treatment modality also significantly influenced 2-year overall survival with 
patients who were treated by radiotherapy as a single treatment modality or in 
combination with surgery or chemotherapy having the worst prognosis. Multivariate 
analysis of the cohort identified smoking history (hazard ratio, HR 3.28, 95% 
confidence interval, CI 1.81 – 9.12, P = 0.023), extracapsular spread (hazard ratio, HR 
0.25, 95% confidence interval, CI 0.1 – 0.63, P = 0.004) and treatment modality (hazard 
ratio, HR 15.1, 95% confidence interval, CI 2.29 – 100.2, P = 0.005) as independent 
prognostic variables for OS.  
 
The mean Recurrence Free Survival (RFS) for the cohort was 72 months and 2-year 
RFS was at 79% (Table 3.5). On univariate analysis, age, smoking history, site of 
primary tumour, disease stage and treatment modality were not found to be significantly 
associated with RFS.  
 
The mean Disease Specific Survival (DSS) for the cohort was 85 months and 2-year 
DSS was at 82 % (Table 3.5). On univariate analysis, smoking history, site of primary 
tumour, neck node status and extracapsular spread and treatment modality were found 
be significantly associated with DSS (Table 3.5). As expected, non-smokers and ex-
smokers had a better 2-year DSS than current smokers (P = 0.018). Oropharyngeal and 
laryngeal tumours were associated with improved survival (P = 0.017). Positive neck 
nodes (P < 0.0001) and presence of extracapsular spread (P < 0.0001), both features of 
tumour aggression, were associated with poor outcomes. Treatment modality also 
significantly influenced 2-year DSS. Patients who had undergone chemoradiation and 
radiotherapy as a single treatment modality had the worst prognosis. However, none of 
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the aforementioned clinicopathological features were identified as independent 
prognostic factors for DSS following a multivariate analysis of the cohort.
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55 
46 
38 
 
75 
74 
56 
41 
 
 
<0.0001 
 
(87, 16) 
(55, 9) 
(58, 16) 
(57, 14) 
 
75 
67 
61 
61 
 
86 
83 
72 
68 
 
 
0.274 
(NS) 
 
(92, 14) 
(61, 13) 
(72, 16) 
(68, 15) 
 
90 
67 
76 
71 
 
87 
86 
77 
75 
 
 
0.215 
(NS) 
History of smoking 
Non-smoker 
Current smoker 
Ex-smoker 
 
(47, 13) 
(124, 71) 
(74, 27) 
 
74 
50 
63 
 
77 
62 
69 
 
 
0.002 
 
(42, 7) 
(111, 24) 
(68, 10) 
 
71 
71 
76 
 
84 
78 
85 
 
0.424 
(NS) 
 
(47, 5) 
(124, 31) 
(74, 9) 
 
86 
73 
82 
 
88 
80 
87 
 
 
0.025 
 
 
 
Site of primary tumour 
Oral cavity 
Oropharynx 
Larynx 
Other 
 
 
(99, 52) 
(60, 25) 
(88, 41) 
(46, 31) 
 
53 
56 
64 
38 
 
60 
68 
69 
48 
 
 
0.017 
 
(89, 25) 
(55, 7) 
(81, 17) 
(32, 6) 
 
65 
72 
68 
65 
 
70 
86 
84 
74 
 
0.177 
(NS) 
 
(99, 23) 
(60, 10) 
(88, 12) 
(46, 13) 
 
73 
75 
93 
61 
 
78 
83 
93 
69 
 
 
0.024 
Neck node status 
Negative 
Positive 
 
 
(146, 60) 
(143, 86) 
 
69 
44 
 
75 
51 
 
<0.0001 
 
(139, 29) 
(114, 25) 
 
74 
62 
 
82 
76 
 
0.339 
(NS) 
 
(146, 25) 
(143, 32) 
 
88 
75 
 
90 
73 
 
0.025 
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              Table 3.5: Univariate analysis related to Overall Survival, Recurrence Free Survival and Disease Specific Survival in the study cohort. 2-year Overall 
and cause- specific survival of the study cohort was significantly associated with smoking history, site of primary tumour, disease stage, neck node 
status, extracapsular spread and treatment modality.  While age appeared to be an important prognostic indicator for overall survival, no 
statistically significant associations were noted for disease specific survival.  None of the aforementioned factors were found to be predictors of 
recurrence free survival in this study cohort.  
 
 
Extracapsular spread 
Yes 
No 
Inconclusive 
 
 
(48, 34) 
(58, 23) 
(2, 0) 
 
- 
- 
- 
 
36 
71 
100 
 
 
<0.0001 
 
(43, 11) 
(50, 8) 
(2, 0) 
 
- 
- 
- 
 
65 
87 
100 
 
0.105 
(NS) 
 
(48, 18) 
(58, 6) 
(2, 0) 
 
- 
- 
- 
 
53 
90 
100 
 
 
<0.0001 
Disease stage 
Stage I 
Stage II 
Stage III 
Stage IVA & IVB 
Unknown 
 
 
(47, 12) 
(42, 17) 
(43, 21) 
(138, 85) 
(9, 4) 
 
86 
70 
52 
45 
54 
 
89 
81 
70 
45 
78 
 
 
 
<0.0001 
 
(47, 11) 
(41, 10) 
(40, 5) 
(110 , 20) 
(8, 1) 
 
73 
60 
66 
65 
62 
 
84 
79 
88 
72 
83 
 
 
0.346 
(NS) 
 
(47, 5) 
(42, 8) 
(43, 7) 
(138, 34) 
(9, 1) 
 
100 
84 
69 
71 
65 
 
95 
90 
87 
72 
89 
 
 
 
0.015 
Treatment modality 
Surgery alone 
Radiotherapy alone 
Chemotherapy +/- 
Surgery 
Chemoradiation 
Surgery, Chemotherapy 
and Radiotherapy 
Surgery and 
Radiotherapy 
 
 
(54, 17) 
(74, 44) 
(7, 6) 
 
(53, 26) 
 
(45, 12) 
(32, 16) 
 
80 
50 
6 
 
54 
 
70 
55 
 
82 
60 
0 
 
66 
 
78 
69 
 
 
 
 
<0.0001 
 
(54, 11) 
(71, 18) 
(5, 1) 
 
(51, 10) 
 
(44, 6) 
 
(32, 9) 
 
75 
62 
2 
 
69 
 
71 
 
52 
 
83 
78 
50 
 
76 
 
85 
 
70 
 
 
 
 
0.046 
(NS) 
 
(54, 6) 
(74, 18) 
(7, 4) 
 
(53, 13) 
 
(45, 5) 
 
(32, 5) 
 
99 
76 
7 
 
70 
 
81 
 
83 
 
94 
79 
0 
 
81 
 
88 
 
86 
 
 
 
 
 
<0.0001 
80 
 
3.6 Discussion 
 
The incidence of squamous cell carcinomas of the head and neck in Scotland has 
increased by 10.7% from 2004 to 2014 afflicting approximately 1234 patients per 
annum [128]. Furthermore, recent data from the Scottish Cancer Registry indicate that 
from 1988 to 2006, the highest incidence rates were seen for oropharyngeal cancer than 
for any other cancer types [132]. These changing epidemiological trends have been 
attributed to infection with high-risk HPV [132]. Case selection for previous studies 
investigating high-risk HPV related HNSCC in the Scottish population has been limited 
to oropharyngeal tumours [131], [321]  and a mix of laryngeal and oropharyngeal 
tumours [4]. Whereas oropharyngeal cancers have also been the focal point of other 
cohort studies around the UK, this study is a retrospective analysis of a relatively 
heterogeneous group of patients who were diagnosed and treated in a single centre, the 
Ninewells Hospital (NHS Tayside). The availability of a head and neck database for 
case selection and the ease of sample acquisition made NHS Tayside an ideal choice for 
this study. Initially, 436 cases were selected from an existing database of head and neck 
cancer patients by employing known p16 status as an inclusion criterion. Following an 
assessment of the suitability of tissue specimens for downstream experiments and the 
presence of SCC, several cases were excluded from the cohort. Although the total 
sample size was reduced during this meticulous selection process, it ensured a robust 
cohort of 293 patients and is a larger sample size than those used in previous studies. 
 
In the UK, crude incidence rates of head and neck cancer by gender show that there are 
16 new cases for every 100,000 males and 8 for every 100,000 females - giving a male: 
female ratio of 2:1. Incidence rates are strongly related to age and, on an average, nearly 
45% of cases diagnosed each year are in patients aged 65 years and over, although 
patterns may be different for males and females [34]. More than half of the patients in 
this study cohort were males and mean age of diagnosis was 64.5 years, which is in 
keeping with the general trends across the UK. At diagnosis, more than a third of the 
patient population were smokers and nearly a fourth had a history of heavy 
drinking.  Alcohol consumption and tobacco use are major risk factors accounting for 
75% of all head and neck cancers and their effects are synergistic when combined [50]. 
While smoking is strongly associated with laryngeal cancers, alcohol consumption tends 
to be linked to cancers of the oral cavity and pharynx [196].   
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In this cohort, cancers of the larynx and oral cavity constituted the majority of cases 
while OPSCC constituted around 21% of the patient population.  These results are 
somewhat divergent from the WHO distribution wherein a majority of tumours in the 
upper aerodigestive tract arise in the oral cavity (43%) followed by the pharynx (31%) 
and the larynx (26%) [18]. It is likely that the primary tumour site distribution trends 
noted in this cohort is a reflection of smoking and alcohol consumption habits of 
patients that constitute it. However, recent reports suggest that an increasing number of 
patients with HNSCC do not present with a history of smoking and alcohol 
consumption at diagnosis. This trend is especially common in patients with HPV- 
positive OPSCC [44], [74].  
 
Nearly half of the patient population (47%) in this cohort was diagnosed with late stage 
disease (Stage IVA & B).  The stage of the disease at diagnosis will often determine 
prognosis and survival rate in patients with head and neck cancers and the best 
outcomes are seen in patients who are diagnosed early [143]. These findings may 
indicate a lack of awareness in the community on recognition of early signs and 
symptoms of head and neck cancer or a delay in seeking treatment or poor healthcare. 
Social deprivation has also been linked to HNSCC risk in high and low income 
countries across the world [51]. Indeed, higher cancer incidence and lower survival rates 
have also been reported in socioeconomically disadvantaged groups with deprivation 
gaps being the greatest for smoking related cancers [34], [234]. Individuals from 
socioeconomically deprived communities are often subjected to complex circumstances 
which demand more their time and attention and so, the risk of disease is often ignored 
[144]. Given that Dundee comprises 30% of the share of the most deprived 
communities in Scotland
  
[271], the findings on negative health behaviours and disease 
presentation may indicate a need for patient education for preventive healthcare and 
screening programmes that are accessible to all communities.  
Additionally, patients presenting with clinically advanced disease undergo multimodal   
treatment in the form of surgery, chemotherapy and/or radiotherapy which is associated 
with high morbidity [197], [228]. Indeed, only 19% of the patients in the cohort were 
treated with surgery alone, mainly those with early stage diseases, while most others 
were treated with radiation and/or chemotherapy.  
 
Although a 5-year follow up is not complete for the cohort, the majority of the patients 
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were followed up for 3+ years. At the time of censoring, half of the patient population 
had died - the majority of them because of head and neck cancer - 49% were alive at the 
end of the study, comparable with survival rates of 71% at 1 year and 42% at 5 years in 
the European population [107].  
 
Tobacco smoking, anatomic site of primary tumour, involvement of neck nodes, 
presence of extracapsular spread and treatment modality were found to significantly 
influence overall and cause specific survival. The detrimental effects of tobacco 
smoking on prognosis of head and neck cancer patients undergoing radiation therapy 
has been previously documented [44]. It has been hypothesised that decreased 
oxygenation and/or reduced effects of radiation induced killing of tumour cells may 
potentially compromise outcomes in these patients  [112]. The 2-year OS and DSS were 
better for patients with laryngeal and oropharyngeal tumours and are similar to those 
reported by DAHNO for head and neck cancer patients in England [200]. The 2-
year OS was reduced by half in patients with extracapsular spread, a finding that is 
consistent with data from a meta-analysis by Dunne et al. which showed a 5-year 
survival rate of 17% - 55.8% for neck metastasis with extracapsular spread and 44.6% -
76% neck metastasis without extracapsular spread [69].  
 
Treatment modality is often determined by the disease stage at the time of diagnosis. 
Early stage disease or non-metastatic disease is usually treated with single modality 
therapy such as surgery or radiotherapy while patients with advanced disease undergo 
surgery with postoperative radiotherapy or by definitive radiotherapy followed by 
surgery, if necessary [164]. The vast majority of patients in this cohort were diagnosed 
with advanced head and neck cancer and nearly a quarter of the study population had 
undergone definitive radiotherapy. Findings on OS and DSS indicate that patients who 
had undergone definitive radiotherapy had the worst prognosis compared to those who 
had undergone radiotherapy in combination with surgery or chemotherapy or both. 
Indeed, overall and cause specific survival has been shown to be significantly improved 
with concomitant chemotherapy and radiation compared with definitive radiotherapy for 
advanced disease head and neck cancer [19], [176].  
3.7 Summary 
 
Clinical data and archival biopsy specimens were collected for a large heterogeneous 
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cohort of HNSCC from Tayside. Social demographics and clinical characteristics of the 
study population were retrospectively evaluated. The significant impact of smoking and 
disease stage on overall and disease specific survival highlights the need to address 
health behaviours and the lack of public awareness towards head and neck cancer in this 
population.  
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Chapter 4 
PREVALENCE OF HUMAN PAPILLOMAVIRUS-RELATED 
HNSCC IN A TAYSIDE COHORT 
 
The incidence of HPV-related HNSCC in the Western countries has risen rapidly over 
the last decade and is estimated to increase further in the next 20 years [246]. In the UK, 
50 - 55% of OPSCCs have been attributed to infection with high risk HPV [132], [75]. 
On average, 75 - 80 patients are diagnosed and treated for head and neck cancer every 
year at the Ninewells Hospital which is the regional referral centre for patients in 
Tayside. One of the objectives of this study was to determine the prevalence of HPV-
related HNSCC in the Tayside population by analysing archival tumour tissue (See 
Chapter 1, Section 1.7.5). This chapter will focus on the prevalence of high-risk HPV- 
related HNSCC in the sample population by retrospective analysis of archival FFPE 
specimens of patients diagnosed and treated between 2006 and 2011.  
4.1 DNA extraction of FFPE archival tissue 
4.1.1 Determining optimal thickness of tissue sections and comparing DNA 
extraction protocols 
 
Formalin fixation and paraffin embedding (FFPE) is one of the most widely used 
archival storage and preservation methods in surgical diagnostic histopathology of 
disease tissue specimen. FFPE of tissue specimens preserves their morphology and 
cellular architecture and the tissues can be stored for extended periods of time with 
minimal maintenance. Furthermore, the ability to isolate nucleic acids and proteins from 
archived FFPE tissue blocks makes them a valuable resource for translational and 
molecular studies [140]. Isolation of DNA from archival FFPE tissue for molecular 
analyses is a multistep process involving many parameters that will ultimately define 
the quality and quantity of extracted DNA. Despite advances in biomolecular 
techniques, DNA extraction from FFPE tissues remains challenging.  
 
The Tayside Tissue Bank, which serves as an extensive biorepository of tissue 
specimens, was a vital resource for obtaining FFPE blocks for this study. Considering 
the age of the tissue blocks and variability in specimen size, determining the amount of 
tissue and extraction protocol for optimal DNA quality and quantity was necessary. 
Three test FFPE tissue blocks of 0.1 cm
2
, 0.5 cm
2
 and 1 cm
2
 were selected. The process 
of optimisation involved obtaining paraffin curls of 25 µm, 30 µm and 50 µm thickness 
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from each specimen. Tissue sections were deparaffinised and DNA extracted using 
protocols A (QIAamp DNA FFPE Tissue Kit) and B (DNA Lysis Buffer LC) as 
detailed in Section 2.4 of Chapter 2.  
 
The most common method to determine DNA yield and purity is the measurement of 
ratios of absorbance at 260 nm and 280 nm (A260/280) and 260 nm and 230 nm 
(A260/230). As a general guideline, A260/280 ratio of 1.8 - 2.0 and A260/230 ratio of  
2.0 - 2.2 are regarded as acceptable. DNA yield and absorbance ratios obtained with two 
different extraction methods were measured for each test specimen at different section 
thicknesses. The absorbance ratio of A260/280 for the smallest test specimen, Sample1, 
was found to be between 2 - 2.2 with Protocol A and 1.7 - 1.8 with Protocol B (Table 
4.1). The A260/230 absorbance ratios were lower than the recommended value across 
all tissue thicknesses with both protocols. The total DNA yield in a volume of 50 µl was 
found to be appreciably better with extraction Protocol B.  
 
Table 4.1: Comparison of DNA extraction Protocols A and B for DNA purity by Nanodrop 
assessment for Sample 1. The absorbance ratio of A260/280 for the smallest test specimen, was 
found to be between 2 - 2.2 with Protocol A and 1.7 - 1.8 with Protocol B. The A260/230 absorbance 
ratios were variable and lower than the recommended value across all tissue thicknesses. The total 
DNA yield in a volume of 50 µl was found to be appreciably better with extraction Protocol B.  
 
For the second test specimen (Sample 2), an A260/280 absorbance ratio of 2.0 with 
Protocol A and 1.8 with protocol B was noted. These values were also consistent across 
all tissue thicknesses while those of A260/230 absorbance ratio were variable. However, 
DNA yield was considerably higher with Protocol B (Table 4.2).  
 
 
Variable                                          Approximate area 0.1cm2  (Sample 1) 
            QIAamp DNA FFPE Tissue Kit (A)                DNA  Lysis Buffer LC (B) 
5x5µm 
sections 
3x10µm  
sections 
5x10µm 
sections 
5x5µm 
sections 
3x10µm  
sections 
5x10µm 
sections 
 
        DNA 
Concentration 
16.5 ng/µl 7 ng/µl 18.5 ng/µl 29 ng/µl 44 ng/µl 53.5 ng/µl 
   A260/280 2.2 2 2.2 1.7 1.7 1.8 
  A260/230 0.2 -11.7 0.2 0.8 1 1.1 
 
Yield in 50 µl 
volume 
 
    0.8 µg     0.4 µg      0.9 µg      1.5 µg      2.2 µg     2.5 µg 
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Table 4.2: Comparison of DNA extraction Protocols A and B for DNA purity by Nanodrop 
assessment of Sample 2. A consistent A260/280 absorbance ratio of 2.0 with Protocol A and 1.8 with 
protocol B was noted while those of A260/230 absorbance ratio were variable. DNA yield was 
considerably higher with Protocol B. 
 
 
A similar pattern of absorbance ratios was observed following extraction of DNA from 
the third and largest tissue sample with DNA yield being higher for Protocol B (Table 
4.3).  
 
Table 4.3 Comparison of DNA extraction Protocols A and B for DNA purity by Nanodrop 
assessment of Sample 3. An A260/280 absorbance ratio of 1.9 - 2.0 with Protocol A and 1.7 - 1.8 
with protocol B was noted across all tissue thicknesses while those of A260/230 absorbance ratio 
were variable. However, DNA yield was considerably higher with Protocol B. 
 
The primary objective of comparing tissue thickness and extraction protocols was to 
determine the best approach for obtaining amplifiable and pure DNA for genotyping. 
Accordingly, PCR amplification of the human β-globin gene from template DNA (100 
Variable                                                      Approximate area 0.5 cm2  (Sample 2) 
            QIAamp DNA FFPE Tissue Kit (A)                DNA  Lysis Buffer LC (B) 
5x5µm 
sections 
3x10µm  
sections 
5x10µm 
sections 
5x5µm 
sections 
3x10µm  
sections 
5x10µm 
sections 
 
DNA 
Concentration 
165 ng/µl 105 ng/µl 155 ng/µl 273.5 ng/µl 104 ng/µl 408 ng/µl 
 
A260/280 
2 2 2 1.8 1.8 1.8 
A260/230 2.5 2.1 1 1.5 1.8 1.4 
Yield in 50 µl 
volume 
8.3 µg 5.3 µg 7.8 µg 13.7 µg 5.2 µg 20.4 µg 
Variable                                                      Approximate area 1 cm2  (Sample 3) 
            QIAamp DNA FFPE Tissue Kit (A)                DNA  Lysis Buffer LC (B) 
5x5µm 
sections 
3x10µm  
sections 
5x10µm 
sections 
5x5µm 
sections 
3x10µm  
sections 
5x10µm 
sections 
DNA 
Concentration 
44 ng/µl 26.5 ng/µl 31.5 ng/µl 82 ng/µl 33 ng/µl 114 ng/µl 
 
A260/280 
 
       2         1.9          2        1.7        1.8      1.8 
 
A260/230 
 
 
0.4 
 
3 
 
0.3 
 
0.7 
 
1.7 
 
0.7 
 
Yield in 50 µl 
volume 
 
2.2 µg 1.3 µg 1.6 µg 4.1 µg 1.7 µg 5.7 µg 
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ng) obtained with extraction protocols A and B from different tissue thicknesses of each 
test specimen was compared. The PCR products were visualised by agarose gel 
electrophoresis to assess DNA quality and quantity.  
 
For Sample 1, faint bands corresponding to the amplified β-globin gene (260bp) were 
visible for DNA obtained with both extraction protocols and different tissue thicknesses 
(Figure 4.1(A)). However, the strongest PCR product was obtained with Protocol A 
from a tissue thickness of 50 µm. PCR amplification of the β-globin gene for Sample 2 
only yielded products with template DNA obtained with Protocol A at 25 and 50 µm 
tissue thickness (Figure 4.1(B)). For Sample 3, a strong PCR product was observed with 
template DNA obtained with Protocol A at a tissue thickness of 50 µm (Figure 4.1(C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Comparison of DNA extraction Protocols A and B by PCR amplification of the Human 
β-globin gene in test samples 1 (A), 2 (B), and 3 (C). Protocols A (QIAamp DNA FFPE Kit) and B 
(DNA lysis buffer LC) were employed in extracting DNA from test FFPE tissue specimens of 
varying sizes 1 (0.1 cm
2
), 2 (0.5 cm
2
) and 3 (1 cm
2
) at tissue thicknesses of 25, 30 and 50 µm each. 
Extracted DNA was assessed for quality by amplification of a 260bp fragment of the human β-
globin gene. Bands corresponding to template DNA with Protocol A at a tissue thickness of 50 µm 
were consistently strong and clear. The additional bands noted in figures (A), (B) and (C) were 
identified as non-specific bands (discussed in Section 4.2.5). 
Marker 
25 µm 
 QKit  LC 
30 µm 
QKi
t 
LC 
50 µm 
QKit LC 
β -globin      
(260bp) 
Non-specific 
bands 
300bp 
(A) 
Marker 
25 µm 
Qkit LC 
30 µm 50 µm 
Qkit Qkit LC LC 
 β -globin 
   (260bp) 
Non - 
specific  
bands 
(B) 
Marker 
25 µm 
QKit LC 
30 µm 
QKit LC QKit LC 
50 µm 
β -globin 
  (260bp) 
Non-specific 
bands 
(C) 
 88 
 
 
 
Assessment of the purity of DNA using a Nanodrop showed no significant distinction 
among the three tissue thicknesses, however, the DNA yield was consistently higher 
with Protocol B. On the contrary, PCR analysis of template DNA demonstrated that 
extraction Protocol A provided the best results with consistently strong amplification of 
DNA from a tissue thickness of 50 µm. Subsequent DNA extractions for archived study 
FFPE tissue specimens were therefore carried out using the QIAamp DNA FFPE tissue 
kit (Protocol A).   
 
4.1.2 Extraction of genomic DNA from study specimens for PCR analysis 
 
Archived FFPE tissue blocks were obtained from the Tayside Tissue Bank and tissue 
specimens were assessed for their suitability in PCR analysis. Genomic DNA was 
extracted from 320 specimens using the QIAamp FFPE Tissue kit. The concentration 
and absorbance ratios of extracted DNA samples showed that the absorbance ratio of 
A260/280 was 1.9 - 2.1 for most samples while that of A260/230 was 2 - 2.3. 
Depending on the size of the specimen, DNA concentration was variable across samples 
with concentrations as low as 4 ng/µl for a few specimens.  
 
4.2 Detection of HPV DNA in the archived specimens 
4.2.1 Optimising PCR reactions 
 
The Polymerase Chain Reaction (PCR) is a powerful and sensitive technique for the 
amplification of DNA segments. Successful amplification of a DNA sequence is 
dependent on several parameters which include template DNA, primers, DNA 
polymerase, reagents such as dNTPs and magnesium and thermal cycling temperatures. 
Optimisation of PCR reagent concentrations and cycling conditions improves product 
yield and reproducibility between reactions, while reducing non-specific and unwanted 
products.  
 
PCR analysis for this study was performed using the Taq DNA Polymerase system 
supplied by New England Biolabs, which provides an optimised protocol and a buffer 
solution with added dNTPs and magnesium. Ideal thermal cycling temperatures were 
subsequently ascertained for different primer pairs used in the study.  
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Marker 
  3T3 
100 ng 
  HaCaT 
  100 ng 
  HaCaT 
  100 ng 
   SiHa 
  100 ng 
   HeLa 
 100 ng 
4.2.2 Selecting controls for PCR Reactions 
 
The use of negative and positive controls is important to validate the results of gene 
expression obtained by PCR. DNA extracted from HaCaT, SiHa or HeLa cell lines were 
employed as positive controls for the detection of human β-globin, HPV L1 and HPV 
E1 respectively. Figure 4.2 below is an illustration of the quality of template positive 
control DNA obtained from cell lines.  
 
 
 
 
 
 
 
Figure 4.2: Agarose gel electrophoresis image of template DNA to assess quality of DNA extracted 
from HaCaT, SiHa and HeLa cell lines. DNA extracts from HaCaT, SiHa and Hela cell lines were 
employed as controls for PCR amplifications of the human β-globin gene, HPV L1 and E1 genes 
respectively. SiHa and HeLa cell lines harbour HPV-16 and HPV-18 respectively and were 
employed as controls for PCR amplification of HPV-16 E7 and HPV-18 E7 genes.  
 
4.2.3 Selecting HPV types for investigation 
 
A major portion of evidence on the presence of HPV in HNSCC in the literature points 
to high-risk HPV-16 as an important causative factor [195]. In order to ascertain the 
incidence of other high risk HPV types prevalent in the sample patient population from 
the Tayside catchment area, investigations for this study used, as a guideline, the most 
common HPV types which had been identified by various scientific groups in British 
patient populations. As such, the prevalence of HPV types 16, 18, 33, and 52 was 
investigated [4], [131], [321], [264], [178], [75].  
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4.2.4 Determining optimal cycling conditions for each PCR 
 
Target genes human β-globin, HPV L1 and E1 were amplified with consensus primer 
pairs GH20/PC04, MY09/MY011 and CP1/CPIIG respectively. E7 genes of HPV types 
16, 18, 33 and 52 were amplified with type specific primer pairs as outlined in Chapter 
2, Table 2.2. 
 
A guideline annealing temperature for each primer pair was obtained from relevant 
literature. The protocol recommended by New England Biolabs successfully amplified 
target genes for most primers albeit with weak and non-specific products in certain 
instances. Therefore, parallel reactions were set up with different annealing 
temperatures to optimise the PCR product. Figure 4.3 below is a representation of 
amplification of target gene HPV E1 at various annealing temperatures, of which 52
o
C 
was found to be the most ideal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Optimising consensus primers. Parallel PCR reactions were set up to determine the 
optimal annealing temperature for each primer pair. Template DNA from HeLa cell extracts was 
employed to amplify a188bp fragment of the HPV E1 gene using CPI/IIG primers. An annealing 
temperature of 52
o
C was found to be the most ideal for this primer pair. 
 
Test reactions were also carried out to ensure that each primer pair was specific to the 
target gene of interest. Figures 4.4 (A) and (B) are an illustration of the specificity of 
primer pairs amplifying the HPV-16 E7 and HPV-18 E7 genes.  
 
 
 
Marker 
HeLa  
53
o
C   52
o
C 54
o
C 
HeLa HeLa 
HPV E1 
(188bp) 
200bp 
Non-specific bands 
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Figure 4.4 (A) & (B): Optimising type specific primers (A) A PCR reaction was carried out to 
amplify a 108bp fragment of the HPV-16 E7 employing a type specific primer pair. DNA extracted 
from SiHa and HeLa cell lines which harbour HPV-16 and 18 respectively, were used as template 
DNA.  As expected, a PCR product of the correct size is seen corresponding to the sample 
containing the SiHa extract. (B) A similar PCR reaction was carried out to amplify the HPV-18 E7 
gene. A PCR product of correct molecular weight is seen corresponding to the samples containing 
HeLa. The plasmid Plxsn 6b E6 was employed as a negative control along with DNA from SiHa cell 
lines. 
 
4.2.5 Troubleshooting non-specific bands 
 
While all the PCRs successfully amplified target genes, the appearance of non-specific 
bands prompted further investigation. When the experiments were repeated with 
variations in primer/template concentrations and cycling conditions, the additional 
bands persisted (Figure 4.5A). However, when a reaction was carried out with single 
primer controls (Figure 4.5 B) non-specific bands corresponding to these primers were 
not seen. The non-specific PCR products were therefore attributed to primer 
dimerisation. Further attempts to eliminate these bands were deemed unnecessary as 
they did not interfere with any of the target sequences.  
 
 
 
 
 
 
 
Marker 
No Template 
control HeLa SiHa 
HPV-16 E7 
  (108bp) 
(A) 
100bp 
Marker SiHa HeLa HeLa 
Plxsn 
 6b E6 
  HPV-18 E7 
       (104bp) 
(B) 
100bp 
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Figure 4.5 (A) & (B): Troubleshooting non-specific PCR products (A) Parallel PCR reactions at 
annealing temperatures ranging from 57
o
C – 59oC were set up to amplify  human β-globin from 
DNA extracted from HaCaT cell lines. Increasing annealing temperature failed to completely 
eliminate the non-specific bands. (B) In order to investigate the possibility of primer dimerisation a 
PCR reaction was carried out to amplify human β-globin using HaCaT template DNA and single 
primers from the GH20/PC04 pair as controls. A non-specific product was only visible in Lane 2 
corresponding to the template HaCaT DNA suggesting that the non-specific bands may correspond 
to primer dimers.  
 
4.2.6 Determining the presence of amplifiable DNA with human β-globin gene 
 
The quality of DNA extracted from FFPE specimens can vary from one sample to 
another depending on factors such as type of fixative, duration of fixation and post 
fixation storage [120]. Amplifying a fragment of a housekeeping gene is an effective 
way to assess the quality of DNA extracted from archived FFPE tissue specimens.  
Extracted DNA from 320 FFPE specimens was subjected to PCR to amplify a 260bp 
fragment of the human β-globin gene using the GH20/PC04 primer pair with DNA from 
HaCaT and SiHa cell lines serving as positive controls. Out of 320 samples, 293 (92%) 
were positive for β-globin. PCR products visualised as bands on the gel were of varying 
intensities ranging from very strong bands to weak bands. Figure 4.6 below shows β-
globin amplification in 24 patient DNA samples. In the detailed image of Gel 1, bands 
corresponding to the β-globin gene are visible for Specimen IDs 66-71 along with 
positive controls HaCaT and SiHa. No band is visible in relation to the ‘No Template 
Control’. 
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bands 
    
(A) (B) 
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Figure 4.6: PCR assessment of DNA quality. DNA extracted from archived FFPE specimens was 
analysed for the presence of human β-globin by amplifying a 260bp fragment of the β-globin gene 
using the GP04/PC05 primers. Image of Gel 1 has been enlarged to show β-globin was amplification 
in samples 66-71. DNA extracted from SiHa and HaCaT cell lines was used as positive controls.  
 
4.2.7 Determination of the presence of HPV L1 and E1 genes 
 
The 27 extracted DNA samples negative for human β-globin gene were excluded from 
the cohort. The remaining 293 samples were put through PCR to amplify a 450bp 
fragment of the HPV consensus L1 gene using the MY09/MY011 primer pair. Of the 
293 samples, 42 were positive for HPV L1 gene. Samples negative for HPV L1 gene 
were further investigated for the presence of consensus HPV E1 gene by performing 
PCR to amplify a 188bp fragment of the E1 gene using CPI/CPIIG primers. DNA from 
HeLa or SiHa cell lines served as positive controls for both the sets of PCR reactions. 
Eleven samples were found to be positive for HPV E1. Figure 4.7 below is a 
representation of PCR amplification of HPV E1 gene from Specimens 139 - 150.  
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Figure 4.7: PCR analysis for the HPV E1 gene. DNA extracted from archived FFPE specimens was 
analysed for the presence of HPV E1 by amplifying a 188bp fragment of the HPV E1 gene using the 
consensus CPI/IIG primers. ‘SID’ denotes Sample ID. DNA extracted from HeLa cell lines was 
used as a positive control, and SIDs 146 -150 were found to be positive for the E1 gene. 
 
4.2.8 Determining types of high-risk HPV 
 
The 53 samples positive for HPV L1 or E1 were investigated further to determine the 
specific HPV genotype by amplifying fragments of the E7 gene of HPV types 16, 18, 33 
and 52. Fifty samples positive for HPV L1 or E1 were also positive for HPV-16 E7, two 
samples were positive for HPV-18 E7 and one for HPV-33 E7. Six of the genotyped 
samples were sequenced to confirm the specificity of the PCR products. Figure 4.8 is an 
illustration of PCR amplification of the HPV-16 E7 gene in specimens 2, 14, 45, 55, 84, 
88, 133, 134 and 348. 
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Figure 4.8: PCR analysis for HR-HPV type 16. DNA extracted from archived FFPE specimens was 
analysed for the presence of HPV 16 by amplifying a 108bp fragment of HPV 16 E7 gene using type 
specific primers. ‘SID’ denotes Sample ID. DNA extracted from SiHa cell lines was used as a 
positive control (image of another gel with controls from the same experiment). As evident in this 
gel, SIDs 45, 84, 88, 134 and 348 were found to be positive for HPV 16. 
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The workflow diagram below summarises the overall final results of the PCR 
component of the study (Figure 4.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 4.9: PCR workflow diagram. Study samples were initially tested for DNA quality by 
amplifying the house keeping gene human β-globin. Samples negative for β-globin were excluded 
from the study. The remaining samples (n=293) were genotyped for HR-HPV using consensus 
primers MY09/MY011 and CPI/IIG followed by type specific primers for HPV types 16, 18, 33 and 
52. HR-HPV type 16 was detected in 50 samples, HR-HPV type 18 in 2 samples and type 33 in 1 
sample. 
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4.3 Prevalence of HPV in the study population 
4.3.1 p16 status of the study cohort 
 
A known p16 status for each patient was a key inclusion criterion for this study. 
Archived biopsy or resection specimens of patients were selected from an existing 
database of HNSCC carcinoma patients based on the availability of a p16 status. Out of 
293 patients, 47 (16%) were positive for p16 and the remaining 246 (84%) were p16-
negative (Figure 4.10).  
 
 
 
Figure 4.10: p16 status of the study cohort. Archived FFPE tumour samples were selected for the 
study based on the availability of a p16 status for each patient.  Out of 293 patients, 47 (16%) were 
p16-positive and the remaining 246 (84%) were p16- negative. 
 
4.3.2  Variability in patient demographics and tumour histopathology by p16 
status 
 
The p16-positive and negative groups were compared for significant associations based 
on demographics and tumour histopathology (Table 4.4). More than half of the patients 
in the p16-positive group were under the age of 58 years (P = 0.002). They were either 
non-smokers or ex-smokers while patients in the p16-negative group were 
predominantly current smokers (P < 0.001). More than half of the patients in the p16-
positive group (28/47; 60%) were also light to moderate drinkers (P < 0.05).  
 
Significant differences were noted between the two patient groups with respect to 
anatomic site of primary tumour, grade of differentiation and disease stage (Table 4.4). 
The majority of p16-positive tumours (60%) arose in the oropharynx and were either 
poorly differentiated (23%) or moderate to poorly differentiated (25%), while p16-
p16 status of the cohort 
p16 Positive
p16 Negative
84% 84% 
16% 
High-risk HPV 16 
High-risk HPV 18 
High-risk HPV 33 
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negative tumours were more common in the larynx (99%) or oral cavity (95%) and were 
likely to be either well or moderately differentiated (P < 0.001, P = 0.002). Although 
p16-positive patients were more likely to present with late stage disease (P = 0.003), 
overall survival was better compared to the negative group (P = 0.004) and had a 
decreased likelihood of recurrence as well (P = 0.03). 
    Variable p16-negative 
 
   (n=246) 
p16-positive 
 
   (n=47) 
Total No. 
 
(n=293) 
Pearson’s 
CHI Square 
Age 
 
≤ 58 
59 – 64 
65 – 73 
≥ 74 
 
Total  
 
 
 
67 (73%) 
51(84%) 
65 (90%) 
63 (93%) 
 
246  
 
 
25(27%) 
10 (16%) 
7 (10%) 
5 (7%) 
 
47  
 
 
92 
61 
72 
68 
 
293 
 
 
 
 
P = 0.002 
History of smoking  
 
Non smoker 
Smoker 
d
 
Ex-smoker 
 
Total 
 
 
 
31 (66%) 
116 (93%) 
59 (80%) 
 
206 
 
 
16 (34%) 
8 (7%) 
15 (20%) 
 
39 
 
 
47 
124 
74 
 
245 
 
 
 
 
P < 0.001 
History of alcohol 
consumption 
 
Light-moderate drinker 
Heavy drinker 
Non drinker 
Ex-heavy drinker 
Alcohol status 
unknown
a
 
 
Total  
 
 
 
 
89 (76%) 
63 (89%) 
32 (94%) 
9 (100%) 
53 (85%) 
 
 
246 
 
 
 
28 (24%) 
8 (11%) 
2 (6%) 
0 (0%) 
9 (15%) 
 
 
47 
 
 
 
117 
71 
34 
9 
62 
 
 
293 
 
 
 
 
 
P = 0.03 
   
Site of primary 
tumour 
 
Oral cavity 
Oropharynx 
Larynx 
Other
b
 
 
Total 
 
 
 
 
94 (95%) 
24 (40%) 
87 (99%) 
41 (89%) 
 
246 
 
 
 
5 (5%) 
36 (60%) 
1 (1%) 
5 (11%) 
 
47 
 
 
 
99 
60 
88 
46 
 
293 
 
 
 
 
 
P < 0.001 
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a. Alcohol status unknown- data on alcohol history at diagnosis was unavailable 
b. Other – includes hypopharynx, pharynx, nasopharynx and unknown primary 
c. Unknown –where primary tumour was unknown and stage of disease could not be determined  
d. The categories ‘Light smoker’, ‘Moderate smoker’, ‘Heavy smoker’ and ‘other’ introduced in Table 3.2 were collapsed 
to into the category ‘smoker’  
 
 
Table 4.4: Baseline characteristics of patients stratified based on p16 status. Significant differences 
were noted between patients with p16-positive and negative tumours in social demographics, site of 
primary tumour, histological grade of tumour differentiation, disease stage, overall and recurrence 
free survival. 
 
 
4.3.3 Relationship between p16 status and survival 
 
After a median follow-up period of 46 months, the p16-positive group had a larger 
proportion of survivors (32/47; 68%) compared to the p16-negative group (112/246; 
45%). A Kaplan Meier analysis of overall survival rates demonstrated favourable 
prognosis for patients with p16-positive tumours (Figure 4.11). Mean survival time (in 
Grade of tumour 
differentiation 
 
Well differentiated 
Moderately 
differentiated 
Poorly differentiated 
Moderate to poorly 
differentiated 
 
Total 
 
 
 
 
5 (100%) 
 
111 (93%) 
88 (77%) 
 
21 (75%) 
 
225 
 
 
 
0 (0%) 
 
8 (7%) 
27 (23%) 
 
7 (25%) 
 
42 
 
 
 
5 
 
119 
115 
 
28 
 
267
a
 
 
 
 
 
 
P = 0.002 
Disease stage 
 
Stage I 
Stage II 
Stage III 
Stage IVA & IV B 
Unknown
c
 
 
Total  
 
 
 
46 (98%) 
39 (93%) 
36 (84%) 
105 (76%) 
8 (89%) 
 
234 
 
 
1 (2%) 
3 (7%) 
7 (16%) 
33 (24%) 
1 (11%) 
 
45 
 
 
47 
42 
43 
138 
9 
 
279 
 
 
 
 
P = 0.003 
Overall survival 
 
Alive 
Dead 
 
Total 
 
 
 
112 (78%) 
134 (90%) 
 
246 
 
 
32 (22%) 
15 (10%) 
 
47 
 
 
144 
149 
 
293 
 
 
 
P = 0.004 
Recurrence 
 
Yes 
No 
 
Total  
 
 
 
51 (93%) 
195 (82%) 
 
246 
 
 
4 (7%) 
43 (18%) 
 
47 
 
 
55 
238 
 
293 
 
 
  
P = 0.03 
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months) for p16-positive patients was 67 months (95% Confidence Interval 57 – 77) 
compared to only 55 months for p16-negative patients (95% Confidence Interval 49 – 
62) (Log Rank (Mantel-Cox) CHI Sq. 6.4 (df 1) P = 0.01).  
 
 
 
Figure 4.11: Kaplan-Meier plot for overall survival based on p16 status. Overall survival for 
patients with p16-positive tumours (represented by the blue line) was significantly better compared 
to patients with p16-negative tumours (represented by the green line).  
 
The median follow-up period for recurrence free survival was 43 months and a greater 
incidence of recurrence was recorded in p16-negative compared to those with p16-
positive tumours. A Kaplan Meier analysis demonstrated improved disease free survival 
for p16- positive patients compared to their negative counterparts (Figure 4.12). Mean 
disease free survival time for p16-positive patients was 75 months (95% Confidence 
Interval 68.3 – 81.5) compared to 64 months for p16-negative patients  (95% 
Confidence Interval 63.5 – 74.3) (Log Rank (Mantel –Cox) CHI Sq. 5.571 (df 1) P = 
0.018). 
 
 
 
P = 0.01 
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Figure 4.12: Kaplan-Meier plot for recurrence free survival based on p16 status. Patients with p16-
positive tumours (n=47) represented by the blue line demonstrated better disease free survival 
compared to those with p16-negative tumours (n=246) represented by the green line. 
 
A Kaplan Meier analysis was performed to determine disease specific survival in p16- 
positive patients and negative patients (Figure 4.13). Mean disease specific survival 
time for p16-positive patients was 79 months (95% Confidence Interval 71.6 – 87.2) 
compared to 83 months for p16 negative  patients  (95% Confidence Interval 74.8 – 
90.6). No significant improvement in disease specific survival was noted between the 
two patient groups (Log Rank (Mantel –Cox) CHI Sq. 2.39 (df 1) P = 0.122). 
 
 
 
 
 
 
 
 
 
P = 0.018 
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Figure 4.13: Kaplan-Meier plot for disease specific survival based on p16 status. Although patients 
with p16-positive tumours (represented by the blue line) had better disease specific survival 
compared to those with p16-negative tumours (represented by the green line), it was not found to 
be statistically significant. 
 
4.3.4 HPV prevalence based on detection of viral DNA 
 
PCR amplification of viral DNA revealed that 18% (n=53) of the study population was 
HPV DNA positive. Of the positive samples, an overwhelming majority were high-risk 
HPV type 16 (94%), while types HPV types 18 and 33 constituted 6%. Figure 4.14 
below summarises the prevalence of high-risk HPV DNA in the study population.  
 
P = 0.121 
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Figure 4.14: Prevalence of high-risk HPV DNA in the study cohort. Archival FFPE tissue 
specimens were genotyped by PCR for high-risk HPV. While the vast majority of patient samples 
were negative for viral DNA (n= 240), 50 samples were positive for high-risk HPV 16, 2 for HPV 
type 18 and 1 for HPV type 33. 
 
4.3.5  Prevalence of HPV based on HPV DNA status and p16 overexpression 
 
In order to ascertain the actual prevalence of HPV in the study population, patients were 
classified based on the presence of HPV DNA and/or p16 overexpression. Four groups 
were identified: HPV DNA-ve/p16-ve, HPV DNA-ve/p16+ve, HPV DNA+ve/p16-ve 
and HPV DNA+ve/p16+ve as described by Weinberger et al. [319]. Tumours were 
defined as ‘true positive’ only if they were positive for both HPV DNA and p16, and 
‘true negative’ when they were negative for both.  Tumours positive for either HPV 
DNA or p16 were defined as ‘Equivocal’ [75]. The bar chart below represents the 
proportion of the four groups in the study cohort (Figure 4.15). Almost 80% of the 
cohort was true negative and 14% true positive. Equivocal groups constituted the 
remaining 6% and were excluded from subsequent analyses.  
 
 
 
 
18% 82% 
HPV DNA status of cohort 
HPV DNA Positive HPV DNA Negative
94% 
2% 
4% 
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Figure 4.15: Classification of study cohort based on HPV DNA and/or p16 expression. Patients 
were divided into 4 groups - HPV DNA-ve/p16-ve or ‘True negative’ (n= 233), HPV DNA-
ve/p16+ve or ‘Equivocal’ (n=7), HPV DNA+ve/p16-ve or ‘Equivocal’ (n=13), HPV DNA+ve/p16+ve 
or ‘True positive’ (n=40). 
 
4.3.6 Variability in patient demographics and tumour histopathology by HPV 
status 
 
The majority of HPV-positive patients were found to be in the younger age group of 58 
years or under (P = 0.001) and were either ‘non-smokers’ or ‘Ex-smokers’, compared to 
the HPV-negative group where most patients were ‘Current smokers’ (P < 0.001) 
(Table 4.5). Patients with HPV-positive tumours were more likely to be ‘light to 
moderate drinkers’ at the time of diagnosis compared to those with HPV-negative 
tumours who were either ‘light to moderate drinkers’ or ‘heavy drinkers’ (P = 0.005). 
Surprisingly, the number of cases diagnosed did not increase with each year, although a 
surge in cases diagnosed was noted in the year 2010. HPV-positive tumours arose 
predominantly in the oropharynx (33/40; 83%) while HPV-negative tumours arose in 
the oral cavity (93/233; 39%) and the larynx (84/233; 36%). Further analysis of the 
anatomic site of origin of HPV-positive tumours revealed that 24 out of 40 tumours 
arose in the tonsils and 9 in the base of the tongue (Table 4.6). Although both groups 
presented with late stage disease, HPV-positive patients were more likely to present 
with nodal metastasis (P < 0.001). Substantial differences in histopathological features 
such as tumour differentiation, extracapsular spread and presence of tumour invasive 
front were noted between the groups. While a significant proportion of HPV-negative 
tumours were either well or moderately differentiated, HPV-positive patients were 
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likely to present with poor or moderate to poorly differentiated tumours (P < 0.001). 
HPV-positive tumours were also less likely to exhibit extracapsular spread (P = 0.001) 
and an invasive cohesive front (P < 0.001), both of which are features of tumour 
aggression. At the time of censoring, more than half of the patients from the HPV-
negative group were deceased compared to only 30% (12/40) from the HPV-positive 
group (P = 0.002). No significant associations were found between histological features 
of tumours such a presence of lymphovascular and perineural invasion and tumour HPV 
status presumably because of the large amount of missing data for these variables 
 Variable HPV-negative 
(n=233) 
HPV- positive 
(n=40) 
Total No. 
(n=273) 
Pearson’s CHI 
Square 
Age 
 
≤ 58 
59 – 64 
65 – 73 
≥ 74 
 
                 Total 
 
 
 
60 (72%) 
47 (87%) 
64 (91%) 
62 (94%) 
 
     233 
 
 
23 (28%) 
7 (13%) 
6 (9%) 
4 (6%) 
 
40 
 
 
83 
54 
70 
66 
 
273 
 
 
 
 
P = 0.001 
History of    smoking 
 
Non smoker 
Current smoker 
Ex-smoker 
 
Total 
 
   
     27 (64%) 
112 (97%) 
56 (80%) 
 
195 
 
 
 
15 (36%) 
4 (3%) 
14 (20%) 
 
33 
 
 
42 
116 
70 
 
228 
 
 
 
 
P = 0.000 
History of alcohol 
consumption 
 
Light to moderate drinker 
Heavy drinker 
Non drinker 
Ex-heavy drinker 
 
Total 
 
 
 
 
78 (76%) 
63 (91%) 
32 (94%) 
9 (100%) 
 
    182 
 
 
 
25(24%) 
6 (9%) 
2 (6%) 
0 (0%) 
 
        33 
 
 
 
103 
69 
34 
9 
 
         215 
 
 
 
 
 
     P = 0.005  
Year of diagnosis 
 
2006 
2007 
2008 
2009 
2010 
2011 
 
Total 
 
 
26 (90%) 
60 (85%) 
38 (100%) 
42 (89%) 
32 (70%) 
35 (83%) 
 
233 
 
 
3 (10%) 
11 (15%) 
0 (0%) 
5 (11%) 
14 (30%) 
7 (17%) 
 
40 
 
 
29 
71 
38 
47 
46 
42 
 
273 
 
 
 
 
 
    P = 0.005 
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Site of primary tumour 
 
Oral  cavity 
Oropharynx 
Larynx 
Other
a
 
 
Total 
 
 
 
91 (97%) 
21 (39%) 
84 (100%) 
37 (90%) 
 
233 
 
 
3 (3%) 
33 (61%) 
0 (0%) 
4 (10%) 
 
40 
 
 
94 
54 
84 
41 
 
273 
 
 
 
 
P = 0.000 
Grade of tumour 
differentiation 
 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Moderate to poorly 
differentiated 
 
                 Total 
 
 
 
 5 (100%) 
110 (96%) 
  80 (77%) 
     19 (76%) 
 
 
214 
 
 
 
0 (0%) 
5 (4%) 
24 (23%) 
        6 (24%) 
 
         
         35 
 
 
 
5 
115 
104 
          25 
 
         
       249 
 
 
 
 
 
 
P = 0.000 
Disease  staging 
 
Stage I 
Stage II 
Stage III 
Stage IVA & IVB 
Unknown
b
 
 
Total 
 
 
 
42 (98%) 
39 (95%) 
34 (85%) 
101 (78%) 
5 (83%) 
 
221 
 
 
1 (2%) 
2 (5%) 
6 (15%) 
29 (22%) 
1 (17%) 
 
39 
 
 
43 
41 
40 
130 
6 
 
260 
 
 
 
P ≥ 0.05 
(NS) 
Neck node status 
 
Negative 
Positive 
 
Total 
 
 
 
131 (96%) 
99 (74%) 
 
230 
 
 
5 (4%) 
34 (26%) 
 
39 
 
 
136 
133 
 
269 
 
 
 
P = 0.000 
Presence of extracapsular 
spread 
 
Yes 
No 
Inconclusive
c
 
 
Total 
 
 
 
37 (88%) 
32 (58%) 
0 (0%) 
 
69 
 
 
 
5 (12%) 
23 (42%) 
2 (6%) 
 
30 
 
 
 
42 
55 
2 
 
99 
 
 
 
 
 
P = 0.001 
Presence of non-cohesive 
invasive front 
 
Yes 
No 
 
Total 
 
 
 
 
66 (97%) 
76 (78%) 
 
142 
 
 
 
2 (3%) 
22 (22%) 
 
24 
 
 
 
68 
98 
 
166 
 
 
 
 
P = 0.000 
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a. Other – includes hypopharynx, pharynx, nasopharynx and unknown primary 
b. Unknown – where primary tumour was unknown and disease stage could not be determined           
c. Inconclusive – where primary tumour was unknown, surgery was not a modality of treatment or data was missing 
 
.Table 4.5: Characteristics of patients based on HPV status. Significant differences were noted 
between patients with HPV-positive and negative tumours in social demographics, site of primary 
tumour, histological grade of tumour differentiation, neck node status, presence of extracapsular 
spread and non-cohesive invasive front and overall survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of 
lymphovascular invasion 
 
Yes 
No 
Inconclusive
c
 
 
Total 
 
 
 
 
31 (89%) 
110 (85%) 
2 (100%) 
 
143 
 
 
 
4 (11%) 
20 (15%) 
0 (0%) 
 
24 
 
 
 
35 
130 
2 
 
167 
 
 
 
 
P = 0.7 
(NS) 
Presence of perineural 
invasion 
 
Yes 
No 
 
Total 
 
 
 
 
20 (100%) 
93 (85%) 
 
113 
 
 
 
0 (0%) 
17 (15%) 
 
17 
 
 
 
20 
110 
 
130 
 
 
 
 
P = 0.05 
(NS) 
Recurrence 
 
Yes 
No 
 
Total 
 
 
 
49 (93%) 
184 (84%) 
 
233 
 
 
4 (7%) 
36 (16%) 
 
40 
 
 
53 
220 
 
273 
 
 
P = 0.07 
(NS) 
Survival status 
 
Alive 
Dead 
 
Total 
 
 
 
102 (79%) 
131 (92%) 
 
233 
 
 
28 (21%) 
12 (8%) 
 
40 
 
 
130 
143 
 
273 
 
 
  P = 0.002 
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Head and Neck 
subsite group 
Clinical anatomic 
location 
No. of patients Type of high-risk 
HPV 
 
Oral cavity 
Dorsum of tongue 
Palate 
Anterior 1/3 of tongue 
1 
1 
1 
HPV 16 
HPV 16 
HPV 16 
 
Oropharynx 
Base of tongue 
Tonsil 
 
9 
24 
HPV 16 
HPV 16 
 
 
Other 
Unknown primary 
Pharynx 
Nares 
Nasal cavity 
1 
1 
1 
1 
HPV 16 
HPV 16 
HPV 16 
HPV 18 
 
 
Table 4.6: Summary of HPV-positive tumours by anatomic location in the head and neck. The 
majority of HPV-positive tumours (33/40; 83%) arose from the oropharynx with the tonsils and 
base of the tongue being the most common subsites of origin. An overwhelming majority of the 
HPV-positive tumours were infected with high-risk type 16.  
 
 
4.3.7 Relationship between HPV status and survival 
  
After median follow-up periods of 44 months, a greater proportion of survivors was 
seen in the HPV-positive group (28/40; 70%) compared to the HPV-negative group 
(102/233; 44%). Indeed, a Kaplan Meier analysis of overall survival rates demonstrated 
favourable prognosis for patients with HPV-positive tumours (Figure 4.16). Mean 
survival time for HPV-positive patients was 63 months (95% CI 54 – 72.8) compared to 
only 53 months for HPV negative (46.3 – 59.7) (Log Rank (Mantel-Cox) CHI Sq. 7.11 
df (1) P = 0.008). The Cox proportional hazards analysis was performed to validate the 
independent prognostic significance of HPV along with other variables such as age, 
smoking history, site of primary tumour, disease stage, neck node status and 
extracapsular spread (all of which were significantly influenced overall survival in 
univariate analyses). After controlling for age, smoking status, site of primary tumour, 
disease stage, neck node status and extracapsular spread a positive tumour HPV status 
was found to be an independent prognostic indicator (HR 0.216; 95% CI  0.06 – 0.771) 
as was the absence of extracapsular spread (Table 4.7).  
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Figure 4.16: Kaplan-Meier plot for overall survival. HPV status of patients in the study was defined 
by the presence of HPV DNA and p16 overexpression. Four groups of patients were identified; 
HPV-positive (HPV DNA+ve/p16+ve), HPV-negative (HPV DNA-ve/p16-ve), Equivocal 
(HPVDNA+ve/p16-ve or HPV DNA-ve/p16+ve). Patients in the cohort with ‘Equivocal’ status were 
excluded from the analysis. Overall survival of the HPV-positive group (represented by the green 
line) was significantly higher than that of the HPV-negative group (represented by the blue line).  
  
P = 0.008 
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Variable Univariate analysis 
(P value) 
Multivariate analysis –
Hazard ratio (95% CI) 
P value 
Age 
 
≤ 58 
59 – 64 
65 – 73 
≥ 74 
 
 
 
 
≤ 0.001 
 
 
(reference category) 
0.66 (0.207 – 2.103) 
1.239 (0.542 – 2.832) 
1.639 (0.555 – 4.839) 
 
 
0.604 
0.483 
0.611 
0.371 
History of smoking 
 
Non smoker 
Current smoker 
Ex-smoker 
 
 
 
 
 
0.006 
 
 
(reference category) 
0.807 (0.300 – 2.170) 
0.595 (0.188 – 1.884) 
 
 
 
0.671 
0.671 
0.378 
Site of primary 
tumour 
 
Oral  cavity 
Oropharynx 
Larynx 
Other 
 
 
 
 
 
0.01 
 
 
 
(reference category) 
1.658 (0.614 – 4.473) 
1.131 (0.456 – 2.805) 
1.860 (0.630 – 5.497) 
 
 
 
 
0.617 
0.318 
0.790 
0.261 
Stage of disease 
 
Stage I 
Stage II 
 
Stage III 
 
Stage IVA & IVB 
 
 
 
 
 
 
≤ 0.001 
 
 
(reference category) 
 
3.525 (1.088– 11.423) 
1.340 (0.149 – 12.064) 
 
 
 
 
0.84 
 
0.36 
 
0.794 
Extracapsular spread 
 
Yes 
No 
Inconclusive 
 
 
 
 
 
≤ 0.001 
 
 
(reference category) 
0.321 (0.145 – 0.708) 
0.000 
 
 
 
0.19 
0.005 
0.976 
 
HPV status 
 
Negative 
Positive 
 
 
 
0.008 
 
 
 
(reference category) 
0.216 (0.06 – 0.771) 
 
 
 
 
 
 
 
0.018 
 
Table 4.7: Cox regression analysis for overall survival.  On univariate analysis, age, smoking 
history, site of primary tumour, disease stage, neck node status, extracapsular spread and HPV 
status were found to be significantly associated with overall survival. After controlling for 
confounding variables, HPV positivity and extracapsular spread were found to be independent 
prognostic indicators. 
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HPV positivity was associated with improved recurrence free survival (Figure 4.17). 
Mean disease free survival time for HPV-positive patients was 72 months (95% CI 65 – 
79) compared to 66 months for HPV-negative  patients (95% CI 61 – 72) (Log Rank 
(Mantel-Cox) CHI Sq. 4.5 (df1) P = 0.03). 
 
 
 
 
 
Figure 4.17: Kaplan-Meier plot for recurrence free survival. HPV positivity (n=40) represented by 
the green line was associated with better disease free survival. 
 
Surprisingly, a positive tumour HPV status did not confer a significant improvement in 
disease specific survival (Figure 4.18). Mean cause specific survival time for HPV-
positive patients was 73 months (95% CI 65.8 – 81.2) compared to 82 months for HPV 
negative (73.7 – 89.9) (Log Rank (Mantel-Cox) CHI Sq. 2.39 df (1) P = 0.122). 
 
 
 
 
 
 
 
P = 0.03 
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Figure 4.18: Kaplan-Meier plot for disease specific survival. Although patients with HPV-positive 
tumours (represented by the green line) had better disease specific survival compared to those with 
HPV-negative tumours (represented by the blue line), it was not found to be statistically significant.  
 
4.3.8 Detection of HPV DNA by In Situ Hybridisation 
HPV testing in a clinical setting is carried out utilising a variety of tests, most 
commonly, PCR, p16 immunohistochemistry (IHC) and In Situ Hybridisation (ISH). 
Although consensus is divided over a universally accepted algorithm for HPV testing, a 
combination of p16 IHC and DNA ISH has been found to be favourable [255]. Given 
the changes in testing practice trends over the course of this study, a decision was taken 
to further investigate the HPV status of all ‘true positive’ study samples by HPV DNA 
ISH.  
 
Study samples positive for viral DNA by PCR (n = 53) along with 8 negative control 
samples were tested by DNA ISH at the Department of Clinical Pathology in Ninewells 
Hospital. The test results were interpreted by two independent observers (AS and SW). 
Observations were compared and differences in opinions were reconciled. Surprisingly, 
only 29 out of 53 (55%) samples tested positive for HPV by DNA ISH. Furthermore, 
only 24 samples were positive for viral DNA by PCR and p16. Out of 24 negative 
samples, 8 were positive for HPV DNA by PCR and 16 samples were positive for both 
p16 and HPV DNA by PCR. All tissue samples sent as negative controls were also 
negative for HPV by ISH. Figures 4.19 (A), (B), (C) and (D) represent ISH detection of 
P = 0.122 
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HPV in specimens 88, 45, 137 and 161 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.19: Detection of high-risk HPV by DNA ISH in histological sections of cohort specimens. 
(A) Poorly differentiated squamous cell carcinoma involving the dorsum of the tongue (x400) 
demonstrating HPV staining in tumour cell nuclei. (B) ISH positive for HPV in a poorly 
differentiated squamous cell carcinoma involving the anterior 2/3 of the tongue (x400) (C) 
Oropharyngeal squamous cell carcinoma demonstrating dot like ISH signal for HPV (D) Squamous 
cell carcinoma of the tonsil negative for HPV ISH.  
 
4.4 Discussion 
The research presented in this chapter was undertaken to establish the prevalence of 
HPV in a cohort of HNSCC patients in Tayside, Scotland. This study involved a 
retrospective analysis of archived FFPE tumour biopsy specimens obtained from the 
local tissue bank. Although FFPE tissue is an invaluable resource for obtaining nucleic 
acids - especially DNA for molecular analyses - its isolation is often challenging. 
Formalin fixation leads to the generation of nucleic acid protein cross linkages and can 
greatly affect DNA quality. Furthermore, temperature and pH of a fixative, when not 
adequately controlled, can adversely affect the quality of DNA leading to its 
degradation [97].  
 
(A) (C) 
(B) (D) 
SID 88 SID 137 
SID 45 SID 161 
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Preliminary experiments were carried out to determine the best approach for optimal 
recovery of DNA from the archived tissue. Two protocols; the QIAamp FFPE DNA 
extraction kit and an in-house DNA lysis buffer (LC) were compared. DNA 
concentration and total yield obtained with buffer LC was consistently higher than that 
obtained with the Qiagen kit. While the LC buffer protocol employs a simple ethanol 
precipitation purification step, the Qiagen kit uses silica based spin columns for nucleic 
acid purification. Multi-step processing of lysates and loss of DNA in the silica spin 
columns may explain the apparent low DNA yield with the Qiagen kit [182]. 
Absorbance ratio A260/230 values were often very low or variable with both protocols 
indicating either a problem with the tissues or contamination with organic compounds 
or solvents (such as phenol and glycogen) utilised in the extraction process [286]. 
However, comparison of PCR results confirmed that template DNA isolated with the 
Qiagen kit was more amplifiable than that obtained with the in-house protocol as 
observed in previously published data [273].  
 
Ever since a causal association between high-risk HPV and HNSCC was first proposed 
by Syranjen et al., [294] the presence of HPV DNA in HNSCC has been reported by 
numerous groups [218], [13], [99]. Previous studies exploring prevalence of HPV in the 
British population have focused on oropharyngeal cancers alone and where 
heterogeneous cohorts were selected, the sample sizes were small [264], [75], [321], [4]. 
In effect, this study is perhaps the first to investigate the prevalence of HPV in a large 
heterogeneous Scottish cohort of squamous cell carcinomas of the head and neck. High-
risk HPV DNA was detected in 18% of the study sample. Previously, Maitland et al. 
[185] and Anderson et al. [4] have investigated HPV DNA in small heterogeneous 
cohorts in the English and Scottish populations respectively. While HPV DNA was 
detected in 46% of oral squamous biopsies and normal oral tissues by Maitland et al., 
Anderson et al. reported HPV DNA in 10% of the population. A systematic review by 
Kreimer et al. looking at the prevalence of HPV worldwide reported an overall 
prevalence of 25% [148]. While the findings of this study are somewhat similar to those 
of other studies, there exists some variability in reported results of prevalence. This 
variability may be attributed to differences in sample sizes, variability in sample sources 
(fresh frozen vs FFPE) and the use of different primer sets and probes for detection of 
the virus [148]. The vast majority of viral genotypes detected in this study were HPV 
type 16, with other high-risk HPV types 18 and 33 comprising much smaller 
proportions. These findings are consistent with results reported by the other studies 
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[148], [101]. Oropharyngeal tumours comprised 20% of the study sample and more than 
half of the OPSCCs tested positive for high-risk HPV type 16. These statistics are in 
line with other studies conducted on the British population [321], [131], [4],  but higher 
than the European average of 28% [148].  
 
Immunohistochemical validation of p16 overexpression as a surrogate marker for HPV- 
related HNSCCs, especially OPSCC, has been widely documented [282], [318]. 
Expression of the E7 viral oncoprotein leads to functional inactivation of pRB, a 
negative regulator of the p16INK4A tumour suppressor gene product, resulting in 
subsequent overexpression of the p16 protein.  Consequently, high-risk HPV-associated 
head and neck tumours often demonstrate nuclear and cytoplasmic p16 overexpression, 
a histological feature predominantly absent in HPV-negative tumours. Tumour samples 
for this study were selected based on the availability of a p16 status. Accordingly, 16% 
of the study cohort was p16-positive while the remaining 84% was p16-negative. 
Similar results were reported by Larsen et al. in a pooled analysis of 3625 patients 
where p16 overexpression (reported as staining equal to or exceeding 70% of the cells) 
was seen in 19.5% (n = 764) of the subjects [157]. However, it must be noted here that 
the findings of this study are based on a cohort of heterogeneous tumours while that of 
Larsen et al. are based predominantly on tumours arising in the oropharynx. In this 
study, a comparison of baseline clinical characteristics between patients with p16-
positive and negative tumours indicated that those with p16-positive tumours were 
younger and were more likely to be non-smokers at diagnosis. Patients with p16-
negative tumours were more likely to present with a history of heavy drinking at 
diagnosis. Assessments of histopathological features show that p16-positive tumours 
were mostly poorly or moderate to poorly differentiated tumours arising predominantly 
in the oropharynx. Although patients with p16-positive tumours presented with late 
stage disease, they had better overall and recurrence free survival rates. HPV/p16 
positive tumours have been recognised by previous studies as a clinically and 
morphologically distinct subgroup [322]. While the results presented in this section are 
based on tumour p16 status alone, the findings are consistent with those reported by 
other studies [289], [318].  
 
Although data suggests that p16 overexpression is an independent prognostic predictor 
in the tonsillar subset of HNSCC [154], its efficiency as a single test for detection of 
high-risk HPV in HNSCCs is debatable [283]. However, p16 immunostaining, when 
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used in conjunction with viral DNA detection methods has been shown to have optimal 
sensitivity and specificity [283],  [93]. In this study, samples were initially screened and 
selected based on p16 status and followed up with HPV DNA detection by PCR using a 
combination of consensus and type specific primers. Four categories of tumours were 
identified, HPV DNA-ve/p16-ve or ‘True negative’, HPV DNA-ve/p16+ve or 
‘Equivocal’, HPV DNA +ve/p16-ve or ‘Equivocal’ and HPV DNA +ve/p16+ve or 
‘True positive’. Incongruent p16 and HPV DNA testing results noted in 7% of the study 
population is similar to that reported by Evans et al. suggesting that neither approach is 
a reliable standalone for accurate reporting of HPV infection in HNSCC [75]. 
Overexpression of p16 in the absence of viral DNA was noted primarily in non-
oropharyngeal sites and suggests that p16 IHC may not be a reliable marker of HPV 
infection in tumours arising in sites other than the oropharynx [32]. It may also be 
indicative of an alternate mechanism of disruption of the pRB pathway [189]. On the 
other hand samples that were HPV DNA +ve/p16-ve may be indicative of a biologically 
irrelevant HPV infection [256].  
 
High-risk HPV infection was identified in 14% of the study population and is higher 
than the prevalence reported in a previous study conducted on a heterogeneous cohort in 
the South East of Scotland [4]. Consistent with reports of previous studies, HPV-
positive patients in this study cohort were younger with no history of smoking at 
diagnosis [291], [321]. HPV infection is the most commonly transmitted sexual 
infection and occurs through direct skin or mucosal contact [309]. The apparent social 
demographics of patients with HPV-related HNSCC may be attributed to changes in 
lifestyle practices, for example, higher number of oral sex partners or first sexual 
encounter at a younger age along with a fall in tobacco use over the recent years [189], 
[54]. Amongst the head and neck anatomic subsites, the oropharynx is especially 
susceptible to infection with high-risk HPV [99], a finding consistent with this study. 
High-risk HPV was detected in only three oral cavity tumours and none of the laryngeal 
tumours were positive for the virus. The oropharynx, particularly the lingual and 
palatine tonsils, is lined by reticulated epithelium which may be more prone to infection 
with HPV. By inhibiting virus-specific T-cells, and thereby allowing the virus to evade 
an immune response during initial infection and subsequent malignant transformation, 
the reticulated epithelium of the oropharynx probably offers an immune privileged site 
for initial infection and subsequent malignant transformation. In addition, the natural 
breaks in the reticulated epithelium leave the basement membrane exposed to deposition 
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of the virus [324]. Generally, patients with HPV-associated OPSCC present with Stage 
III or IV disease and cystic nodal metastasis has been reported as a prominent feature of 
tonsillar squamous cell carcinomas [189], [103]. Indeed, patients with HPV-related 
tumours in this cohort were diagnosed with Stage IV disease and nodal metastasis. A 
closer look at the HPV-positive oropharyngeal tumours in this study revealed that the 
vast majority arose in tonsils followed by base of tongue. In addition to social 
demographics and clinical characteristics of patients with HPV-related HNSCC, this 
study also reports findings on histological features of the tumour samples. Interestingly, 
the majority of HPV-positive tumours were poorly differentiated and were more likely 
not to exhibit extracapsular spread and presence of a non-cohesive invasive front. 
Although HPV-positive tumours have been widely classified as poorly differentiated 
owing to the divergence in appearance of tumour cells from the stratified epithelium 
that lines the oropharynx, such tumours arise in the tonsillar crypts and tumour cells 
tend to resemble cells of the reticulated epithelium from where they arise. In a recent 
review article, the author recommends classification of HPV-positive tumours as “well 
differentiated” as it is perhaps more appropriate and is in keeping with tissue 
morphology and expected clinical behaviour of this subset of HNSCC [323]. Absence 
of extracapsular spread and a non-cohesive invasive front may also be attributed to the 
non-aggressive nature of these tumours.  
 
The impact of HPV as predictive marker for improved treatment outcomes and survival 
has been established by numerous studies [79], [158], [253]. In this study, HPV-positive 
patients had improved overall survival (70%) compared to HPV-negative patients 
(44%). This was similar to the overall survival rates noted for p16-positive patients 
(68%). Likewise, mean recurrence free survival time for HPV-positive patients was 
significantly improved compared to that of HPV-negative patients. The results related to 
survival rates from this study are similar to other studies, albeit slightly lower [321], [4] 
which may be attributed to differences in study cohorts (heterogeneous vs 
oropharyngeal). Interestingly, HPV positivity did not confer a significant improvement 
in disease specific survival even though it was discernible in the Kaplan Meier plot 
(Figure 4.18). Similar findings were noted for patients with p16 positive tumours. The 
findings of studies reporting on the relationship between HPV status and cause specific 
survival are varied. Wells et al. found a significant association between HPV status and 
cause specific survival in a cohort of 60 patients and similar findings were reported by 
Dahlgren et al. [321], [57]. However, both studies were carried out on a cohort of 
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oropharyngeal/tonsillar squamous cell carcinomas and fresh frozen biopsy specimens 
were employed in the study by Dahlgren et al.. In a large mixed cohort study, 
employing fresh frozen biopsy specimens, conducted by Gillison et al., HPV-positive 
HNSCC patients were estimated to have significantly reduced risk of death from cancer 
compared with those with HPV-negative tumours after adjusting for confounding 
factors [101]. The differences in cause specific survival between this study and others 
may be attributed to differences in cohort type and size and in percentages of deaths due 
to cancer. Additionally, disease specific survival curves can often be misleading as they 
do not include death caused by disease related factors such as treatment [252]. Ritchie et 
al., examined the relationship between survival and HPV status in a mixed cohort of 
141 patients and found that patients with HPV-positive tumours also tended to have 
better disease-specific survival than those with HPV-negative tumours among all 
carcinomas but this association was not statistically significant, a finding concurrent 
with this study [254].  
 
As the practice trends in diagnostic HPV testing have evolved over the course of this 
study, a decision was taken to test all the samples in this study positive for HPV DNA 
with DNA ISH. Interestingly, only a little more than half of the samples (55%) tested 
positive for HPV by ISH and fewer still for HPV DNA by PCR, p16 and DNA ISH 
culminating in an overall HPV prevalence of 8%. ISH differs from PCR and p16 IHC in 
that it allows for detection of HPV DNA within the nuclei of infected tumour cells. 
Additionally, the physical state of the virus as indicated by punctate staining for 
integrated virus and diffuse staining for episomal virus is also evident with ISH [310]. 
However, a major drawback of the ISH is its lack of sensitivity as it is only able to 
detect HPV when there are around 10 copies of virus per cell [310]. Indeed, Schache et 
al. investigated the sensitivity, specificity and prognostic significance of ISH among 
other techniques by comparing it to the ‘gold standard’ RNA qPCR and found that ISH 
demonstrated only 88% sensitivity and conferred the least prognostic significance [264].  
 
4.5 Conclusion 
In this study, tumour samples were defined as HPV-positive only if they were positive 
for both HPV DNA and p16. As such, the study cohort was grouped into 3 classes; true 
HPV-positive (HPV DNA+ve/p16+ve), HPV-negative (HPV DNA-ve/p16-ve) and 
Equivocal (HPV DNA+ve/p16-ve or HPV DNA-ve/p16+ve). High-risk HPV was 
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prevalent in 14% of the sample population with HPV type 16 being the most 
predominant genotype. An overwhelming majority of HPV-positive tumours were 
oropharyngeal SCCs arising in the ‘Tonsils’ and ‘Base of Tongue’. The clinical 
characteristics of patients with HPV-positive and negative tumours and associated 
histopathological features were consistent with that reported in the literature. Thus, the 
findings reported in this chapter of the thesis contribute to existing knowledge that 
patients with HPV positive tumours are a clinically and demographically distinct patient 
population with a clear survival advantage afforded by a positive tumour HPV status.  
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Chapter 5 
INVESTIGATION OF EBP50 AS A POTENTIAL NOVEL MARKER 
OF HPV-ASSOCIATED HNSCC 
 
Ezrin-Radixin-Moesin Binding Phosphoprotein 50 (EBP50), a PDZ domain scaffolding 
protein, is found in abundance at the plasma membranes of polarised epithelial cells 
where these proteins form complexes that regulate tissue architecture and cell migration. 
While our lab has previously shown that EBP50 is a novel target of the high-risk HPV 
E6 oncoprotein [237], there is very little published work in this area with the 2011 work 
of Accardi et al., on the coordinated degradation of EBP50 by E6 and E7 oncoproteins 
of high-risk-HPV type 16, being possibly the only published report to date of direct 
relevance [2]. Moreover, even though expression patterns of EBP50 and its clinical 
significance have been studied previously in colorectal cancer [186], [188] and breast 
cancer [187], studies for HNSCC have not been conducted. This, in addition to the 
knowledge that high-risk HPV is an important risk factor for certain types of HNSCC 
[326], [218] prompted an investigation into the distribution of EBP50 protein in HPV-
associated HNSCC tumour specimens from a heterogeneous study cohort. This chapter 
which will focus initially on EBP50 staining patterns obtained by immunohistochemical 
analysis of randomly selected specimens, followed by a detailed assessment of 
distribution patterns of the protein in HPV- positive and HPV- negative specimens.  
 
5.1 Selection of anti-EBP50 antibody and its optimisation 
Immunostaining of tissue sections from the study cohort was carried out utilising a 
polyclonal anti-EBP50 antibody according to the protocol outlined in Chapter 2 Section 
2.9. Preliminary experiments to determine optimal antibody dilutions were carried out 
on normal oral mucosa FFPE sections using antibody dilutions recommended by the 
manufacturer (10 µg/ml) as a guideline.  The resulting staining was very strong with a 
high background. Additional antibody titrations at higher dilutions (1:1000, 1:1500. 
1:2000 and 1:3000) were set up along with varying incubation times (overnight, 60 min 
and 40 min) and H2O2 concentrations. Optimal EBP50 staining with minimal 
background was obtained with an antibody dilution of 1:2000 after 40 min incubation at 
room temperature. Figure 5.1 (A), (B) demonstrate strong EBP50 membrane and 
cytoplasmic staining at an antibody dilution of 1:3000  with overnight and 60 min 
incubation times respectively and images (C), (D) show EBP50 membrane staining at 
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antibody dilutions of 1:2000 with 60 and 40 min incubations respectively .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Optimisation of antibody dilution. FFPE sections of normal oral mucosa were incubated  
with anti- EBP50 antibody (PA1-090, Fisher Scientific UK, Bishop Meadow Road, Loughborough, 
Leics, LE11 5RG, UK) at dilutions of 1:1000, 1:1500, 1:2000 and 1:3000 (A) / (B) EBP50 
immunoreactivity in sections incubated with the primary antibody at 1:3000 dilution overnight and 
60 min respectively. A higher level of non-specific background staining was observed with 
overnight incubation and EBP50 signal was found to be slightly weak with one hour incubation 
(Magnification x100); (C) / (D) EBP50 immunoreactivity in sections incubated for one hour and 40 
min respectively with the primary antibody dilutions of 1:2000. Although a higher dilution of 
1:2000 did not completely eliminate non-specific background staining, EBP50 staining in the 
cytoplasm and plasma membranes were found to be optimal at this dilution (Magnification x400). 
 
In order to confirm specificity of the polyclonal antibody PA1-090 for the target protein 
EBP50, an antibody blocking assay was performed. As the immunising peptide for the 
commercial antibody employed in this study was unavailable for purchase, the 
commercial antibody was blocked with an ‘in-house’ Glutathione S Transferase (GST) 
tagged recombinant EBP50 protein. Tissue sections were incubated with primary anti-
A B 
Anti-EBP50 1: 3000_overnight incubation  Anti-EBP50 1: 3000_60 min incubation 
C D 
Anti-EBP50 1: 2000 _60 min incubation Anti-EBP50 1: 2000_40 min incubation 
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EBP50 antibody alone (Figure 5.2 (B)), anti-EBP50 antibody with added GST protein 
(2 µg) and secondary antibody alone a controls (Figure 5.2 (C), (A) and anti-EBP50 
antibody with added GST-EBP50 protein (2 µg or 5 µg) incubated either for 20 min or 
overnight (Figure 5.2 (D), (E), & (F)). EBP50 membrane and cytoplasmic signals were 
detected with both primary antibody only and primary antibody with added GST. 
Shorter incubation with primary antibody and GST-EBP50 mixture merely resulted in a 
reduction in the intensity of the signal. However, a longer overnight incubation with the 
antibody-recombinant protein mixture resulted in much of the antibody being absorbed 
and a complete signal block was achieved, thereby confirming that the primary antibody 
PA1-090 was indeed specific for EBP50. 
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Figure 5.2: Antibody neutralisation assay to determine specificity of the primary antibody. The 
commercial primary antibody PA1-090 was neutralised with GST tagged EBP50  (A) FFPE section 
incubated with secondary antibody showing negative EBP50 expression; (B) / (C) sections 
incubated with primary antibody PA1-090 alone and GST + PA1-090 respectively. Membrane and 
cytoplasmic EBP50 expression was detected in both; (D), (E) & (F) EBP50 expression in sections 
following incubation with neutralised primary antibody (+ GST-EBP50 2 µg) for 20 min, overnight 
and primary antibody (+ GST-EBP50 5 µg) overnight respectively. Complete blocking of primary 
antibody was achieved following overnight incubation with blocking peptide (Magnification x 100).   
A 
No primary antibody 
B 
Anti-EBP50 1:2000 
C 
Anti-EBP50 + GST (2 µg) 
D 
Anti-EBP50 + GST-EBP50 (2 µg) 
20 min incubation 
E 
Anti-EBP50 + GST-EBP50 (2  µg) 
Overnight incubation 
F 
Anti-EBP50 + GST-EBP50 (5  µg) 
Overnight incubation 
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5.2 EBP50 expression in normal oral mucosa 
Epithelial cells, along with tight junctions, form a highly specialised polarised barrier 
separating the apical cell surface from the basolateral membranes and disruption of this 
polarity appears to be an early event in the development of human epithelial tumours 
[209]. EBP50 localises at the apical membranes of polarised human epithelial cells 
where it promotes the maintenance of normal tissue architecture by forming complexes 
with other cell polarity proteins [206]. The loss of EBP50 expression at apical 
membranes, its distribution to the cytoplasm and nuclear overexpression have all been 
observed in several types of human cancer [95]. Since procuring normal oral mucosa for 
this study was challenging, a ‘normal’ tonsil specimen was obtained for 
immunohistochemical analysis of EBP50 distribution.  EBP50 expression patterns 
observed in the tonsil tissue served as a baseline for comparison of protein distribution. 
Membrane or cytoplasmic EBP50 expression was detected in different layers of the 
normal oral epithelium. Figure 5.3 is a representative image of EBP50 staining in a 
tonsil specimen. EBP50 expression was predominantly membranous in suprabasal 
layers of the epithelium (Figure 5.3 (B) & (D)). No immunoreactivity was detected in 
the Stratum Corneum. A gradual shift in EBP50 expression from membranous to 
predominantly cytoplasmic was observed from suprabasal to the basal layers of the 
epithelium (Figure (B) & (C)). No nuclear EBP50 immunoreactivity was detected.  
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Figure 5.3 EBP50 expression in normal oral epithelium (A) section stained with secondary antibody 
only showing negative EBP50 expression (Magnification x400); (B) section stained with anti-EBP50 
antibody (Magnification x100); (C) basal cells of the epithelium demonstrating cytoplasmic EBP50 
expression with no membrane immunoreactivity (Magnification x400); (D) EBP50 expression was 
seen predominantly in the plasma membranes of cells in the suprabasal layers of normal oral 
epithelium (Magnification x 400). 
 
5.3 EBP50 expression in primary head and neck squamous cell 
carcinomas 
In order to study EBP50 expression in primary squamous cell tumours of the upper 
aerodigestive tract, 156 specimens were selected from the main study cohort. This 
smaller cohort included all samples positive for HPV DNA along with a random 
selection of HPV DNA negative specimens from different anatomic sites of origin. 
Sections of 5 µm thickness were mounted on slides and stained for EBP50 according to 
the protocol detailed in Section 2.9 of Chapter 2. The resulting cytoplasmic and 
membrane EBP50 expression patterns were analysed under a light microscope and 
B 
D 
A 
C 
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grouped into 4 categories, each of which is described in detail in the subsections below.  
 
5.3.1 Expression pattern 1: Predominantly cytoplasmic with absence of EBP50 
expression in the plasma membranes of epithelial cells 
 
The most common expression pattern observed in the cohort was predominantly 
cytoplasmic. Unlike normal oral mucosal epithelial cells, EBP50 expression in the 
plasma membranes of tumour cells was completely absent. Cytoplasmic staining was of 
a similar intensity to that observed in the basal layers of normal oral mucosal 
epithelium. Figure 5.4 is a representation of membrane excluded and ‘predominantly 
cytoplasmic’ type of EBP50 expression in a poorly differentiated tumour arising in the 
oral cavity. Membranous EBP50 expression is evidently absent in two different tumour 
cell fields of the specimen (Figure 5.4 (D) & (F)). 
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Figure 5.4: ‘Predominantly cytoplasmic’ type of EBP50 expression (SID 87) (A) section of OSCC 
stained with secondary antibody only showing negative EBP50 expression (Magnification x100); (B) 
FFPE section of a poorly differentiated tumour involving the retromolar trigone stained with anti-
EBP50 antibody (Magnification x100); (C) / (E) Random fields of the section showing cytoplasmic 
EBP50 expression in the tumour cells. No immunoreactivity for EBP50 was detected in the plasma 
membranes of the cells (Magnification x100); (D) / (F) Images of (C) / (E) respectively at higher 
magnification (x400). 
A 
B 
C D 
E F 
A 
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5.3.2 Expression pattern 2: Weak or negligible cytoplasmic EBP50 expression  
 
Weak cytoplasmic staining was the second most commonly recurring distribution 
pattern observed in the cohort. Decreased EBP50 expression was evident in the 
cytoplasm of tumour epithelial cells, thereby resulting in weak staining or almost 
negligible immunoreactivity in some specimens. Decreased cytoplasmic signal was also 
accompanied by an absence of membranous EBP50 expression similar to the first 
staining pattern. Figure 5.5 is a representation of ‘Weak/negligible cytoplasmic’ type of 
EBP50 expression. Decreased cytoplasmic staining and lack of membrane expression 
can be visualised in Figure 5.5 (D) and (F).  
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Figure 5.5: ‘Weak/negligible’ type of EBP50 expression (SID 137) (A) section of OSCC stained with 
secondary antibody only showing negative EBP50 expression (Magnification x100); (B) FFPE 
section of a tumour involving the base of tongue stained with anti-EBP50 antibody (Magnification 
x100); (C) / (E) Random fields of the section showing weak or negligible cytoplasmic EBP50 
expression in a majority of the tumour cells. No immunoreactivity for EBP50 was detected in the 
plasma membranes of the cells (Magnification x100); (D) / F) Images of (C) / (E) respectively at 
higher magnification (x400).  
 
A B 
C D 
E F 
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5.3.3 Expression patterns 3 & 4: Mixed EBP50 distribution and other less common 
expression patterns 
 
A third less frequently recurring heterogeneous EBP50 expression pattern was observed 
in a few specimens wherein EBP50 could be detected in the plasma membranes of a few 
tumour cells while it was either absent or weak in the others. Likewise, a few specimens 
demonstrated mixed cytoplasmic expression of EBP50 ranging from clear positive to 
weak or negligible immunoreactivity. Figure 5.6 is a representation of mixed or 
‘Heterogeneous’ EBP50 expression in a moderately differentiated squamous cell 
carcinoma of the buccal mucosa. While EBP50 expression was predominantly 
cytoplasmic, membranous immunoreactivity ranging from weak/negligible to strong 
was detected in a few groups of tumour cells (Figure 5.6 (D), (F). 
  
Other less common staining patterns observed in a few samples in the cohort included 
strong cytoplasmic expression of EBP50 with no immunoreactivity in the plasma 
membranes of tumour cells (Figure 5.7). 
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Figure 5.6: ‘Heterogeneous’ type of EBP50 expression (SID 89) (A) section of OSCC stained with 
secondary antibody only showing negative EBP50 expression (Magnification x100); (B) FFPE 
section of a moderately differentiated tumour of the buccal mucosa stained with anti-EBP50 
antibody (Magnification x100); (C) / (E) Random fields of the section showing positive staining for 
EBP50 in the cytoplasm of tumour cells and mixed EBP50 expression ranging from weak to 
positive in the plasma membranes (Magnification x100); (D) / (F) Images of C/E respectively at 
higher magnification (x 400).  
 
A B 
C D 
E F 
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Figure 5.7: ‘Other’ type of EBP50 expression (SID 274) (A) section of OSCC stained with 
secondary antibody only showing negative EBP50 expression (Magnification x100); (B) FFPE 
section of a moderately differentiated laryngeal tumour stained with anti-EBP50 antibody 
(Magnification x100); (C) / (E) Random fields of the section showing strong EBP50 expression in 
the cytoplasm of tumour cells. No membrane EBP50 immunoreactivity was detected (Magnification 
x100); (D) / (F) Images of D/G respectively at higher magnification (x 400). 
 
  
A B 
C D 
E F 
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5.4 Implications of EBP50 expression in HNSCC 
The EBP50 expression patterns identified through IHC analysis of tumour specimens in 
the study cohort were classified as ‘Predominantly cytoplasmic (Membrane excluded)’, 
‘Weak/Negligible cytoplasmic (Membrane excluded)’, ‘Heterogeneous (mixed 
membranous and/or cytoplasmic)’ and ‘Other’. Out of 156 specimens, ‘predominantly 
cytoplasmic’ EBP50 expression was detected in 76 (49%) samples, ‘Weak/negligible 
cytoplasmic’ pattern in 44 (28%), ‘heterogeneous’ and ‘other’ patterns in 26 (17%) and 
10 (6%) samples respectively. 
 
5.4.1 EBP50 expression and clinicopathological characteristics of the study cohort 
 
The clinical and pathological characteristics of the study subset were subsequently 
analysed based on EBP50 expression patterns (Table 5.1). It was noted that smoking 
status and disease stage were significantly associated EBP50 expression. While tumour 
samples of ‘smokers’ demonstrated ‘predominantly cytoplasmic’ EBP50 expression, 
‘non-smokers’ and ex-smokers were more likely to have tumours exhibiting with 
‘weak/negligible cytoplasmic’ EBP50 expression (P = 0.019). Nearly three-quarters of 
the patients (73%) with tumours expressing ‘weak/negligible cytoplasmic’ EBP50 also 
presented with late stage disease (P = 0.02). Analysis of the tumour histopathology of 
patients in the study subset showed that the majority of tumours with ‘weak/negligible 
cytoplasmic’ EBP50 expression (71%) originated in the oropharynx while those with 
‘predominantly cytoplasmic’ or heterogeneous EBP50 distribution arose in the oral 
cavity and the larynx (P < 0.001). Interestingly, patients with tumours that demonstrated 
‘weak/negligible cytoplasmic’ EBP50 expression were also more likely to have positive 
neck nodes, overexpression of p16 and positive tumour HPV status (P < 0.001). EBP50 
expression patterns were not found to have significant associations with grade of 
tumour differentiation, alcohol consumption, overall survival or recurrence. 
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Variable EBP50 staining patterns 
 
 
Predominantly 
cytoplasmic 
expression 
Weak/negligible 
cytoplasmic 
expression 
Hetero-
geneous 
expression 
Other Total Pearson’s 
CHI 
Square 
History of 
smoking 
 
Non-smoker 
Smoker 
Ex-smoker 
 
Total 
 
 
 
9 (15%) 
36 (60%) 
15 (25%) 
 
60 
 
 
 
12 (32%) 
8 (22%) 
17 (46%) 
 
37 
 
 
 
5 (22%) 
11 (48%) 
7 (30%) 
 
23 
 
 
 
1 (11%) 
6 (67%) 
2 (22%) 
 
9 
 
 
 
27 
61 
41 
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P = 0.019 
History of 
alcohol 
consumption 
 
Light – moderate 
drinker 
Heavy drinker 
Non-drinker 
Ex-heavy drinker 
Alcohol status 
unknown 
 
Total 
 
 
 
 
33 (43%) 
 
      15 (20%) 
        8 (10%) 
 2 (3%) 
     18 (24%) 
 
 
76 
 
 
 
 
27 (61%) 
 
        7 (16%) 
        2 (5%) 
0 (0%) 
        8 (18%) 
 
 
44 
 
 
 
 
12 (46%) 
 
    8 (31%) 
    3 (12%) 
    0 (0%) 
    3 (11%) 
 
 
26 
 
 
 
 
3 (30%) 
 
 5 (50%) 
 0 (0%) 
 1 (10%) 
 1 (10%) 
 
 
10 
 
 
 
 
75 
 
   35 
   13 
3 
   30 
 
 
156 
 
 
 
 
 
 
 
 
P = 0.14 
(NS) 
Site of primary 
tumour 
 
Oral cavity 
Oropharynx 
Larynx 
Other 
 
Total 
 
 
 
17 (22.4%) 
17 (22.4%) 
23 (30%) 
19 (25%) 
 
76 
 
 
 
5 (11%) 
31 (71%) 
2 (4%) 
6 (14%) 
 
44 
 
 
 
7 (27%) 
9 (35%) 
7 (27%) 
3 (11%) 
 
26 
 
 
 
1 (10%) 
2 (20%) 
6 (60%) 
1 (10%) 
 
10 
 
 
 
30 
59 
38 
29 
 
156 
 
 
 
 
 
P < 0.001 
Grade of 
differentiation 
 
Well 
differentiated 
Moderately 
differentiated 
Poorly 
differentiated 
Moderate – 
poorly 
differentiated 
 
Total 
 
 
 
 
1 (1%) 
 
32 (44%) 
 
33 (45%) 
 
7 (10%) 
 
 
73 
 
 
 
 
0 (0%) 
 
7 (18%) 
 
26 (67%) 
 
6 (15%) 
 
 
39 
 
 
 
 
0 (0%) 
 
11 (44%) 
 
12 (48%) 
 
2 (8%) 
 
 
25 
 
 
 
 
0 (0%) 
 
2 (25%) 
 
6 (75%) 
 
0 (0%) 
 
 
8 
 
 
 
 
1 
 
52 
 
77 
 
15 
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P = 0.243 
(NS) 
Disease stage 
 
Stage I 
Stage II 
Stage III 
Stage IVA & 
IVB 
Unknown 
 
Total 
 
 
13 (18%) 
12 (17%) 
12 (17%) 
33 (45%) 
 
2 (3%) 
 
72 
 
 
3 (7%) 
1 (2%) 
4 (9%) 
32 (73%) 
 
4 (9%) 
 
44 
 
 
4 (18%) 
3 (13%) 
6 (26) 
9 (39%) 
 
1 (4%) 
 
23 
 
 
3 (30%) 
2 (20%) 
3 (30%) 
1 (10%) 
 
1 (10%) 
 
10 
 
 
23 
18 
25 
75 
 
8 
 
149
a
 
 
 
 
 
 
P = 0.02 
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a. Patients with missing or unavailable data were excluded from analysis 
b. Patients with ‘Equivocal’ HPV status were excluded from analysis 
c. EBP50 staining could not be determined in one HPV-positive specimen 
 
Table 5.1: Social demographics and clinicopathological characteristics of patients based on EBP50 
expression. Significant associations were noted between EBP50 expression and smoking history, site 
of primary tumour, stage of disease, metastasis to cervical lymph nodes, tumour p16 and HPV 
status. Weak/negligible cytoplasmic EBP50 expression demonstrated strong correlations to positive 
p16 and HPV status.  
 
  
Neck node 
status 
 
Negative 
Positive 
 
Total 
 
 
 
43 (59%) 
30 (41%) 
 
73 
 
 
 
5 (11%) 
39 (89%) 
 
44 
 
 
 
14 (54%) 
12 (46%) 
 
26 
 
 
 
8 (80%) 
2 (20%) 
 
10 
 
 
 
70 
83 
 
153
a
 
 
 
 
 
P < 0.001 
p16 status 
 
Positive 
Negative 
 
Total 
 
 
7 (9%) 
69 (91%) 
 
76 
 
 
32 (73%) 
12 (27%) 
 
44 
 
 
3 (11%) 
23 (89%) 
 
26 
 
 
2 (20%) 
8(80%) 
 
10 
 
 
44 
112 
 
156 
 
 
 
P < 0.001 
HPV status 
 
Positive 
Negative 
 
Total 
 
 
6 (9%) 
63 (91%) 
 
69 
 
 
29 (83%) 
6 (17%) 
 
35 
 
 
3 (12%) 
22 (88%) 
 
25 
 
 
1 (11%) 
8 (89%) 
 
9 
 
 
39
c
 
99 
 
138
b
 
 
 
 
P < 0.001 
Overall survival 
 
Alive 
Dead 
 
Total 
 
 
 
31 (41%) 
45 (59%) 
 
76 
 
 
 
27 (61%) 
17 (39%) 
 
44 
 
 
 
15 (58%) 
11 (42%) 
 
26 
 
 
 
6 (60%) 
4 (40%) 
 
10 
 
 
 
79 
77 
 
156 
 
 
 
 
P = 0.12 
(NS) 
Recurrence 
 
Yes 
No 
 
Total 
 
 
18 (24%) 
58 (76%) 
 
76 
 
 
5 (11%) 
39 (89%) 
 
44 
 
 
1 (4%) 
25 (96%) 
 
26 
 
 
1 (10%) 
9 (90%) 
 
10 
 
 
25 
131 
 
156 
 
 
 
P = 0.067 
(NS) 
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5.4.2 EBP50 expression and survival in patients with HNSCC  
 
The relationship between EBP50 expression and overall survival in head and neck 
cancer patients was investigated. Kaplan Meier curves (Figure 5.8) revealed that 
patients with ‘weak/negligible cytoplasmic’ EBP50 expression had the highest overall 
survival while those with ‘predominantly cytoplasmic’ EBP50 expression had the worst 
survival (Median 49 months, 50% vs 68%; 5 years, 46% vs 60%, P > 0.05). Although 
overall survival rates were higher for the group with ‘weak/negligible cytoplasmic’ 
EBP50 expression, the smaller sample size of this cohort in relation to the original study 
cohort (156 vs 293) means that the significance of this correlation should be interpreted 
with caution (P =0.3).  
 
 
 
 
 
Figure 5.8: Kaplan-Meier plot for EBP50 expression and overall survival (OS). The association 
between EBP50 expression and overall survival in a cohort of 156 patients with HNSCC was 
analysed. Patients with weak/negligible cytoplasmic EBP50 had higher OS compared to those with 
‘predominantly cytoplasmic’, ‘heterogeneous’ and ‘other’ expression patterns. Patients with 
‘predominantly cytoplasmic’ expression tended to have the worst OS rates. The OS curves were 
analysed by Log Rank (Mantel Cox) test. 
 
Similarly, Kaplan Meier curves for recurrence free survival (RFS) (Figure 5.9) revealed 
that patients with ‘weak/negligible cytoplasmic’ EBP50 expression had higher RFS 
rates compared to those with ‘predominantly cytoplasmic’ EBP50 expression (5 years, 
64% vs 87%, P = 0.04). The impact of clinical and histological variables on RFS was 
P = 0.3 
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investigated through univariate survival analysis. Smoking status at diagnosis (P = 
0.001), and EBP50 expression (P = 0.04) were found to be significantly associated with 
RFS. However, no significant independent associations were found following 
multivariate analysis.  
 
 
 
 
 
Figure 5.9: Kaplan-Meier plot for EBP50 expression and recurrence free survival (RFS). The 
association between EBP50 expression and recurrence free survival in a cohort of 156 patients with 
HNSCC was investigated.  Patients with ‘weak/negligible cytoplasmic’ EBP50 expression were 
likely to be disease free longer than those with ‘predominantly cytoplasmic’ EBP50 expression. 
However, patients with ‘heterogeneous’ EBP50 expression appeared to have the highest recurrence 
free survival rates. RFS curves were analysed by Log Rank (Mantel Cox) test.  
 
Interestingly, Kaplan Meier curves for disease specific survival (DSS) (Figure 5.10) 
revealed that patients with ‘Heterogeneous’ EBP50 expression had a lower risk of death 
from HNSCC compared to those with ‘predominantly cytoplasmic’ and 
‘weak/negligible cytoplasmic’ EBP50 expression (2 years, 90% vs 83% and 79%, P = 
0.331). Although patients with tumours exhibiting ‘weak/negligible cytoplasmic’ 
EBP50 expression appeared to have the highest risk of death from HNSCC at 2 years, 
they were more likely to have better survival rates compared to those with 
‘predominantly cytoplasmic’ EBP50 expression in the long term. However, with a P 
value of 0.331 these results should not be considered statistically significant.  
 
 
P = 0.04 
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Figure 5.10: Kaplan-Meier plot for EBP50 expression and disease specific survival (DSS). The 
association between EBP50 expression and disease specific survival in a cohort of 156 patients with 
HNSCC was investigated. Patients with ‘heterogeneous’ EBP50 expression had a lower risk of 
death from HNSCC compared to those with ‘predominantly cytoplasmic’ and ‘weak/negligible 
cytoplasmic’ EBP50 expression. Patients with tumours exhibiting ‘weak/negligible cytoplasmic’ 
EBP50 expression appeared to have the worst prognosis until 3 years before showing a clear 
improvement over patients with ‘predominantly cytoplasmic’ EBP50 expressing tumours. DSS 
curves were analysed by Log Rank (Mantel Cox) test.  
 
5.4.3 EBP50 as a potential marker of HPV infection in head and neck cancer 
 
For the purpose of this study, a specimen was deemed HPV positive if it is p16 and 
HPV DNA positive. Therefore, one way to compare p16 and EBP50 expression as 
indicators of HPV infection is to test the relative strength of their dependence with HPV 
DNA status. Two independent Pearson’s CHI Squared tests (  ) were performed on 
SPSS – one to test the dependence between EBP50 expression and HPV DNA status 
and the other to test dependence between p16 expression and HPV DNA status. Each 
test showed strong correlation between HPV DNA status and the indicator variables. 
The P values for both tests being identical (P < 0.001), the strength of goodness of fit of 
the variables was compared. The Likelihood Ratio for p16 status (87) was marginally 
higher than EBP50 expression (79.4) (Table 5.2).  
 
 
 
 
 
P = 0.331 
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HPV DNA 
Status 
(n = 156) 
p16 overexpression P value & 
Likelihood 
Ratio Value 
EBP50 expression P value & 
Likelihood 
Ratio Value 
 Positive  Negative  
 
P < 0.001 
       87 
Weak/negligible Other  
 
P < 0.001 
     79.4 
Positive 39 (75%) 13 (25%) 38 (73%) 14 
(9%) 
Negative 5 (5%) 99 (95%) 6 (6%) 98 
(63%) 
 
Table 5.2: EBP50 expression and p16 status correlation with HPV DNA status. Two independent 
Pearson’s CHI Squared tests showed strong correlation between HPV DNA status and the 
indicator variables. The Likelihood Ratio for p16 status (87) was only marginally higher than 
EBP50 expression (79.4) indicating that Weak/negligible EBP50 expression may indeed be a novel 
marker of HPV-positive HNSCC. 
 
 
5.5 Discussion 
EBP50 was independently identified by Reczek and colleagues as a scaffolding protein 
which binds to the Ezrin-Radixin-Moesin (ERM) family of cytoskeletal proteins where 
they reciprocally stabilise each other to maintain a polarised state of epithelial cells 
[249]. Since then, numerous studies have reported on the potential role of EBP50 
expression in carcinogenesis, including breast cancer [35], Schwanomma [87], 
hepatocellular carcinoma [276], colorectal [114] and gastric cancers [183]. EBP50 
expression has been most extensively studied in breast cancer.  
 
In this study, a preliminary investigation was undertaken to determine EBP50 
expression by IHC in squamous cell carcinomas of the upper aerodigestive tract. This is 
the first study to investigate EBP50 expression and its implications on survival in head 
and neck cancer. In addition, this study also determined EBP50 expression in high-risk 
HPV positive tumours and attempted to establish its validity as a marker of HPV 
infection in HNSCC. High-risk HPV mediated degradation of EBP50 has been 
previously established by our lab and was also reported by Accardi et al. [2]. However, 
the impact of HPV positivity on EBP50 expression in head and neck cancer is a novel 
research topic.  
 
Difficulties with background staining of tissue sections were encountered during 
optimisation of IHC protocol. A common problem in IHC analysis, background staining 
stems from several factors ranging from antigen-antibody reactions and detection 
methods to other general factors. Endogenous peroxidase activity, the attraction of 
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primary and secondary antibodies (Abs) to endogenous Fc receptors (FcRs) and tissue 
proteins are some of the contributing factors [117]. Tissue sections were incubated in 
varying concentrations of Hydrogen Peroxide (H2O2) to counter background staining 
possibly arising from endogenous enzymes. However, this step failed to completely 
eliminate it. Detection of unwanted background staining in sections incubated with 
secondary antibody only (i.e control without primary antibody) and those incubated 
with neutralised primary antibody indicated that the background may be related to 
interaction of the secondary antibody with endogenous FcRs or tissue proteins. While 
theories of antibodies reacting with endogeneous FcRs have been largely confounding 
[31], a more plausible explanation appears to be the increased hydrophobicity of tissue 
proteins resulting from cross-linking during fixation. Indeed, increased background 
staining as a result of hydrophobic and ionic interactions of tissue proteins is commonly 
seen in squamous epithelial tissue among others [117]. Further attempts to eliminate 
non-specific staining in the study cohort sections were discontinued as it did not 
interfere with the EBP50 signal.  
 
As a preliminary step in this study, the distribution of EBP50 in normal tonsillar 
epithelium was investigated. In the suprabasal layers of the epithelium, prominent 
membranous EBP50 expression was observed while cytoplasmic EBP50 expression was 
almost negligible. However, a gradual increase in the strength of cytoplasmic staining 
was noted in the basal layers of the epithelium while plasma membranes of the 
epithelial cells in the basal layers were immunonegative for EBP50. EBP50 expression 
varies in different tissues. For example, in polarised epithelia such as liver, kidneys, 
trachea, small intestine, stomach and prostate,  increased EBP50 expression with an 
intracellular distribution at apical luminal membranes of cells was reported [95]. In 
stratified squamous epithelium such as the skin, esophagus and tonsils, weak to 
moderate cytoplasmic EBP50 staining was observed tending toward stronger 
immunoreactivity in the deeper layers. While, eccrine glands in the skin have 
demonstrated cytoplasmic EBP50 with strong apical membranous immunoreactivity, 
adenexa showed weak diffuse cytoplasmic staining. Similarly in the serous acinar cells 
of the salivary glands, weak cytoplasmic EBP50 expression was accompanied by 
prominent linear luminous membranous staining [288]. Investigation of EBP50 
expression in a cohort of 156 HNSCC specimens in this study uncovered 4 patterns of 
immunoreactivity. Predominantly cytoplasmic expression was seen in a majority of the 
samples followed by ‘weak/negligible cytoplasmic’ EBP50 expression, ‘heterogenous 
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expression’ and other less common patterns. A noteworthy finding was the absence or 
lack of EBP50 expression in the plasma membranes of tumour cells. With the exception 
of a few samples with mixed membrane/cytoplasmic EBP50 expression, HNSCC 
specimens in this cohort were immunonegative for membranous EBP50. Examination 
of normal oral epithelium revealed that cells in the basal proliferative layer of the 
epithelium showed no immunoreactivity for EBP50 along the membranes. Therefore, a 
lack of membranous EBP50 expression in the tumour specimens may indicate that these 
tumours are comprised of a predominantly proliferative pool of epithelial cells. 
Alternatively, it may suggest a mis-localisation of the EBP50 protein from membrane to 
cytoplasm in squamous cell tumours of the head and neck. A similar EBP50 expression 
pattern was reported by Malfettone et al. following immunohistochemical analyses of 
colorectal tumour specimens. They found that while EBP50 was localised to the apical 
membranes of epithelial cells and in the cytoplasm of enterocytes of distant normal 
mucosa and mucosa adjacent to the tumour respectively, immunoreactivity in colorectal 
tumour samples was predominantly cytoplasmic [188], [186]. In another example, 
immunohistochemical analysis of normal and diseased breast tissue by Mangia et al., 
found that EBP50 expression was localised in the apical membranes of cells in normal 
breast tissue and in the cytoplasm of invasive breast carcinoma cells [187]. 
Interestingly, Malfettone et al. also reported nuclear expression of EBP50 [186]. 
However, no conclusive evidence of nuclear EBP50 immunoreactivity was found in this 
study.  
 
The relationship between EBP50 expression patterns and clinicopathological 
characteristics of the cohort was analysed and significant associations were noted with 
smoking history at diagnosis, site of primary tumour, disease stage, lymph node status, 
p16 status and HPV status. Interestingly, ‘predominantly cytoplasmic’ and 
‘heterogeneous’ EBP50 expression patterns were more likely to be seen in ‘smokers’ 
with tumours arising in non-oropharyngeal sites such as the oral cavity and larynx with 
no involvement of neck nodes. These patients were also more likely to present with a 
negative p16 and HPV status. On the other hand, ‘weak/negligible cytoplasmic’ EBP50 
expression was noted in patients who were either ‘non-smokers’ or ‘ex-smokers’ at the 
time of diagnosis and had tumours arising in the oropharynx. Patients were more likely 
to present with positive neck nodes and late stage disease Furthermore, this expression 
pattern was strongly associated with a positive p16 and HPV status suggesting that 
tumours with ‘weak/negligible cytoplasmic’ EBP50 expression may have a different 
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pathology from those expressing ‘predominantly cytoplasmic EBP50. High-risk HPV 
E6 oncoprotein has the potential to interact with and mediate degradation of a subset of 
PDZ-containing cell polarity regulators including human Dlg (hDlg) and human 
Scribble (hScrib) [90], [214] and EBP50 [2]. Furthermore, HPV E6 targets specific 
cellular pools of cell polarity proteins [191], [145]. Consequently, it may be surmised 
that the reduced EBP50 expression evident in the group of predominantly 
oropharyngeal tumours in this cohort may be a result of high-risk HPV E6-mediated 
degradation of membrane pools of EBP50.  
 
Paradoxically, no significant association was noted between EBP50 protein distribution 
and tumour differentiation in this study. EBP50 expression and tumour differentiation 
appears to be closely linked to the cellular compartment and the type of tumour in 
which it is expressed. For example, nuclear expression was reported to be strongly 
related to poor histological grade in colorectal tumours [188], whereas cytoplasmic 
EBP50 overexpression in breast cancer was not linked to tumour differentiation [235]. 
Interestingly, an investigation of the relationship between EBP50 expression as an 
independent variable and clinical outcomes of patients in the cohort showed that 
patients with ‘predominantly cytoplasmic’ EBP50 expression had the worst prognosis 
and reduced cytoplasmic EBP50 expression was associated with better OS and RFS. 
These results are very similar to survival data related to tumour HPV status in the 
cohort, although a statistically significant association of expression with OS was not 
observed. Previous reports on clinical outcomes and EBP50 expression are varied, 
seemingly linked to subcellular localisation of the protein [235], [183]. Paradiso et al. 
investigated the association of EBP50 expression in invasive breast carcinomas and 
clinical outcomes and found that cytoplasmic EBP50, high or low, did not correlate with 
OS or DFS [235]. Likewise, a study by Xiao-Guang et al. on EBP50 expression in 
gastric cancer found no correlation between overall survival rates and EBP50 
expression [183]. Focusing on the two largest groups, patients with ‘predominantly 
cytoplasmic’ and ‘weak/negligible cytoplasmic’ EBP50 expressing tumours,  and 
comparing their DSS survival rates, a marked improvement was observed for the latter 
group while the survival rate of the former group steadily declined over time. However, 
since the DSS analysis was not statistically significant, EBP50 expression may not be a 
valuable indicator of prognosis in patients with HNSCC.  
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5.6 Conclusion 
The research undertaken in this chapter ascertained EBP50 expression in normal and 
diseased mucosal epithelium in the upper aerodigestive tract. EBP50 was expressed 
predominantly in the plasma membranes of cells in the suprabasal layers of normal oral 
epithelium becoming more cytoplasmic in the deeper layers. In a majority of study 
specimens, EBP50 expression was ‘predominantly cytoplasmic’ or ‘heterogeneous’ and 
the specimens were tumours involving the oral cavity, larynx, hypopharynx and 
pharynx. A smaller group of tumours mostly involving the oropharynx demonstrated 
reduced or negligible cytoplasmic EBP50 expression. Furthermore, this expression 
pattern strongly correlated with a positive HPV status. The preliminary findings in this 
chapter suggest that EBP50 expression is different in oropharyngeal and non-
oropharyngeal tumours and this difference may be linked to its degradation by high-risk 
HPV.  
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Chapter 6 
FINAL DISCUSSION 
 
6.1 HPV in HNSCC and purpose of the study 
Squamous cell carcinomas of the head and neck affect around 600,000 patients per year 
worldwide [83] and display wide aetiological, biological, phenotypical and clinical 
heterogeneity which makes them difficult to treat with a generalised treatment modality. 
HNSCC were typically associated with risk factors such as smoking and alcohol 
consumption, however, over the last decade, global incidence trends have witnessed a 
sharp rise in a subset of HNSCC that are aetiologically associated with high-risk HPV 
rather than the traditional risk factors  [42]. Indeed, infection with high-risk HPV-16 is 
now recognised as an important risk factor for the development of OPSCC, particularly 
in the developed Western countries [326].  
 
HPV-driven HNSCC represent a clinically distinct disease group compared to other 
HNSCC with affected patients tending to be younger males who are typically non-
smokers [98]. Evidence suggests that oral HPV infection may be sexually transmitted 
[147] and that the increase in HPV-driven HNSCC may be in part due to changing 
sexual behaviour patterns [199]. Furthermore, since HPV-positive tumours respond 
better to chemotherapy and radiotherapy compared to HPV-negative tumours,  patients 
have a better disease-free and overall survival [79] and also tend to have lower 
incidences of second primary tumours and a decreased risk of relapse [172]. This causal 
association between HNSCC and sexually transmitted high-risk HPV infection and 
improved clinical outcomes seen in patients with HPV-related HNSCC has important 
implications for the prevention, accurate diagnosis and treatment of HPV-associated 
HNSCC.  
 
Currently, HPV testing in routine clinical practice is focused on accurate diagnosis of 
virus-induced cancer to inform clinical management. HPV infection is identified 
through DNA based detection methods such as PCR or ISH usually in combination with 
p16 IHC. Given the increasing global incidence of OPSCC, efforts should be made to 
understand the underlying pathogenesis better, identify cases early on in the disease 
process and, in the long run, prevent acquisition of oral HPV infection. Although over a 
hundred HPV subtypes have been identified, only over a dozen have been classified as 
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high-risk. Interestingly, head and neck cancer is almost always associated with high risk 
HPV type 16 which accounts for over 90% of the cases [282], [291] and, in addition, 
high-risk HPV does not appear to affect all mucosal head and neck anatomic sites 
equally as the vast majority of HPV-driven HNSCC arise from the mucosal lining of the 
oropharynx [282], [253], [167]. Given the close proximity of head and neck subsites 
and the challenges associated with attributing a site of origin for some large primary 
tumours, these statistics may be misleading. The reasons why most HNSCC arise as a 
result of infection with HPV-16 are not clear and viral predilection for the mucosal 
lining of the oropharynx needs further elucidation. Identification of additional molecular 
markers of HPV-driven HNSCC will shed light on the underlying pathogenesis of HPV- 
induced tumours of the head and neck.  
 
Prevalence of HPV-associated HNSCC appears to vary with geographic location and 
time, with higher incidence rates in the US compared to Europe [119], [122], [49].  
Apart from a recent report suggesting that OPSCC, possibly linked to HPV, is the 
fastest increasing cancer in men in Scotland [132], there are very few dedicated and 
comprehensive Scotland-specific studies which have reported on the incidence of HPV-
positive HNSCC. In this direction, the research undertaken in this study has attempted 
to advance existing knowledge on the prevalence of HPV-driven HNSCC in Scotland. 
Currently, p16 IHC is the most commonly used surrogate marker of HPV infection but a 
growing body of research has expressed uncertainty regarding its efficacy as a reliable 
indicator of HPV-positive HNSCC [283], [141], [202]. While a novel single step 
detection method, the RNAscope, has been proposed by some groups [315], [263], there 
is scant research about other biomarkers of HPV. Data from our lab and a report by 
Accardi et al. [2] indicate that EBP50, an adaptor protein, is a novel target of the high-
risk HPV E6 oncoprotein. This, and the existing dearth of information on the molecular 
markers of HPV-induced tumourigenesis in the head and neck, prompted an 
investigation of EBP50 and its expression in the study cohort. This study involved a 
retrospective analysis of archival FFPE specimens for a cohort of 293 HNSCC patients 
diagnosed and treated in NHS Tayside. The samples were tested for the presence of 
HPV DNA by PCR. These results, along with available p16 IHC results, were used to 
define HPV status of the cohort. A smaller subset of HPV-positive and negative 
samples were analysed for EBP50 expression patterns by IHC. The relationship 
between HPV status, EBP50 expression patterns and clinical characteristics of the 
cohort including survival outcomes was analysed.  
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6.2 Characteristics of the study cohort 
 As mentioned in the previous section, designating a site of origin for certain tumours in 
the upper aerodigestive track can be challenging because of the close proximity of head 
and neck subsites. Consequently, tumours arising in the base of the tongue or tonsil may 
sometimes be misclassified as originating in other head and neck subsites [135]. 
Therefore a relatively heterogeneous cohort, consisting of patients who were diagnosed 
and treated in a single centre, was selected for this study because it was more likely to 
reflect the true prevalence of HPV-related HNSCC in the region. 
 
The crude incidence rates of HNSCC in the UK are strongly related to gender and age 
with a male : female ratio of 2:1 and an average patient age of 65 years [34]. More than 
half of the patients in this study cohort were males and the mean age of diagnosis was 
64.5 years, which is in keeping with the general trends across the UK. These cohort 
characteristics are also comparable to those of a recent large scale prospective clinical 
cohort study of 5511 head and neck cancer patients recruited from various centres 
across the UK where the mean age of patients was reported to be 61 years and female 
patients comprised only 27% of the cohort [221]. Surprisingly, the distribution of 
tumours in this cohort, based on anatomic site of origin, was somewhat different from 
tumour categories reported in the Head and Neck 5000 study. While cancers of the 
larynx and oral cavity constituted the majority of cases in this cohort, oropharyngeal 
tumours constituted the largest category in the Head and Neck 5000 study followed by 
oral cavity and laryngeal tumours [221]. Given that the Head and Neck 5000 study is 
more recent (2011-2014) compared with our study (2006-2011), it is probably 
consistent with the trend of rising incidences in oropharyngeal cancers [34] [232], 
[128], [131]. Additionally, it is likely that the primary tumour site distribution trends 
noted in this cohort is a reflection of smoking and alcohol consumption habits of 
patients that configure it.  
 
At diagnosis, more than a third of the patient population were smokers and nearly a 
fourth had a history of heavy drinking (current or ex-heavy drinker). These findings 
highlight negative health behaviour patterns in this population. Smoking/alcohol 
consumption and associated health outcomes such as long-term disease conditions and 
mortality often vary between countries, cities and regions [88]. Scotland is known to 
have a relatively poor health profile when compared to the rest of the UK and European 
countries and this, in turn, has been attributed to social deprivation [88], [36]. 
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Interestingly, nearly half the study population was diagnosed with late stage disease, a 
finding consistent with other cohort studies [221]. An advanced disease stage at 
diagnosis has been associated with socioeconomic inequalities [229]. Although, an 
assessment of socio-economic backgrounds was not performed for this study, the 
Scottish Index of Multiple Deprivation 2013 reported Dundee city as having 30% of the 
share of the most deprived communities in Scotland.  
 
HNSCC treatment often depends on the stage of disease at diagnosis and patients 
presenting with clinically advanced disease undergo multimodal treatment in the form 
of surgery, chemotherapy and/or radiotherapy [197]. Consequently, a large proportion 
of the patients in this cohort had undergone combined modality treatment in the form of 
chemoradiation, surgery with chemoradiation or surgery with radiotherapy and this is 
consistent with the general organ-preserving trends in treatment approaches noted in the 
literature [37], [85].  
 
The 2-year OS and DSS rates for the study cohort were 62% and 82% respectively. 
Although the OS rate is comparable to that seen in the European population [107] it 
differs considerably from DSS rate. Patients with HNSCC often have comorbid 
conditions as a consequence of their smoking and drinking habits and have higher 
incidence of death from causes unrelated to head and neck cancer [259]. Smoking 
history at diagnosis, treatment modality and extracapsular spread were independent 
prognostic indicators for overall survival in this cohort and these observations are 
consistent with previous reports [63], [37], [121]. 
 
6.3 Incidence of high-risk HPV-related HNSCC in Tayside 
One of the objectives of this study was to establish the prevalence of high-risk HPV and 
its impact on clinical outcomes in the study population. HPV testing for research 
purposes has been a continually evolving subject with considerable variability in the 
testing method of choice employed in cohort studies investigating viral incidence. In 
routine clinical practice in Scotland, HPV-related HNSCC is diagnosed either by p16 
IHC alone or by employing a combination of p16 IHC and PCR (see Appendix A). The 
decision to investigate HPV status employing a combination of p16 and PCR in this 
cohort was influenced by the general trends in HPV testing prevailing in the literature at 
the time, its cost effectiveness as well as the fact that a p16 status was already available 
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for patients in the cohort.  
 
Less than a quarter (14%) of the Tayside study population was found to be HPV-
positive. The incidence rate reported in this study was much lower than the European 
average of 40% [1] and incidence rates of 70% reported in the US [54] but higher than 
that reported at a national level [4]. This variability may be attributable, in part, to 
geographic location [119]. For example, in a seminal study investigating the etiologic 
role of HPV in a large cohort of 253 patients with HNSCC in the US, Gillison et al. 
reported an incidence rate of 25% [101]. Our study was similar to that of Gillison et al. 
in sample size (293 vs 253) and type (heterogeneous) but a higher prevalence of HPV-
associated HNSCC in North America may account for the higher incidence rate of 25% 
[148]. Other potential sources of variability include type of cancer sample analysed and 
the method of HPV detection employed in a study. For example, Wells et al. and 
Anderson et al. reported incidence rates of 45% and 10% respectively in Scottish 
cohorts. While Wells et al. investigated the etiological role of HPV in cohort of 
oropharyngeal tumours employing HPV DNA detection by PCR and p16 IHC, 
Anderson et al. employed PCR alone in a heterogeneous cohort of HNSCC patients 
[321], [4].  
 
Not surprisingly, the vast majority of tumours in this cohort were high-risk HPV-16 
positive and were tumours arising in the oropharynx - particularly in the tonsil. These 
results are consistent with other studies where heterogeneous cohorts were employed 
[1], [4]. HPV-positive tumours of oropharyngeal origin arise most commonly in the 
lingual and palatine tonsillar crypts [323]. It is hypothesised that the reticulated 
epithelium lining the tonsillar crypts provides an immune-privileged site by inhibiting 
virus-specific T cells and facilitating immune evasion at the time of initial HPV 
infection and subsequent virus-induced malignant transformation [323]. Furthermore, 
disruptions in the reticulated epithelium leave the basement membrane exposed to viral 
particle deposition without the need for mechanical abrasion of the mucosa, making the 
tonsils more susceptible to HPV infection and subsequent malignant transformation 
[323]. High-risk HPV was also detected in tumours arising in the oral cavity, the 
pharynx and the nasal cavity. The prevalence of HPV in non-oropharyngeal head and 
neck subsites has been somewhat dichotomous. For example, a prevalence of 16% of 
high-risk HPV was reported in a recent cohort study of Taiwanese patients with 
squamous cell carcinomas of the oral cavity [163]. In another heterogeneous cohort 
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study  Gillison et al. reported the presence of HPV DNA in the oral cavity (16%), 
larynx (26%) and the hypopharynx (3%) [101]. In a systematic review, Kreimer et al. 
[148] reported that 23.5% of oral cavity tumours and 24% of laryngeal tumours were 
HPV DNA positive, findings which are similar that reported by Mehanna et al. [194]. It 
is important to note here that the findings reported by these studies were based 
predominantly on HPV DNA detection by PCR and are considerably higher than the 
incidence rates noted in non-oropharyngeal sites in this study (7/293; 2.3%). Contrarily, 
Lopes et al. were able to demonstrate that the prevalence of high-risk HPV in squamous 
cell carcinomas of the oral cavity was very low by employing a combination of 
consensus and quantitative PCR and ISH, [178]. Given the tendency of PCR based 
methods to be non-specific when used alone, the higher incidence rates seen in the 
literature may be misleading. The findings of low HPV prevalence in non-
oropharyngeal sites reported this study concur with that of Lopes et al. [178] and 
provide additional evidence that the oropharynx has a higher predilection for 
transformation by oncogenic HPV. However, the etiologic role of high-risk HPV in 
non-oropharyngeal sites remains unclear and highlights the need for additional large 
scale epidemiological studies to uncover any significant associations. 
 
Paradoxically, only 24 out of 40 HPV positive samples in this cohort also tested positive 
for high-risk HPV by DNA ISH. ISH differs from PCR and p16 IHC in that it allows for 
detection of HPV DNA within the nuclei of infected tumour cells. Additionally, the 
physical state of the virus as indicated by punctate staining for integrated virus and 
diffuse staining for episomal virus is also evident with ISH [310]. However, a major 
drawback of the ISH is its lack of sensitivity as it is only able to detect HPV when there 
are around 10 copies of virus per cell [310]. Despite, the high specificity of this method, 
estimated false negative rates of 13-41% have been reported in HNSCC owing to its 
low sensitivity and a tendency for probe cross hybridisation [308], [40]. While a lack of 
concordance between DNA ISH and other routinely used HPV testing methods has been 
reported by previous studies [282], [269], the reason for discrepancies observed in this 
study is unclear and may be due to reduced copy numbers/positive tumour cells in the 
specimens. However, a comment on the feasibility of DNA ISH for risk stratification in 
routine clinical practice is beyond the scope of this thesis.  
 
Overall survival and recurrence free survival was significantly improved for HPV-
positive patients in this cohort. Furthermore, tumour HPV status was an independent 
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prognostic factor for overall survival. The 2-year OS rate for HPV-negative patients was 
57% compared to 77% for HPV-positive patients. These results are comparable to a 
study by Evans et al. in a Welsh cohort where 3-year survival was reported to be 32.2% 
for HPV-negative patients and 82.6% for HPV-positive patients [75]. However, the 
study by Evans et al. [75] comprised patients with oropharyngeal tumours only and it is 
relevant to reiterate, in this context, the scope and depth of the study in this thesis in 
relation to other studies undertaken.  Several groups have reported on favourable 
prognosis conferred by HPV-positivity in HNSCC [79], [174], [173], but some others 
have reported contradictory findings which showed no association between HPV-
positivity and patient prognosis [141], [71]. One hypothesis to explain these conflicting 
results is that most studies reporting improved clinical outcomes in HPV- positive 
cancers were conducted on predominantly oropharyngeal tumour cohorts. Overall 
survival in this study was not influenced by the heterogeneity of the cohort. On the 
other hand, no significant associations were found between DSS and HPV status in this 
cohort. The findings of studies reporting on the association between HPV status and 
cause specific survival are varied. For example, Wells et al. [321] and Dahlgren et al. 
[57] found a significant association between HPV status and cause specific survival. 
However, both studies were carried out on a cohort of oropharyngeal/tonsillar squamous 
cell carcinomas and fresh frozen biopsy specimens were employed in the study by 
Dahlgren et al. [57]. On the other hand, Ritchie et al. [254] found no significant 
association between tumour HPV status and DSS, a finding concurrent with this study.  
The differences in cause specific survival between this study and others may be 
attributed to differences in cohort type and size and in percentages of deaths due to 
cancer. Additionally, disease specific survival curves can often be misleading as they do 
not include death caused by disease related factors such as treatment [252].  
 
6.4 EBP50 - a novel marker of HPV-associated HNSCC 
The second objective of this study was to evaluate EBP50, a cytoskeletal adaptor 
protein targeted by the high-risk HPV, as a novel diagnostic marker for HPV-related 
HNSCC. HPV and its association with HNSCC is a continually evolving field of 
research with numerous studies investigating diagnostic testing and treatment modalities 
for patients. However, very little research has been undertaken to uncover the molecular 
events that lead to HPV-induced tumorigenesis.  A widely accepted hypothesis is that 
the virus infects the proliferating basal layer of epithelial surfaces at a site of injury. By 
 151 
 
 
subsequent internalisation, evasion of host immune response and replication, the virus 
propagates persistent infection [202]. Viral integration into the host genome is an 
important step resulting in the overexpression of viral oncoproteins E6 and E7. 
Overexpression of E6 and E7 leads to disruption of the p53 and pRB pathways, among 
others, resulting in cell proliferation and genomic instability [161], [25]. Overexpression 
of p16, a surrogate marker of HPV infection, is one such consequence of the E7 
oncoprotein mediated disruption of the pRB pathway. However, p16 overexpression has 
also been observed in the absence of HPV positivity, in both oropharyngeal and non-
oropharyngeal sites in the head and neck and has been postulated to be due to genetic 
mutations such as loss of Rb or amplification of Cyclin D1 [328]. Additionally, the 
oncogenic activity of E6 has  been attributed to its ability to bind to and degrade PDZ 
domain containing cell polarity proteins including EBP50 [204], [2].  
 
In this study, the influence of high-risk HPV on EBP50 was investigated by 
immunohistochemical analysis of a cohort of HPV-positive and negative HNSCC 
patients. Four groups of EBP50 expression patterns were identified; ‘predominantly 
cytoplasmic’, ‘weak/negligible cytoplasmic’, ‘heterogeneous’ and ‘other’ less common 
patterns. The majority of tumour samples demonstrated a ‘predominantly cytoplasmic’ 
EBP50 expression pattern. Interestingly, membranous EBP50 expression was absent in 
nearly all the samples in the cohort except for a few with ‘heterogeneous’ and ‘other’ 
staining patterns. This is in stark contrast to membranous EBP50 immunoreactivity 
observed within the supra-basal layers of the epithelium in a normal tonsillar specimen 
in this study and also reported in other tissues [95].  While the role of EBP50 has been 
studied in breast cancer [235], Schwanomma [87], hepatocellular carcinoma [276], 
colorectal and gastric cancers [186], [183], this is the first study to report on its 
expression in HNSCC. A ‘predominantly cytoplasmic’ EBP50 expression accompanied 
by a complete absence of membranous immunoreactivity has been previously reported 
in breast and colorectal carcinoma [95], [186]. Gerogescu et al. noted that EBP50 is 
either absent or ‘overexpressed in an altered intracellular distribution’ in tumours and 
proposed that EBP50 may function as a tumour suppressor when it is localised at the 
plasma membrane and as an oncogenic protein when it is localised in the cytoplasm 
[95].  The absence of membrane EBP50 and its expression in the cytoplasm observed in 
a large number of HNSCC samples in this study may represent an altered protein 
distribution and appears to suggest a tumour suppressor role for EBP50.  
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EBP50 proteins possess two PDZ binding domains and a C-terminal binding domain 
through which they form protein-protein complexes at the interface of the plasma 
membrane and cytoplasm [249]. Formations of such protein-protein complexes allow 
them to exercise anchoring functions. For instance, EBP50 associates with β-catenin 
forming an important component of the E-cadherin-β-catenin protein complex for 
cortical stabilisation in epithelial cells [276]. Similarly, it binds to Epidermal Growth 
Factor (EGFR), a transmembrane protein implicated in carcinogenesis [329]. Disruption 
of EBP50 protein complexes could trigger a sequence of events leading to a malignant 
phenotype. In a study investigating EBP50-EGFR interplay, Claperon et al., reported 
that a loss of EBP50 at the plasma membrane and cytoplasmic overexpression in tumour 
cells may contribute to biliary carcinogenesis by EGFR activation [48].  The authors 
were able to demonstrate that depletion of EBP50 in biliary carcinoma cells increased 
the activity of EGFR at the cell surface and this enhanced EGFR activity triggered a 
disruption in adherens junctions by inducing internalisation of E-cadherin and β-catenin 
[48]. Indeed, overexpression of EGFR and its ligand TGFα is commonly seen in 
HNSCC [105]. Thus, it can be hypothesised that an aberrant activity of the EGFR 
signalling pathway brought about by ectopic localisation of the EBP50 protein and 
subsequent loss of its tumour suppressor function may, in part, contribute to the 
formation of squamous cell carcinomas of the head and neck.  
 
An alternative mechanism by which EBP50 in squamous epithelial cells may contribute 
to tumour formation is by directly influencing the β-catenin/Wnt signalling pathway as 
seen in colorectal cancer [114]. β-catenin is stabilised at cell-cell junctions through its 
interaction with EBP50 [146]. In vitro studies by Hayashi et al., found that depletion of 
EBP50 from plasma membranes of polarised intestinal epithelial cells induced in 
Epithelial Mesenchymal Transition (EMT), nuclear translocation of β-catenin with 
elevation of Wnt/ β-catenin transcriptional targets, and increased cell migration and 
invasion. Normal cell morphology and reduced motility were restored only by re-
expression of the protein specifically at the plasma membrane, reinforcing the tumour 
suppressor function of EBP50 at plasma membranes of epithelial cells [114]. 
 
Interestingly, ‘predominantly cytoplasmic’ EBP50 expression patterns were more likely 
to be seen in ‘smokers’ with tumours arising in non-oropharyngeal sites such as the oral 
cavity and larynx with no involvement of neck nodes. These patients were also more 
likely to present with a negative p16 and HPV status. On the other hand, a smaller 
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proportion of the study samples demonstrated a ‘weak/negligible’ cytoplasmic staining 
and patients with tumours exhibiting reduced cytoplasmic EBP50 were ‘non-smokers’ 
or ‘ex-smokers’ at the time of diagnosis and had tumours arising predominantly in the 
oropharynx. These patients were also more likely to present with positive neck nodes 
and late stage disease and were positive for p16 and HPV. Thus, each EBP50 staining 
pattern correlates with a distinct patient profile very similar to characteristics of patients 
with HPV-positive and negative tumours.  
 
A sustained high-level expression of HPV oncoproteins E6 and E7 is vital to the 
development and maintenance of virally induced malignant phenotype. The high-risk 
HPV E6 oncoprotein has a PDZ binding motif (PBM) in its carboxyl terminus, a feature 
absent in low-risk benign HPVs,  which allows it to interact with PDZ domain 
containing cell polarity proteins [10]. In addition to contributing to E6-mediated 
malignant transformation of tissues, E6-PDZ domain protein interactions play a crucial 
role in the viral life cycle. For example, viral interaction with hScrib has been shown to 
stabilise E6 in the early stages of the viral life cycle by increasing the levels of E6 
protein [226]. Such PBM-dependent stabilising interactions with E6 have also been 
suggested for other PDZ domain containing proteins such as hDlg1 and MAGI-1 [213]. 
Such a stabilising role for EBP50 is yet to be uncovered. It is evident, however, that 
HPV-16 E6 interaction with EBP50 may support malignant transformation of epithelial 
tissue by the virus. Accardi et al. were able to demonstrate that HPV-16 E6 binds to and 
induces degradation of the EBP50 protein in vitro and is assisted by the E7 oncoprotein 
[2]. In addition to their in vitro data, the authors were also able to show that EBP50 
levels were very low in SiHa and CaSki cell lines, both of which are HPV-16-positive 
cervical cancer derived cell lines. Based on this evidence, low or negligible levels of 
EBP50 observed in a proportion of predominantly oropharyngeal HPV-16-positive 
tumours in this cohort is suggestive of a virus induced degradation of the cell polarity 
protein. Cavatorta et al. reported similar findings of low or absent expression of Dlg, a 
PDZ substrate of high-risk HPV, in invasive cervical carcinoma specimens where low 
levels of the protein correlated with the presence of high-risk HPV [38]. Furthermore 
there are reports of E6 targeting specific cellular pools of substrate proteins. For 
example, HPV E6 has been shown to specifically target nuclear pools of hDlg and 
nuclear and membrane bound forms of MAGI-1 [145]. Based on findings of this study, 
it may be hypothesised that the low/negligible EBP50 protein levels seen in HPV-
positive tumour cells may be a result of E6 targeted degradation of membrane bound 
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pools of EBP50. The E6 oncoprotein has been shown to inactivate PTEN through PDZ 
domain proteins, leading to increased pAkt activation and subsequent increased cell 
proliferation  [45].  EBP50 has been shown, in vitro, to facilitate the formation of a 
ternary complex of the PTEN tumour suppressor protein with PDGFR at the plasma 
membrane of mouse embryonic fibroblasts thus keeping in check the activation of PI3K 
pathway in response to PDGF stimulation [297]. It is possible that malignant 
transformation in HPV-infected tissues may in part be a result of E6-mediated 
degradation of EBP50 and subsequent disruption of the PTEN-PDGFR complex leading 
to a prolonged activation of the Akt/PI3K signalling pathway. Indeed, Accardi et al. 
were able to demonstrate that HPV E6-mediated degradation of EBP50 induced 
activation of the Akt/PI3K signalling pathway [2].  
 
A few HPV-positive specimens in this study did not demonstrate ‘weak/negligible 
cytoplasmic’ EBP50. E6 phosphorylation by Protein Kinase A (PKA) inhibits its ability 
to bind to and degrade PDZ domain proteins [152] and it is possible that EBP50 
degradation in these tumour samples was inhibited by PKA phosphorylation. A smaller 
proportion of study samples demonstrated a mixed or ‘heterogeneous’ EBP50 
expression pattern in which the protein could be detected in the plasma membranes of a 
few tumour cells while it was either absent or weak in the others. Likewise, a mixed 
cytoplasmic expression was also noted wherein a few specimens demonstrated 
cytoplasmic EBP50 immunoreactivity ranged from clear positive to weak or negligible. 
The clinicopathological characteristics of patients with tumours exhibiting a mixed 
expression pattern were similar to those with ‘predominantly cytoplasmic’ expression. It 
may be surmised that tumour cells demonstrating mixed EBP50 expression represent 
various stages of loss of tissue architecture and tumour invasiveness. Although 
‘weak/negligible cytoplasmic’ EBP50 expression was associated with improved clinical 
outcomes in a univariate analysis, EBP50 expression was not an independent prognostic 
factor in multivariate analysis suggesting that other factors may compete or interact with 
EBP50 expression to influence survival [235]. 
 
The preliminary findings on EBP50 expression in HNSCC reported in this study 
support the hypothesis that downregulation of EBP50 may contribute to HPV-mediated 
malignant transformation of epithelial tissues in the head and neck region making 
EBP50 a potential marker for HPV-related HNSCC. Furthermore, it may be surmised 
that the loss of tumour suppressor function of EBP50 either by aberrant localisation or 
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downregulation/degradation by high-risk HPV may be implicated in the molecular 
pathogenesis of HNSCC, albeit through different signalling pathways.  
 
6.5  Strengths of the study 
This study included a large, well-characterised cohort of all HNSCC cases from a 
geographically defined population diagnosed over a six-year period and treated at a 
single NHS centre. The sample size of 293 patients is much larger than that of other 
UK- wide cohort studies investigating the prevalence of HPV in HNSCC. Furthermore, 
this cohort not only includes tumours arising in the oropharynx but also from other head 
and neck subsites. Patient case notes were reviewed to record missing clinical data and 
to update survival data. This ensured that the existing database was current and 
complete. The use of official death certificate records (General Register Office) ensured 
that the key clinical outcome of disease specific survival was ascertained with accurate 
data. Meticulous selection of tumour specimens based on the presence of a substantial 
amount of tumour tissue and its suitability for downstream experiments ensured that the 
study cohort is robust. Scoring of ISH results and EBP50 IHC staining patterns was 
undertaken by two independent observers and EBP50 staining in 10% of the study 
samples was additionally scored by a third observer ensuring that the interpretation of 
test results is free of bias.  
  
6.6 Limitations of the study 
This was a retrospective study and data pertaining to certain pathological features such 
as ‘field change’, ‘perineural invasion’ and ‘lymphovascular invasion’ was missing. 
This was also due to inclusion of cases into the study where surgery was not a treatment 
modality and available specimens were diagnostic biopsies. Clinical data pertaining to 
smoking and alcohol was based on information provided by the patients at the time of 
diagnosis. Smoking history was not available in pack-years. At the end of the study 
mean length of follow-up was 39 months and only three quarters of the study population 
was followed up for 5 years. Cause of death data was obtained from the GRO and may 
be subject to errors as is the case with many national registration systems. Thus by 
relying on information from GRO death certificates, the number of head and neck 
cancer deaths may have been overestimated. Analysis of EBP50 expression in normal 
mucosa of the upperaerodigestive tract was restricted to a single specimen owing to the 
unavailability of normal specimens.  
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6.7 Significance of the study 
The diagnosis, treatment and prevention of HPV-related HNSCC is a complex problem 
and there is a critical need for additional diagnostic and prognostic biomarkers. Current 
literature on the prevalence of high-risk HPV in the Scottish population is limited by 
small study samples with a focus on specific subsites. Furthermore, ongoing research is 
largely directed toward treatment of HPV-positive tumours and there is relatively little 
information on the underlying molecular pathogenesis of HPV induced tumorigenesis. 
This study is the largest retrospective analysis of HPV incidence in a heterogeneous 
Scottish cohort. It is also the first study to report on EBP50 expression in HNSCC. The 
results obtained from HPV DNA analysis by PCR of tumour samples combined with 
p16 status has contributed to existing knowledge on the global incidence of HPV-
associated HNSCC. It has also highlighted potential negative health behaviours in the 
population and the need for patient education and motivation. Furthermore, the findings 
on EBP50 expression provide preliminary but strong evidence in support of the 
diagnostic value of EBP50 as a marker of HPV-related HNSCC.  
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Chapter 7 
CONCLUSION 
 
HPV-associated HNSCC represent a distinct disease entity with unique clinical and 
molecular characteristics. There is considerable variability in the reported incidence 
rates of HPV-related HNSCC worldwide depending on the geographic area and type of 
HPV detection assay complicated further by challenges associated with assigning a ‘site 
of origin’ for larger tumours given the close proximity of head and neck subsites [135]. 
The base of the tongue and palatine tonsils are the most commonly affected head and 
neck anatomic subsites and also where survival advantage of HPV-positive tumour 
status has been extensively reported [79], [99], [321], [295]. Occasionally, other 
subsites such as the larynx, oral cavity and hypopharynx are affected. However, the 
prognostic significance of HPV positivity in these subsites is debatable.  Recently, 
OPSCC was reported as the fastest increasing cancer in men in Scotland and it was 
suggested to be linked to infection with high-risk HPV [132]. Very few studies have 
investigated the incidence of HPV in HNSCC across the UK, fewer still in Scotland. 
Most of them are limited by small study samples and a tendency to focus on specific 
head and neck subsites. Furthermore, there is very little research on molecular 
pathogenesis and biomarkers of HPV-driven tumorigenesis as most studies focus on 
virus detection and treatment of HPV-related HNSCC.  
 
This retrospective study set out to determine the prevalence of high-risk HPV infection 
in a heterogeneous cohort of HNSCC patients diagnosed and treated in a single NHS 
treatment centre. It also sought to explore expression patterns of the cytoskeletal adaptor 
protein EBP50, a target of high-risk HPV E6 oncoprotein, in a subset of HNSCC 
samples. 
 
 The specific aims of this study were 
 
1) To determine the prevalence of high-risk HPV and its impact on clinical 
outcomes in a sample population of HNSCC patients in Tayside, Scotland. 
2) To evaluate EBP50, a cytoskeletal adaptor protein targeted by the high-risk 
HPV, as a novel marker for HPV-related HNSCC. 
 
The main experimental findings of this study are chapter specific and are summarised 
within Chapters 4 (Prevalence of Human Papillomavirus related HNSCC in a Tayside 
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cohort) and 5 (Investigation of EBP50 as a potential novel marker of HPV associated 
HNSCC). The main findings with respect to the study aims will be summarised in the 
following sections. 
 
7.1 Determination of the prevalence of high-risk HPV and its impact 
on clinical outcomes in the study population 
7.1.1 Prevalence of HPV in the sample population 
 The p16 status of all the study samples was already available. HPV DNA status of all 
the study samples was determined by PCR using consensus and type specific primers. 
High-risk HPV infection was detected in less than a quarter of the cohort. The majority 
of the cohort was HPV negative (80%) and a small proportion (6%) was ‘equivocal’. 
All the study HPV-positive samples, except one, were infected with high-risk HPV type 
16.  
 
7.1.2 Influence of HPV on patient demographics and tumour histopathology 
The social demographics and clinical characteristics of patients with HPV-positive 
tumours were different from those with HPV-negative tumours. These patients were 
more likely to belong to a younger age group of 58 years or under and were not smokers 
at the time of diagnosis. The majority of the HPV-positive tumours were of 
oropharyngeal origin, poorly differentiated and did not demonstrate features of tumour 
aggression such as the presence of extracapsular spread and cohesive invasive tumour 
front.  
 
7.1.3 Influence of HPV on all cause, disease specific and disease free survival 
As expected, a greater proportion of survivors were seen in the HPV-positive group 
compared to the HPV-negative group. Patients with HPV-positive tumours 
demonstrated an improved overall and recurrence free survival. However, HPV-
positivity was not a prognostic indicator for disease specific survival.  
 
7.2 Evaluation of EBP50 as a novel marker for HPV-related 
HNSCC 
7.2.1 EBP50 expression in normal oral mucosa and primary HNSCC 
EBP50 expression in normal tonsillar mucosa and a subset of HPV-positive and 
negative tumour samples was analysed by immunohistochemistry employing a 
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polyclonal anti-EBP50 antibody. In normal oral mucosa, EBP50 expression is 
predominantly membranous in suprabasal layers of the epithelium with a gradual shift 
in distribution from membranous to predominantly cytoplasmic in the basal layers of 
the epithelium. On the other hand, absence of EBP50 expression in the plasma 
membranes of tumour cells was a recurring pattern in a majority of the tumour samples. 
Furthermore, EBP50 was predominantly expressed in the cytoplasm of nearly half of 
the tumour samples. In a smaller proportion of the samples cytoplasmic EBP50 was 
either absent or very weak. Mixed EBP50 immunoreactivity was observed in a very 
small proportion of tumour samples.  
 
7.2.2 EBP50 expression in relation to clinicopathological characteristics of the 
study cohort 
EBP50 expression was significantly associated with smoking status at the time of 
diagnosis, site of primary tumour, disease stage, neck node status, HPV and p16 status. 
Weak or negligible cytoplasmic EBP50 expression was observed largely in patients 
with tumours of the oropharynx presenting with advanced disease, no history of 
smoking at the time of diagnosis, positive p16 and HPV status. In contrast, cytoplasmic 
EBP50 expression was observed primarily in patients with a smoking history, non-
oropharyngeal tumours, negative p16 and HPV status. EBP50 expression showed a 
strong correlation, only marginally lower than p16 overexpression, with HPV DNA 
status. 
 
7.2.3 EBP50 expression in relation to clinical outcomes of the study cohort 
 Although patients with weak/negligible cytoplasmic tumour EBP50 expression showed 
improved all cause, recurrence free and disease specific survival, no significant 
associations were found between clinical outcomes and EBP50 staining.  
 
7.3 Implications of the study findings  
Data and statistics provided by population based studies are essential for determination 
of the true prevalence of a disease. HPV in HNSCC in the Scottish population has been 
previously reported by Anderson et al. [4] and LAR Wells et al. [321]. While the 
prevalence reported in this study contributes to existing knowledge on HPV incidence 
in head and neck cancer in Scotland, it varies from reported results from other regions. 
This may be attributed to sample selection and size and primers used in HPV DNA 
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detection. The clinical characteristics of the sample population and histopathological 
traits based on tumour HPV status reported in this study are concurrent with current 
literature [155]. HPV positivity correlated with improved overall and recurrence free 
survival, but not with cause-specific survival. These results are, to a small degree, 
incongruous with those reported by LAR Wells et al. [321] and may be attributed to the 
heterogeneous nature of the sample population in this study. Indeed, improved survival 
is often reported in oropharyngeal tumour cohorts [272], [5] while mixed or non-
oropharyngeal cohorts have shown no difference in survival between HPV-positive and 
HPV-negative patients diagnosed with head and neck cancer [240]. 
 
The novel research undertaken in this study has shown that EBP50 is differentially 
expressed in HNSCC depending on tumour HPV status. It certainly contributes to recent 
evidence that regulation of EBP50 by HPV has a crucial role in HPV-associated 
carcinogenesis [2].  The ‘predominantly cytoplasmic’ staining pattern observed in 
nearly half of the study cohort has been previously reported in colorectal and breast 
cancer [114], [187]. These findings are suggestive of a shift in subcellular localisation 
of the EBP50 protein from membrane to cytoplasm in squamous cell tumours of the 
head and neck and reinforce a tumour suppressor role for EBP50. Weak/ negligible 
cytoplasmic EBP50 expression seen in a small proportion of tumours that originated 
predominantly in the oropharynx and were HPV-positive is suggestive of a virus 
induced degradation of the cell polarity protein. These findings parallel those of 
Cavatorta et al. on the influence of high-risk HPV on hDlg in cervical cancer specimens 
[38]. Clinical and histological characteristics of the two dominant EBP50 expression 
patterns are similar to those reported for HPV-negative and positive head and neck 
tumours and provide further evidence supporting a two distinct disease processes.  
 
EBP50 expression was not an independent prognostic indicator in HNSCC. Although 
improved survival rates were noted for reduced cytoplasmic EBP50 expressing tumours, 
only recurrence free survival was significant. These results, although not statistically 
significant, are very similar to survival data related to tumour HPV status in the cohort. 
Previous reports on clinical outcomes and EBP50 expression are varied, seemingly 
linked to subcellular localisation of the protein [183], [235]. It is possible that the 
survival rates noted in this study are merely reflective of the HPV status of the tumours 
and its influence on survival. Furthermore, other factors may compete or interact with 
EBP50 expression to influence survival. Therefore, the findings of this study also 
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provide evidence that unlike p16, EBP50 expression is not an independent prognostic 
indicator in HNSCC.  
 
The findings of this study support current consensus that HPV-positive HNSCC are 
different from HPV-negative HNSCC in its clinical features, tumour histopathology and 
molecular traits. The prevalence of high-risk HPV in this Scottish cohort was relatively 
low compared to that of other countries. Findings on social demographics and clinical 
characteristics have highlighted negative health behaviours in this population indicating 
a need for patient education for preventive healthcare and screening programmes that 
are accessible to all communities.  Preliminary findings on EBP50 expression in this 
cohort indicate that it may be a valuable marker for HPV- positive HNSCC. It also 
suggests that loss of EBP50 may support tumour progression through different 
signalling pathways in HPV-positive and negative head and neck cancer and its 
modulation may be a potential therapeutic strategy in improving clinical outcomes in 
these patients.  
 
7.4 Future direction 
The variability in incidence rates across studies reiterates the need for uniform and 
standardised HPV testing protocols. Current literature does not provide conclusive 
evidence on the etiologic role of HPV in non-oropharyngeal head and subsites and 
additional large-scale cohort studies are needed to elucidate significant associations, if 
any, and related impact on patient prognosis. Additionally, given the rising incidence of 
oropharyngeal cancers in Scotland, a large prospective cohort study of oropharyngeal 
patients would establish current HPV prevalence in the Scottish population and whether 
incidence rates have changed over time. Further studies on EBP50 expression in 
normal, dysplastic, carcinoma in situ specimens will be helpful in determining whether 
loss of membranous EBP50 and its aberrant subcellular localisation is an early or late 
stage marker in head and neck tumour progression.  
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APPENDIX A 
Practice trends in HPV testing for HNSCC 
 
 Presented in this section are excerpts from a Scotland-wide survey on practice trends in 
HPV testing for head and neck squamous cell carcinomas which was undertaken 
concurrently with the research in this thesis. 
 
Oral pathologists/general pathologists specialising in head and neck pathology from 
each of the Scottish NHS boards were invited to take part in a survey on routine 
diagnostic HPV testing for HNSCC in their local NHS centres. A participation invite 
with the survey link was circulated among the specialists via the Scottish pathology 
network (SPaN).  
 
A. Diagnostic testing for high-risk HPV-related HNSCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A: Routine screening of all HNSCC specimens for high-risk HPV was reported 
by 29% of the respondents. The vast majority, however, said they tested for HPV only 
when the specimens were from a specific subsite like the oropharynx or when they 
received a special clinical request for HPV status. Age of the patient and discussions at 
multidisciplinary team meetings were also some other circumstances under which 
diagnostic HPV investigations were carried out. 
 
29% 
71% 
 184 
 
 
 
 
 
 
 
 
Figure B: The p16 immunohistochemistry was the most common single assay used in 
practice. An equal proportion of respondents said they employed p16 as first line assay 
followed by PCR. PCR as a lone assay for determining tumour HPV status was 
employed by one NHS board.  
 
B. Interpretation of p16 immunohistochemistry results and scoring methods 
A general lack of consistency was observed in the interpretation of p16 IHC results 
across the NHS boards.  Specimens were scored: as positive for HPV if 70% or more of 
the tumour cells showed nuclear and cytoplasmic staining (33%), as positive, equivocal 
or negative for HPV based on the presence or absence of staining (33%), positive for 
HPV if tumour cells showed strong diffuse nuclear staining (17%).  
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C. Variability in practice trends among specialists of the same NHS boards 
 
 
 
 
 
Figure C: Variability in testing practices and reporting of results was observed within 
individual health boards. For example, out of four respondents from Board A, two 
respondents employed p16 IHC as a lone test for determination of tumour HPV status 
while the others used ISH and p16 along with PCR. In Board B, the scoring protocol 
used to report p16 IHC results by two respondents were different. 
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APPENDIX B 
Results of HPV genotyping 
 
Table A: Result of HPV genotyping 
Specimen 
ID 
Beta 
Globin 
HPV L1 HPV E1 HPV 
Status_based on 
genotyping for 
L1 or E1 gene 
Type specific 
PCR 
1 Positive Negative Negative Negative NA 
a
 
2 Positive Negative Weak 
positive 
Weak positive HPV 18 
4 Positive Negative Negative Negative NA 
5 Positive Negative Negative Negative NA 
6 Positive Negative Negative Negative NA 
7 Positive Negative Negative Negative NA 
8 Positive Negative Negative Negative NA 
9 Positive Negative Negative Negative NA 
10 Positive Negative Negative Negative NA 
11 Positive Negative Negative Negative NA 
12 Positive Negative Negative Negative NA 
14 Positive Negative Negative Negative NA 
15 Positive Negative Negative Negative NA 
16 Positive Negative Negative Negative NA 
17 Positive Negative Negative Negative NA 
18 Positive Negative Negative Negative NA 
19 Positive Negative Negative Negative NA 
20 Positive Negative Negative Negative NA 
21 Positive Negative Negative Negative NA 
22 Positive Negative Negative Negative NA 
23 Positive Negative Negative Negative NA 
26 Positive Negative Negative Negative NA 
27 Positive Negative Negative Negative NA 
28 Positive Negative Negative Negative NA 
29 Positive Negative Negative Negative NA 
30 Positive Negative Negative Negative NA 
31 Positive Negative Negative Negative NA 
36 Positive Negative Negative Negative NA 
37 Positive Negative Negative Negative NA 
38 Positive Negative Negative Negative NA 
40 Positive Negative Negative Negative NA 
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41 Positive Negative Negative Negative NA 
42 Positive Negative Negative Negative NA 
43 Positive Negative Negative Negative NA 
44 Positive Negative Negative Negative NA 
45 Positive Positive NA Positive HPV16 
47 Positive Negative Negative Negative NA 
48 Positive Negative Negative Negative NA 
51 Positive Negative Negative Negative NA 
53 Positive Negative Negative Negative NA 
55 Positive Positive NA Positive HPV 33 
58 Positive Negative Negative Negative NA 
59 Positive Negative Negative Negative NA 
60 Positive Negative Negative Negative NA 
61 Positive Negative Negative Negative NA 
62 Positive Negative Negative Negative NA 
63 Positive Negative Negative Negative NA 
65 Positive Negative Negative Negative NA 
66 Positive Negative Negative Negative NA 
67 Positive Negative Negative Negative NA 
68 Positive Negative Negative Negative NA 
69 Positive Negative Negative Negative NA 
70 Positive Negative Negative Negative NA 
71  Positive Negative Negative Negative NA 
73 Positive Negative Negative Negative NA 
74 Weak 
Positive 
Negative Negative Negative NA 
75 Positive Negative Negative Negative NA 
76 Positive Negative Negative Negative NA 
77 Positive Negative Negative Negative NA 
79 Positive Negative Negative Negative NA 
80 Positive Negative Negative Negative NA 
81 Positive Negative Negative Negative NA 
82 Positive Negative Negative Negative NA 
83 Positive Negative Negative Negative NA 
84 Positive Negative Weak 
positive 
Weak Positive HPV16 
85 Positive Negative Negative Negative NA 
86 Positive Negative Negative Negative NA 
87 Positive Negative Negative Negative NA 
88 Positive Positive NA Positive HPV16 
89 Positive Negative Negative Negative NA 
90 Positive Negative Negative Negative NA 
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91 Positive Negative Negative Negative NA 
92 Positive Negative Negative Negative NA 
94 Positive Negative Negative Negative NA 
95 Positive Negative Negative Negative NA 
97 Positive Negative Negative Negative NA 
98 Positive Negative Negative Negative NA 
99 Positive Negative Negative Negative NA 
101 Weak 
Positive 
Negative Negative Negative NA 
102 Positive Negative Negative Negative NA 
104 Positive Negative Negative Negative NA 
108 Positive Negative Negative Negative NA 
109 Positive Negative Negative Negative NA 
110 Positive Negative Negative Negative NA 
112 Positive Negative Negative Negative NA 
113 Positive Negative Negative Negative NA 
114 Positive Negative Negative Negative NA 
115 Positive Negative Negative Negative NA 
116 Positive Negative Negative Negative NA 
117 Positive Negative Negative Negative NA 
118 Positive Negative Negative Negative NA 
121 Positive Negative Negative Negative NA 
123 Positive Negative Negative Negative NA 
127 Positive Negative Negative Negative NA 
128 Positive Negative Negative Negative NA 
129 Positive Negative Negative Negative NA 
131 Positive Negative Negative Negative NA 
132 Positive Negative Negative Negative NA 
133 Positive Negative Weak 
positive 
Weak Positive HPV16 
134 Positive Positive NA Positive HPV16 
135 Positive Weak 
Positive 
NA Weak Positive HPV16 
136 Positive Positive NA Positive HPV16 
137 Positive Positive NA Positive HPV16 
139 Weak 
Positive 
Negative Negative Negative NA 
140 Positive Positive NA Positive HPV16 
142 Positive Positive NA Positive HPV16 
143 Positive Positive NA Positive HPV16 
144 Positive Positive NA Positive HPV16 
145 Positive Positive NA Positive HPV16 
146 Weak 
Positive 
Negative Positive Positive HPV16 
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147 Weak 
Positive 
Weak 
Positive 
Positive Positive HPV16 
148 Positive Positive NA Positive HPV16 
149  Positive Weak 
Positive 
Positive Positive HPV16 
150 Positive Weak 
Positive 
Positive Positive HPV16 
153 Positive Positive Positive Positive HPV16 
154 Positive Positive NA Positive HPV16 
155 Positive Negative Negative Negative NA 
156 Positive Positive NA Positive HPV16 
157 Positive Negative Negative Negative NA 
158 Positive Negative Positive Positive HPV 16 
159 Positive Positive NA Positive HPV16 
161 Positive Negative Negative Negative NA 
162 Positive Negative Negative Negative NA 
163 Positive Negative Negative Negative NA 
164 Positive Negative Negative Negative NA 
165 Positive Negative Negative Negative NA 
166 Positive Negative Negative Negative NA 
167 Positive Negative Negative Negative NA 
168 Positive Positive NA Positive HPV16 
169 Positive Positive NA Positive HPV16 
170 Positive Positive NA Positive HPV16 
171 Positive Negative Negative Negative NA 
172 Positive Negative Negative Negative NA 
173 Positive Negative Negative Negative NA 
174 Positive Positive NA Positive HPV16 
175 Positive Negative Negative Negative NA 
176 Weak 
Positive 
Negative Positive Positive HPV16 
177 Positive Negative Negative Negative NA 
178 Positive Negative Negative Negative NA 
179 Positive Positive NA Positive HPV16 
180 Positive Weak 
Positive 
Positive Positive HPV16 
181 Positive Positive NA Positive HPV16 
183 Positive Positive Positive Positive HPV16 
184 Positive Negative Negative Negative NA 
185 Positive Negative Negative Negative NA 
186 Positive Positive NA Positive HPV16 
187 Positive Negative Negative Negative NA 
188 Weak 
Positive 
Weak 
Positive 
Positive Positive HPV16 
189 Positive Negative Positive Positive HPV16 
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190 Positive Positive Positive Positive HPV16 
191 Positive Negative Negative Negative NA 
192 Positive Positive NA Positive HPV16 
193 Positive Weak 
Positive 
Positive Positive HPV16 
194 Positive Negative Negative Negative NA 
195  Positive Weak 
Positive 
Positive Positive HPV16 
196 Positive Positive NA Positive HPV16 
197 Positive Negative Negative Negative NA 
198 Positive Positive NA Positive HPV16 
199 Positive Negative Negative Negative NA 
201 Positive Negative Negative Negative NA 
204 Positive Negative Negative Negative NA 
205 Positive Negative Negative Negative NA 
206 Weak 
Positive 
Negative Negative Negative NA 
207 Weak 
Positive 
Negative Negative Negative NA 
208 Weak 
Positive 
Negative Negative Negative NA 
209 Positive Negative Negative Negative NA 
210 Positive Negative Negative Negative NA 
211 Positive Negative Negative Negative NA 
212 Weak 
Positive 
Negative Negative Negative NA 
213 Positive Negative Negative Negative NA 
214 Positive Negative Negative Negative NA 
215 Positive Negative Negative Negative NA 
216 Positive Negative Negative Negative NA 
218 Positive Negative Negative Negative NA 
219 Positive Negative Negative Negative NA 
220 Positive Negative Negative Negative NA 
221 Positive Negative Negative Negative NA 
222 Positive Negative Negative Negative NA 
223 Positive Negative Negative Negative NA 
224 Positive Negative Negative Negative NA 
225 Weak 
Positive 
Negative Negative Negative NA 
226 Positive Negative Negative Negative NA 
229 Positive Negative Negative Negative NA 
230 Positive Negative Negative Negative NA 
231 Positive Negative Negative Negative NA 
233 Positive Negative Negative Negative NA 
234 Positive Negative Negative Negative NA 
237 Positive Negative Negative Negative NA 
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238 Positive Negative Negative Negative NA 
239 Positive Negative Negative Negative NA 
240 Positive Negative Negative Negative NA 
241 Positive Negative Negative Negative NA 
242 Positive Negative Negative Negative NA 
243 Positive Negative Negative Negative NA 
244 Positive Negative Negative Negative NA 
245 Positive Negative Negative Negative NA 
247 Positive Negative Negative Negative NA 
250 Positive Negative Negative Negative NA 
251 Positive Negative Negative Negative NA 
253 Positive Negative Negative Negative NA 
255 Positive Negative Negative Negative NA 
256 Positive Negative Negative Negative NA 
257 Positive Negative Negative Negative NA 
258 Positive Negative Negative Negative NA 
259 Positive Negative Negative Negative NA 
260 Positive Negative Negative Negative NA 
261 Positive Negative Negative Negative NA 
262 Positive Negative Negative Negative NA 
263 Positive Negative Negative Negative NA 
266 Positive Negative Negative Negative NA 
267 Positive Negative Negative Negative NA 
268 Positive Negative Negative Negative NA 
269 Positive Negative Negative Negative NA 
270 Positive Negative Negative Negative NA 
271 Positive Negative Negative Negative NA 
273 Positive Negative Weak 
positive 
Weak Positive HPV16 
274 Positive Negative Negative Negative NA 
275 Positive Negative Negative Negative NA 
276 Positive Negative Negative Negative NA 
277 Positive Negative Negative Negative NA 
278  Positive Negative Negative Negative NA 
279 Positive Negative Negative Negative NA 
281 Positive Negative Negative Negative NA 
282 Positive Negative Negative Negative NA 
284 Positive Negative Negative Negative NA 
285 Weak 
Positive 
Negative Negative Negative NA 
286 Positive Negative Negative Negative NA 
287 Positive Negative Negative Negative NA 
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288 Positive Negative Negative Negative NA 
289 Weak 
Positive 
Negative Negative Negative NA 
293 Weak 
Positive 
Negative Negative Negative NA 
294 Positive Negative Negative Negative NA 
295 Positive Negative Negative Negative NA 
297 Positive Negative Negative Negative NA 
298 Positive Positive NA Positive HPV16 
299 Positive Negative Negative Negative NA 
300 Positive Negative Negative Negative NA 
301 Positive Negative Negative Negative NA 
302 Positive Positive NA Positive HPV16 
303 Positive Negative Negative Negative NA 
305 Positive Negative Negative Negative NA 
306 Positive Negative Negative Negative NA 
307 Positive Negative Negative Negative NA 
308 Weak 
Positive 
Negative Negative Negative NA 
311 Positive Negative Negative Negative NA 
312 Positive Negative Negative Negative NA 
314 Positive Negative Negative Negative NA 
316 Positive Negative Negative Negative NA 
319 Positive Positive NA Positive HPV16 
320 Positive Negative Negative Negative NA 
322 Positive Negative Negative Negative NA 
324 Weak 
Positive 
Positive NA Positive HPV16 
326 Positive Positive NA Positive HPV 18 
328 Positive Negative Positive Positive HPV16 
329 Positive Negative Negative Negative NA 
331 Weak 
Positive 
Negative Negative Negative NA 
332 Positive Negative Positive Positive HPV16 
334 Weak 
Positive 
Negative Negative Negative NA 
335 Positive Negative Positive Positive HPV16 
337 Positive Negative Negative Negative NA 
339 Positive Negative Negative Negative NA 
340 Positive Negative Negative Negative NA 
342 Positive Negative Negative Negative NA 
343 Positive Negative Negative Negative NA 
344 Positive Negative Negative Negative NA 
346 Positive Negative Negative Negative NA 
347 Positive Negative Negative Negative NA 
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a. ‘NA’ – Not Applicable. Only samples that were negative for HPV L1 were required to be put 
through PCR for HPV E1 and only samples positive for either HPV L1 or E1 were put 
through PCR for specific HPV types.  
 
 
 
 
 
 
 
 
 
348 Positive Positive Negative Positive HPV16 
349 Positive Negative Negative Negative NA 
350 Positive Negative Negative Negative NA 
351 Weak 
Positive 
Negative Negative Negative NA 
352 Positive Negative Negative Negative NA 
353 Positive Negative Negative Negative NA 
354 Positive Negative Negative Negative NA 
355 Positive Negative Negative Negative NA 
356 Positive Negative Negative Negative NA 
357 Positive Negative Negative Negative NA 
358 Positive Negative Negative Negative NA 
359 Positive Negative Negative Negative NA 
361 Positive Negative Negative Negative NA 
362 Positive Negative Negative Negative NA 
364 Positive Negative Negative Negative NA 
365 Positive Negative Negative Negative NA 
366 Positive Negative Negative Negative NA 
367 Positive Negative Negative Negative NA 
368 Positive Negative Negative Negative NA 
369 Positive Negative Negative Negative NA 
370 Positive Negative Negative Negative NA 
371 Positive Negative Negative Negative NA 
372 Positive Negative Negative Negative NA 
373 Positive Negative Negative Negative NA 
374 Positive Negative Negative Negative NA 
376 Positive Negative Negative Negative NA 
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APPENDIX C 
Scoring of IHC results for EBP50 expression 
 
Table A: Scoring of IHC results for EbP50 expression 
Specimen 
ID 
EBP50 membrane 
staining 
EBP50 cytoplasm 
staining 
Membrane/Cytoplasmic 
EBP50 staining 
EBP50 
expression 
pattern 
99 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
163 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 1 
329 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
89 Mixed staining - traces 
to positive 
Moderate staining Membrane mixed/Cytoplasm+ve 3 
88 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
87 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
85 Mixed staining - traces 
to positive 
Moderate staining Membrane mixed/Cytoplasm+ve 3 
86 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
83 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
81 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
129 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
128 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
158 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
184 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
113 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
328 Traces of membrane 
staining 
Negligible or weak staining Membrane+ve/Cytoplasm-ve 4 
256 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
135 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
162 Membrane excluded Mixed staining - Moderate to 
weak/negligible 
Membrane-ve/Cytoplasm mixed 3 
155 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
140 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
143 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
357 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
250 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
159 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
148 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
348 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
147 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
136 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
168 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
169 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
142 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
171 Traces of membrane 
staining 
Negligible or weak staining Membrane+ve/Cytoplasm-ve 4 
170 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
212 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
181 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
347 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
320 Membrane excluded Mixed staining - Moderate to 
weak/negligible 
Membrane-ve/Cytoplasm mixed 3 
157 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
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233 Membrane excluded Strong cytoplasmic staining Membrane-ve/Strong cytoplasmic 
staining 
4 
153 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
183 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
134 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
156 Membrane excluded Mixed staining - Moderate to 
weak/negligible 
Membrane-ve/Cytoplasm mixed 3 
204 Mixed staining - traces 
to negative 
Moderate staining Membrane mixed/Cytoplasm+ve 3 
133 Membrane excluded Mixed staining - Moderate to 
weak/negligible 
Membrane-ve/Cytoplasm mixed 3 
206 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
194 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
161 Traces of membrane 
staining 
Moderate staining Membrane+ve/Cytoplasm+ve 4 
139 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
193 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
188 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
192 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
175 Mixed staining - 
Positive to excluded 
Moderate cytoplasmic 
staining 
Membrane mixed/Cytoplasm+ve 3 
178 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
144 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
154 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
149 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
166 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
180 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
195 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
176 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
174 Membrane excluded Mixed staining - Strong to 
weak/negligible 
Membrane-ve/Cytoplasm mixed 3 
191 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
145 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
179 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
189 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
172 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
146 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
198 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
165 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
324 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
187 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
14 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
15 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
186 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
6 (Mixed staining - 
Positive to excluded 
Moderate cytoplasmic 
staining 
Membrane mixed/Cytoplasm+ve 3 
196 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
199 Mixed staining - 
Positive to excluded 
C+/-(Mixed staining - 
Moderate to weak/negligible 
Membrane mixed/Cytoplasm 
mixed 
3 
173 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
58 Membrane excluded Moderate cytoplasmic Membrane-ve/Cytoplasm+ve 1 
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staining 
45 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
44 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
43 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
167 Membrane excluded Moderate staining Membrane-ve/Cytoplasm+ve 1 
185 Membrane excluded Mixed staining - Moderate to 
weak/negligible 
Membrane-ve/Cytoplasm mixed 3 
314 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
312 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
372 Inconclusive Moderate cytoplasmic 
staining 
Membrane mixed/Cytoplasm+ve 3 
307 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
306 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
305 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
302 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
303 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
301 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
299 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
298 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
311 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
197 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
288 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
337 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
278 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
322 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
211 Mixed staining- traces 
to negative 
Moderate cytoplasmic 
staining 
Membrane mixed/Cytoplasm+ve 3 
221 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
219 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
361 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
213 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
274 Membrane excluded Strong cytoplasmic staining Membrane-ve/Strong cytoplasmic 
staining 
4 
164 Membrane excluded Mixed staining - Moderate to 
faint/negligible 
Membrane-ve/Cytoplasm mixed 3 
359 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
260 Membrane excluded Strong cytoplasmic staining Membrane-ve/Strong cytoplasmic 
staining 
4 
365 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
350 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
225 Traces of membrane 
staining 
Mixed staining - Moderate to 
faint/negligible 
Membrane+ve/Cytoplasm mixed 3 
276 Mixed staining - traces Strong cytoplasmic staining Membrane mixed/Strong 3 
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to positive cytoplasmic staining 
373 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
367 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
177 Membrane excluded Mixed staining - Moderate to 
faint/negligible 
Membrane-ve/Cytoplasm mixed 3 
370 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
351 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
326 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
371 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
376 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
369 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
137 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
16 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
17 Membrane excluded Mixed staining - Moderate to 
faint/negligible 
Membrane-ve/Cytoplasm mixed 3 
5 Mixed staining - 
Positive to excluded 
Moderate cytoplasmic 
staining 
Membrane mixed/Cytoplasm+ve 3 
4 Traces of membrane 
staining 
Moderate cytoplasmic 
staining 
Membrane+ve/Cytoplasm+ve 4 
2 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
1 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
190 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
55 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
53 Membrane excluded Mixed staining - Strong to 
moderate 
Membrane-ve/Cytoplasm mixed 3 
101 Mixed staining - 
Positive to excluded 
Moderate cytoplasmic 
staining 
Membrane mixed/Cytoplasm+ve 3 
98 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
84 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
201 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
308 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
239 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
285 Membrane excluded Strong cytoplasmic staining Membrane-ve/Strong cytoplasmic 
staining 
4 
284 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
279 Membrane excluded  Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
335 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
364 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
334 Membrane excluded Mixed staining - Moderate to 
faint/negligible 
Membrane-ve/Cytoplasm mixed 3 
266 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
263 Membrane excluded Strong cytoplasmic staining) Membrane-ve/Strong cytoplasmic 
staining 
4 
220 Membrane excluded Mixed staining-Strong to 
negligible/weak 
Membrane-ve/Cytoplasm mixed 3 
271 Mixed staining - 
Positive to excluded 
Strong cytoplasmic staining Membrane mixed/Strong 
cytoplasmic staining 
3 
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273 Mixed staining - 
Positive to excluded 
Strong cytoplasmic staining Membrane mixed/Strong 
cytoplasmic staining 
3 
281 Traces of membrane 
staining 
Negligible or weak staining Membrane+ve/Cytoplasm-ve 4 
332 Membrane excluded Negligible or weak staining Membrane-ve/Cytoplasm-ve 2 
319 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
331 Membrane excluded Moderate cytoplasmic 
staining 
Membrane-ve/Cytoplasm+ve 1 
 
1- Predominantly cytoplasmic EBP50 expression 
2- Weak/negligible cytoplasmic EBP50 expression 
3- Mixed-heterogeneous EBP50 expression 
4- Other less common patterns of EBP50 expression  
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APPENDIX D 
Microscopic images of EBP50 immunohistochemistry  
 
 
The enclosed CD contains images of EBP50 expression in the cohort specimens. The 
images were taken at x 10 and x 40 magnification and are organized into folders labeled 
with the specimen ID. The images may be viewed in tandem with the information in 
Appendix C using the specimen ID.  
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APPENDIX E 
Oral presentations 
 
National  
I have presented annually at the University of Dundee Postgraduate Research 
Symposium. 
 
International 
Current practice trends in HPV testing for head and neck squamous cell carcinomas: A 
Scotland-wide online survey. Presented at the WHO International Agency for Research 
on Cancer meeting on Emerging issues in Head and Neck Cancer in Manduria, Italy, 
June 2014. 
